

☐

I'm not robot


reCAPTCHA

Continue

Dimenhydrinate injection pdf

Dimenhydrinate intramuscular. Dimenhydrinate injection usp.

1. Package insert (for brands listed after the nonproprietary name heading in a monograph; date of package insert given as part of citation) 2. Physicians’ desk reference.



63rd ed. Montvale, NJ: Thomson PDR; 2009. 3. Kirkland WD, Jones RW, Ellis JR et al. Compatibility studies of parenteral admixtures. Am J Hosp Pharm. 1961; 18:694-9. 4. McEvoy GK, ed. AHFS drug information 2011. Bethesda, MD: American Society of Health-System Pharmacists; 2011.



5. Sweetman SC, ed. Martindale: the complete drug reference. 37th aed. London, England: The Pharmaceutical Press; 2011. 6. Parker EA. Staphcillin injection. Am J Hosp Pharm. 1970; 27:67-8. 7. Parker EA. Compatibility digest. Am J Hosp Pharm. 1970; 27:672-3.



[PubMed 5451542] 8. Trissel LA. Trissel’s stability of compounded formulations. 4th ed. Washington, DC: American Pharmacists Association; 2009. 9. Patel JA, Phillips GL.



Guide to physical compatibility of intravenous drug admixtures. Am J Hosp Pharm. 1966; 23:409-11. 10. Bogash RC. Compatibilities and incompatibilities of some parenteral medication. Bull Am Soc Hosp Pharm. 1955; 12:445-8.



11. Dunworth RD, Kenna FR. Preliminary report: incompatibility of combinations of medications in intravenous solutions. Am J Hosp Pharm. 1965; 22:190-1.

12. Moorhatch P, Chiou WL. Interactions between drugs and plastic intravenous fluid bags, part i: sorption studies on 17 drugs. Am J Hosp Pharm. 1974; 31:72-8. [PubMed 4810168]

13. Levin JH, Fieber RA. Stability data for Tubex filled by hospital pharmacists. Hosp Pharm. 1973; 8:310-1.

14. Powers S. Incompatibilities of pre-op medications. Bethesda, MD: Pharmacy Department, National Institutes of Health; 1970 Jan. 16. Cantania PN, King JC. Physico-chemical incompatibilities of selected cardiovascular and psychotherapeutic agents with sodium ethacrynate. Am J Hosp Pharm. 1972; 29:141-6. [PubMed 5020599]

17. USP-NF online. 2020 U.S. Pharmacopeia National Formulary USP 42 NF 37. Rockville, MD: The United States Pharmacopeial Convention; 2020. www.uspnf.com. Updated 2019 Jun 3. Accessed 2020 Jun 5. 18. Kramer W, Ingliott A. Some physical and chemical incompatibilities of drugs for i.v. administration. Drug Intell Clin Pharm. 1971; 5:211-28. 19. McEvoy GK, ed. American hospital formulary service drug information. Bethesda, MD: American Society of Health-System Pharmacists; prior editions. 20. Parker EA. Compatibility digest. Am J Hosp Pharm. 1969; 26:412-3. 21. Parker EA. Compatibility digest. Am J Hosp Pharm. 1969; 26:653-5. 22. Parker EA. Compatibility digest. Am J Hosp Pharm. 1970; 27:327-9. [PubMed 5446269]

23. Parker EA. Compatibility digest. Am J Hosp Pharm. 1974; 31:1076. [PubMed 4432859]

24. Parker EA. Compatibility digest. Am J Hosp Pharm. 1971; 28:805. 25. Souney PF, Solomon MA. Visual compatibility of cimetidine hydrochloride with common preoperative injectable medications. Am J Hosp Pharm. 1984; 41:1840-1. [PubMed 6496520]

26. Riley BB. Incompatibilities in intravenous solutions. J Hosp Pharm. 1970; 28:228-40. 27. Parker EA, Levin HJ. Compatibility digest. Am J Hosp Pharm. 1975; 32:943-4. [PubMed 242217]

28. Misgen R. Compatibilities and incompatibilities of some intravenous solution admixtures. Am J Hosp Pharm. 1965; 22:92-4. 32. Frank JT. Intralipid compatibility study. Drug Intell Clin Pharm. 1973; 7:351-2. 33. Yeo MT, Gazzaniga AB, Bartlett RH et al. Total intravenous nutrition experience with fat emulsions and hypertonic glucose. Arch Surg. 1973; 106:792-6. [PubMed 4196215]

34. Melly MA, Meng HC. Microbial growth in lipid emulsions used in parenteral nutrition. Arch Surg. 1975; 110:1479-81. [PubMed 982]

36. Cashore WJ, Sedaghatian MR. Nutritional supplements with intravenously administered lipid, protein hydrolysate, and glucose in small premature infants. Pediatrics. 1975; 56:8-16. [PubMed 808789]

37. Lynn B. Intralipid compatibility study. Drug Intell Clin Pharm. 1974; 8:75. 38. Electronic Medicines Compendium. London, England: Datapharm Communications Ltd. 39. Fortner CL, Grove WR, Bowie D et al. Fat emulsion vehicle for intravenous administration of an aqueous insoluble drug. Am J Hosp Pharm. 1975; 32:582-4. [PubMed 1155469]

40. Riffkin C. Incompatibilities of manufactured parenteral products. Am J Hosp Pharm. 1963; 20:19-22. 41. Edward M. pH—an important factor in the compatibility of additives in intravenous therapy. Am J Hosp Pharm. 1967; 24:440-9. [PubMed 6075729]

42. Turner FE, King JC. Spectrophotometric analysis of intravenous admixtures containing metaraminol and corticosteroids. Am J Hosp Pharm. 1970; 27:540-7. [PubMed 5431052]

43. Anderson RW, Latiolais CJ. Physico-chemical incompatibilities of parenteral admixtures—Aramine and Solu-Cortef. Am J Hosp Pharm. 1973; 30:128-33. [PubMed 4690467]

44. Smith MC. The dextrans. Am J Hosp Pharm. 1965; 22:273-5. 45. Stokes TP, Sumner ED. Particulate contamination of stability of three additives in 0.9% sodium chloride injection in plastic and glass large-volume containers. Am J Hosp Pharm. 1975; 32:821-6. [PubMed 1146840]

46. Parker EA. Solution additive chemical incompatibility study. Am J Hosp Pharm. 1967; 24:434-9. [PubMed 6075728]

47. Parker EA. Compatibility digest. Am J Hosp Pharm. 1969; 26:543-4. [PubMed 5823457]

48. Parker EA. Parenteral incompatibilities. Hosp Pharm. 1969; 4:14-22. 49. Beatrice MG, Stanaszek WF, Allen LV et al. Physicochemical stability of a preanesthetic mixture of hydroxyzine hydrochloride and atropine sulfate. Am J Hosp Pharm. 1975; 32:1133-7. [PubMed 242215]

50. Leff RD, Roberts RJ. Effect of intravenous fluid and drug solution coadministration on final-infusate osmolality, specific gravity, and pH. Am J Hosp Pharm. 1982; 39:468-71. [PubMed 7072733]

51. Crevar GE, Slotnick IJ. A note on the stability of actinomycin D. J Pharm Pharmacol. 1964; 16:429. [PubMed 14200405]

52. Coles CLJ, Lees KA. Additives to intravenous fluids. Pharm J. 1971; 206:153-4. 53. Rudd L. Pethidine stability in intravenous solutions. Med J Aust. 1978; 2:34. [PubMed 683109]

54. Webb JW. A pH pattern for i.v. additives. Am J Hosp Pharm. 1969; 26:31-5. [PubMed 5763886]

55. Jones RW, Stanko GL. Pharmaceutical compatibilities of Pentothal and Nembutal. Am J Hosp Pharm. 1961; 18:700-2. 56. Turco SJ, Shernin M, Zagar L et al. Stability of aminophylline in 5% dextrose in water. Hosp Pharm. 1975; 10:374-5. 58. Pamperl H, Kleinberger G. Morphologic changes of Intralipid 20% liposomes in all-in-one solutions during prolonged storage. Infusionstherapie. 1982; 9:86-91. 59. Parker EA. Compatibility digest. Am J Hosp Pharm. 1974; 31:775. 60. Wolfert RR. Cox RM. Room temperature stability of drug products labeled for refrigerated storage. Am J Hosp Pharm. 1975; 32:585-7. [PubMed 1155470]

61. Anon. Intravenous fat. Lancet. 1976; 1:1059-60. [PubMed 57458]

62. Sachtler G. Dilantin for i.v. use. Drug Intell Clin Pharm. 1973; 7:418. 63. Burke WA. I.V. drug incompatibilities—Dilantin. Am J IV Ther. 1975; 2:16-8. 64. Baldwin J, Amerson AB. Intramuscular use of diphenylhydantoin. Am J Hosp Pharm. 1973; 30:837-8. [PubMed 4733637]

65. Tobias DC, Kellick KA. Dilantin for i.v. use. Drug Intell Clin Pharm. 1973; 7:418. 66. Chan NL. Dilantin for i.v. use. Drug Intell Clin Pharm. 1973; 7:419. 67. Ammar HO, Salama HA. Studies on the stability of injectable solutions of some phenothiazines, part i: effect of pH and buffer systems. Pharmazie. 1975; 30:368-9. [PubMed 240174]

68. Pickering LK, Rutherford I. Effect of concentration and time upon inactivation of tobramycin, gentamicin, netilmicin, and amikacin by azlocillin, carbenicillin, mecillinam, mezlocillin, and piperacillin. J Pharmacol Exp Ther. 1981; 217:345-9. [PubMed 6453219]

69. Ho NFH, Goeman JA. Prediction of pharmaceutical stability of parenteral solutions. Drug Intell Clin Pharm. 1970; 4:69-71. 72. Trissel LA, Davignon JP, Kleinman LM, et al. NCI investigational drugs pharmaceutical data. Bethesda, MD: National Cancer Institute; 1988. 73. Muhlhauser I, Broermann C, Tsoatsala M et al. Miscibility of human and bovine ultraletale insulin with soluble insulin. BMJ. 1984; 289:1656-7. [PubMed 6439364]

[Free Fulltext PMC]

74. Grant HR. Compatibilities of intravenous admixtures. Hosp Pharmacist. 94 (Mar-Apr) 1962; 15:67-70. 75. Hanson DB, Hendeles L. Guide to total dose intravenous iron dextran therapy. Am J Hosp Pharm. 1974; 31:592-5. [PubMed 4407476]

76. Duke AB, Kelleher J. Serum iron and iron binding capacity after total dose infusion of iron-dextran for iron deficiency anaemia in pregnancy. J Obstet Gynaecol Br Commonw. 1974; 81(11):895-900. [PubMed 4436730]

77. Parker EA. Compatibility digest. Am J Hosp Pharm. 1975; 32:214. [PubMed 274171]

78. Cardella LA, Kesler H, Carter JE et al. Intropin (dopamine hydrochloride) intravenous admixture compatibility: part i: stability with some commonly used antibiotics in 5% dextrose injection. Am J Hosp Pharm. 1976; 33:537-40. [PubMed 1274971]

79. Gardella LA, Zarosinski JF. Intropin (dopamine hydrochloride) intravenous admixture compatibility: part i: stability with common intravenous fluids. Am J Hosp Pharm. 1975; 32:575-8. [PubMed 239594]

80. Garnett W. Diluents for antineoplastic drugs. Drug Intell Clin Pharm. 1971; 5:261. 81. Landersjo L, Stjernstrom G. Studies on the stability and compatibility of drugs in infusion fluids V. Effect of lactate and metal ions on the stability of benzylpenicillin. Acta Pharm Suec. 1978; 15:161-8. [PubMed 31058]

82. Notari RE, Chin ML. Arabinosylcytosine stability in aqueous solutions: pH profile and shelf life predictions. J Pharm Sci. 1972; 61:1189-96. [PubMed 5050364]

83. Murty BSR, Kapoor JN. Properties of mannitol injection (25%) after repeated autoclavings. Am J Hosp Pharm. 1975; 32:826-7. [PubMed 238390]

84. Rosch JM, Pazin GJ, Fireman P. Reduction of amphotericin B nephrotoxicity with mannitol. JAMA. 1976; 235:1995-6. [PubMed 946511]

85. Bergman N, Vellar ID. Potential life-threatening variations of drug concentrations in intravenous infusion systems—potassium chloride, insulin, and heparin. Med J Aust. 1982; 2:270-2. [PubMed 6755202]

86. Parker EA. Compatibility digest. Am J Hosp Pharm. 1970; 27:492-3. 87. Feigen RD, Moss KS. Antibiotic stability in solutions used for intravenous nutrition and fluid therapy. Pediatrics. 1973; 51:1016-26. [PubMed 4196937]

88. Zost ED, Yanchick VA. Compatibility and stability of disodium carbenicillin in combination with other drugs and large volume parenteral solutions. Am J Hosp Pharm. 1972; 29:135-40. [PubMed 4623176]

89. Lynn B. Recent work on parenteral penicillins. J Hosp Pharm. 1971; 29:183-194. 90. Tourville J. Sodium nitroprusside. Drug Intell Clin Pharm. 1975; 9:361-4. 91. Anon. Editorial: Sodium nitroprusside in anaesthesia. Br Med J. 1975; 2:524-5. 92. Hargrave RE. Degradation of solutions of sodium nitroprusside. J Hosp Pharm. 1974; 32:188-9. 93. Anon. Sodium nitroprusside for hypertensive crisis. Med Lett Drugs Ther. 1975; 17:82-3. [PubMed 1177815]

94. Anderson RA, Rae W. Stability of sodium nitroprusside solutions. Aust J Pharm Sci NSI. 1972; (July):45-6. 95. Schumacher GE. Sodium nitroprusside injection. Am J Hosp Pharm. 1966; 23:532. 96. Cruz JE, Marquis DD, Yakata CJ, Kinetics and mechanism of hydrolysis of turosemide. Int J Pharm. 1979; 2:275-81. 97. Thomas R. Mepredilone HCl and heparin sodium precipitation. Hosp Pharm. 1979; 2:275-81. 98. Fleischer NM. Promethazine hydrochloride-morphine sulfate incompatibility. Am J Hosp Pharm. 1973; 30:665. [PubMed 4722839]

99. Lynn B. Pharmaceutical aspects of semi-synthetic penicillins. J Hosp Pharm. 1970; 28:71-86. 100. Meisler JM, Skolaut MW. Extemporaneous sterile compounding in intravenous additives. Am J Hosp Pharm. 1966; 23:557-63. [PubMed 5953067]

101. Guthaus MR (Medical Services, The Upjohn Company, Kalamazoo, MI): Personal communication; 1973 Aug 9. 102. HamLin WE, Riebe KW, Scothorn WW, et al. Pharmacy profile of cleocin phosphate. Presented at 10th annual ASHP midyear clinical meeting. Washington, DC: 1975 Dec 11. 103. Riebe KW, Oesterling TO. Parenteral development of clindamycin 2-phosphate. Bull Parenter Drug Assoc. 1972; 26:139-45. [PubMed 5035118]

104. Therapeutic profile: cleocin phosphate. Kalamazoo, MI: The Upjohn Company; 1973. 105. Wyatt RG, Okamoto GA. Stability of antibiotics in parenteral solutions. Pediatrics. 1972; 49:22-9. [PubMed 5059308]

106. Hiaisi S, Naim JD. Stability studies of hydralazine hydrochloride in aqueous solutions. J Parenter Sci Technol. 1990; 44:30-4. [PubMed 2313490]

107. Whiting DA. Treatment of chromoblastomycosis with local concentrations of amphotericin B. Br J Dermatol. 1967; 79:345-51. [PubMed 6027196]

108. Kirschenbaum BE, Latiolais CJ. Injectable medications—a guide to stability and reconstitution. New York, NY: McMahon Group; 1993. 109. Bair JN, Carew DP. Therapeutic availability of antibiotics in parenteral solutions. Bull Parenter Drug Assoc. 1965; 19:153-63. [PubMed 5837890]

110. Dancy JE, Carew DP. Availability of antibiotics in combination with additives in intravenous solutions. Am J Hosp Pharm. 1966; 23:543-51. [PubMed 5915776]

111. Prasad VK, Granatek AP. Physical compatibility and chemical stability of cephradine sodium in combination with antibiotics and large-volume parenteral solutions, part i. Curr Ther Res Clin Exp. 1974; 16:505-39. [PubMed 4365711]

112. Lynn B. Carbenicillin plus gentamicin. Lancet. 1971; 1:654. [PubMed 4101265]

115. Information for health professionals. Wellington, New Zealand: New Zealand Medicines and Medical Devices Safety Authority. 117. McEvoy GK, ed. American hospital formulary service drug information 95. Bethesda, MD: American Society of Health-System Pharmacists; 1995. 118. Harrison DC. Practical guidelines for the use of lidocaine. Prevention and treatment of cardiac arrhythmias. JAMA. 1975; 233:1202-4. [PubMed 1174178]

120. Anon. Prophylactic use of lidocaine in myocardial infarction. Med Lett Drugs Ther. 1976; 18:1-2. [PubMed 1105126]

121. Dundee JW, Gamble JA, Assaf RA. Plasma diazepam levels following intramuscular injection by nurses and doctors. Lancet. 1974; 2:1461. 123. Tortorici MP. Stability data on frozen i.m. and i.v. solutions. Pharm Times. 1975; 41:68-72. 124. Barbara AC, Clemente C. Physical incompatibility of sulfonamide compounds and polyionic solutions. N Engl J Med. 1966; 274:1316-7. [PubMed 5936416]

125. Brooke D, Bequette RJ. Chemical stability of cyclophosphamide in parenteral solutions. Am J Hosp Pharm. 1973; 30:134-7. [PubMed 4690468]

126. Brooke D, Scott JA. Effect of briefly heating cyclophosphamide solutions. Am J Hosp Pharm. 1975; 32:44-5. [PubMed 235840]

127. Gallelli JF. Stability studies of drugs used in intravenous solutions, part i. Am J Hosp Pharm. 1967; 24:425-33. [PubMed 6075727]

128. Dupont Pharmaceuticals. Nubain, physical compatibility. Wilmington, DE; undated. 129. Kramer W, Tanja JJ. Precipitates found in admixtures of potassium chloride and dextrose 5% in water. Am J Hosp Pharm. 1970; 27:548-53. [PubMed 5431053]

130. Lawson DH. Clinical use of potassium supplements. Am J Hosp Pharm. 1975; 32:708-11. [PubMed 1146831]

131. Lundgren P, Lantieri L. Studies on the stability and compatibility of benzylpenicillin. Acta Pharm Suec. 1970; 7:509-26. [PubMed 5275184]

132. Weber CR, Gupta VD. Stability of phenylephrine hydrochloride in intravenous solutions. J Hosp Pharm. 1970; 28:200-8. 133. Chiou WL, Moorhatch P. Interaction between vitamin A and plastic intravenous fluid bags. Am J Med Assoc. 1973; 223:328. 134. Komesaroff D, Field JE. Pancuronium bromide: a new non-depolarizing muscle relaxant. Med J Aust. 1969; 1:908-11. [PubMed 4182379]

135. Simberloff MS, Thomas L, McGregor D et al. Inactivation of penicillins by carboxydic acid solutions at alkaline pH. N Engl J Med. 1970; 283:116-9. [PubMed 5423147]

136. Hicks CI, Gallardo JB. Stability of sodium bicarbonate injection stored in polypropylene syringes. Am J Hosp Pharm. 1972; 29:210-6. [PubMed 5028472]

137. DeLuca PP, Kowalski RJ. Problems arising from the transfer of sodium bicarbonate injection from ampuls to plastic disposable syringes. Am J Hosp Pharm. 1972; 29:217-22. [PubMed 5028473]

138. D'Arcy PF, Thompson KM. Stability of chlorpromazine hydrochloride added to intravenous infusion fluids. Pharm J. 1973; 210:28. 139. Nahata MC, Zingarelli JR, Hippie TF. Stability of caffeine injection stored in plastic and glass syringes. DICP. 1989; 23:1035. [PubMed 2603448]

140. Murabito AS (Smith Kline & French Laboratories, Philadelphia, PA): Personal communication; 1986 Dec 15. 141. Mann JM, Coleman DL. Stability of parenteral solutions of sodium cephalothin, cephaloridine, potassium penicillin G (buffered), and vancomycin HCl. Am J Hosp Pharm. 1971; 28:760-3. [PubMed 5125170]

142. Appleby DH, John JF. Effect of peritoneal dialysis solution on the antimicrobial activity of cephalosporins. Nephron. 1982; 30:341-4. [PubMed 7110465]

143. Upshaw MD (Medical Information Services, Eli Lilly and Company, Indianapolis, IN): Personal communication; 1972 Jan 10. 144. Gallelli JF, MacLowry JD. Stability of antibiotics in parenteral solutions—penicillins and tetracyclines. Am J Hosp Pharm. 1969; 26:620-5. [PubMed 5352570]

145. Dienstag JL, Neu HC. Tobramycin: new aminoglycoside antibiotic. Clin Med. 1975; 82:13-9. 146. Struher M, Heinrich J. K sorpci pentoksyfyllinu na infuznu supravu Luer. Farm Obz. 1988; 57:405-10. 147. Bergstrom RF, Fites AL. Stability of parenteral solutions of tobramycin sulfate. Am J Hosp Pharm. 1975; 32:887-8. [PubMed 242216]

148. Huber RC, Riffkin C. Inline final filters for removing particles from amphotericin B infusions. Am J Hosp Pharm. 1975; 32:173-6. [PubMed 237416]

149. Rebagay T, Rapp R, Bivins B et al. Residues in antibiotic preparations, i: scanning electron microscopic studies of surface topography. Am J Hosp Pharm. 1975; 32:433-43. [PubMed 5888]

150. Gallelli JF. Assay and stability of amphotericin B in aqueous solutions. Drug Intell. 1967; 1:102-5. 151. Piccioro JJ, Goodman NL, Wheeler WE et al. Particulate matter in reconstituted amphotericin B and assay of filtered solutions of amphotericin B. Am J Hosp Pharm. 1975; 32:381-4. [PubMed 1993398]

152. Gotz V, Simon W. Inline filtration of amphotericin B infusions. Am J Hosp Pharm. 1975; 32:458. [PubMed 1146813]

153. Chatterji D, Hiranaka PK. Stability of sodium oxacillin in intravenous solutions. Am J Hosp Pharm. 1975; 32:130-2. [PubMed 1190234]

154. Facts and Comparisons, Inc. Drug facts and comparisons. St. Louis, MO: 2003. 155. Parodi JF. Stability of frozen antibiotic solutions in Viaflex infusion containers. Hosp Pharm. 1976; 11:178-9. 156. Larsen SS. Stability of benzylpenicillin sodium in frozen aqueous solutions. Dan Tidsskr Farm. 1971; 45:307-16. [PubMed 5156696]

157. Noone P, Pattison JR. Therapeutic implications of interaction of gentamicin and penicillins. Lancet. 1971; 2:575-8. [PubMed 4106106]

158. Boulet M, Marier JR. Effect of magnesium on formation of calcium phosphate precipitates. Arch Biochem Biophys. 1962; 96:629-36. [PubMed 1387181]

159. van den Berg L, Soliman FS. Composition and pH changes during freezing of solutions containing calcium and magnesium phosphate. Cryobiology. 1969; 6:10-4. [PubMed 5810544]

160. Ong JTH, Kostenbauder HB. Effect of self-association on rate of penicillin G degradation in concentrated aqueous solutions. J Pharm Sci. 1975; 64:1378-80. [PubMed 239209]

161. Shoup LK, Thur MP. Stability of frozen buffered penicillin G potassium injection. Hosp Formul Manage. 1968; 3:38-9. 162. Boylan JC, Simmons JL. Stability of frozen solutions of sodium cephalothin and cephaloridine. Am J Hosp Pharm. 1972; 29:687-9. [PubMed 4559536]

163. Grant NM, Clark DE. Imidazole- and base-catalyzed hydrolysis of penicillin in frozen systems. J Am Chem Soc. 1961; 83:4476-7. 164. Lindsay RE, Hem SL. Dosage form for potassium penicillin G intravenous infusion solutions. Drug Devel Commun. 1974-5; 1:211-222. 165. Im S, Latiolais CJ. Physico-chemical incompatibilities of parenteral admixtures—penicillins and tetracyclines. Am J Hosp Pharm. 1966; 23:333-43. 166. Pfeiler HJ, Webb JW. Compatibility of penicillin and ascorbic acid injection. Am J Hosp Pharm. 1976; 33:448-50. [PubMed 5890]

167. Rusmin S, DeLuca PP. Effect of inline filtration on the potency of potassium penicillin G. Bull Parenter Drug Assoc. 1976; 30:64-71. [PubMed 949563]

168. Stolar MH, Carlin HS. Effect of freezing on the stability of sodium methicillin injection. Am J Hosp Pharm. 1968; 25:32-5. [PubMed 5640122]

169. Lynn B. Stability of methicillin in dextrose solutions at alkaline pH. J Hosp Pharm. 1972; 30:81-3. 170. Lynn B. Pharmaceuticals of the semi-synthetic penicillins. Chem Drug. 1967; 187:134-6. 171. Lynn B. Inactivation of methicillin in dextrose solutions at alkaline pH. N Engl J Med. 1971; 285:690. [PubMed 5563485]

172. Mattson CJ, Clark ST, Colangelo A. Stability of clindamycin phosphate in plastic syringes. Presented at 20th annual ASHP midyear clinical meeting. New Orleans, LA: 1985 Dec. 173. Clark ST, Colangelo A. Stability of clindamycin phosphate in plastic syringes. Presented at 20th annual ASHP midyear clinical meeting. New Orleans, LA: 1985 Dec. 174. Cohon MS (Drug Information Services, Upjohn Company, Kalamazoo, MI): Personal communications; 1986 Dec 12, 1988 Jan 27, 1988 Feb 3. 176. Owen RT (UK Medical Information Section, The Wellcome Foundation Ltd., Cheshire, England): Personal communication; 1993 Aug 19. 177. Lesson LJ, Weidenheimer JF. Stability of tetracycline and riboflavin. J Pharm Sci. 1969; 58:355-7. [PubMed 5782032]

178. Turco SJ, Burke WA. Methods of ordering and use of intravenous phosphate (mEq vs mM). Hosp Pharm. 322, 326 (Aug) 1975; 10:320. 179. Pinkus TF, Jeffrey LP. Incompatibility of calcium and phosphate in parenteral alimentation solutions. Am J IV Ther. 1976; 3:22-4. 180. Kaminski MV, Harris DF, Collin CF et al. Electrolyte compatibility in synthetic amino acid hyperalimentation solution. Am J Hosp Pharm. 1974; 31:244-6. [PubMed 4206614]

181. Schlicht JR. Adjustments in etoposide infusion flow rates when using controllers. Am J Hosp Pharm. 1990; 47:2656. [PubMed 2278277]

183. Lee PA, Gwinn JL. Roentgen patterns of extravasation of calcium gluconate in the tissues of the neonate. J Pediatr. 1975; 86:598-601. [PubMed 1127506]

184. Weiss Y, Berkman C. Localized necrosis of scalp in neonates due to calcium gluconate infusions: a cautionary note. Pediatrics. 1975; 56:1084-6. [PubMed 1196761]

185. Ramamurthy RS, Harris V. Subcutaneous calcium deposition in the neonate associated with intravenous administration of calcium gluconate. Pediatrics. 1975; 55:802-6. [PubMed 1134881]

186. Laegerle WL, To JM. Stability of certain amino acids in a parenteral nutrition solution. Am J Hosp Pharm. 1974; 31:776-9. [PubMed 4212349]

187. Kleinman LM, Tangrea JA, Gallelli JF et al. Stability of solutions of essential amino acids. Am J Hosp Pharm. 1973; 30:1054-7. [PubMed 4751187]

188. Rowlands DA. Compatibility of calcium and phosphate in amino acids solution. Am J Hosp Pharm. 1975; 32:360. [PubMed 1130408]

189. Saudak EC (The Upjohn Company): Personal communication; 1973 Jan 3. 190. Rowlands DA, Wilkison WR. Storage stability of mixed hyperalimentation solutions. Am J Hosp Pharm. 1973; 30:436-8. [PubMed 4574336]

191. Aro R (Senior Clinical Research Associate, Fujisawa USA): Personal communication, February 22, 1994. 192. Rodriguez Penin I, Yanez Gonzalez A, Camba Rodriguez A et al. Estabilidad de la mezcla morfina-midazolam en un dispositivo de infusion continua. Farm Hosp. 1991; 15:407-9. 193. Nahata MC, Zingarelli JR, Durrell DE. Stability of caffeine injection in intravenous admixtures and parenteral nutrition solutions. DICP. 1989; 23:466-7. [PubMed 2500782]

194. Hull RL. Use of trace elements in intravenous hyperalimentation solutions. Am J Hosp Pharm. 1974; 31:759-61. [PubMed 4212506]

195. Johnson C, Cloyd J. Parenteral hyperalimentation. Drug Intell Clin Pharm. 1975; 9:493-9. 196. Hankins DA, Riella MC, Scribner BH et al. Whole blood trace element concentrations during total parenteral nutrition. Surgery. 1976; 79:674-7. [PubMed 818725]

197. Hamann MA. Trace element requirements in hyperalimentation. Am J Hosp Pharm. 1974; 31:1035. [PubMed 4215316]

198. Hull RL. Trace element requirements in hyperalimentation. Am J Hosp Pharm. 1974; 31:1038. 199. Heird WC, Winters RW. Total intravenous alimentation in pediatric patients. South Med J. 1975; 68:1173-6. [PubMed 808861]

200. Baker JA, Kirkman H, Woodley C et al. Computer-assisted pediatric hyperalimentation. Am J Hosp Pharm. 1974; 31:1160. [PubMed 4218449]

202. Pomerance HH, Rader RE. Crystal formation: a new complication of total parenteral nutrition. Pediatrics. 1973; 52:864-6. [PubMed 4203556]

203. Bohard RD, Ogawa G. An observation on the stability of cis-dichlorodiammineplatinum (II): a caution regarding its administration. Cancer Treat Rep. 1979; 63:2117-8. [PubMed 575070]

204. Prestayko AW, Cadiz M. Incompatibility of aluminum-containing iv administration equipment with cis-dichlorodiammineplatinum (II) administration. Cancer Treat Rep. 1979; 63:2118-9. [PubMed 575071]

205. Shils ME. Minerals in total parenteral nutrition. Drug Intell Clin Pharm. 1972; 6:385-93. 206. Flack HL, Gans JA, Serlick SE et al. The current status of parenteral hyperalimentation. Am J Hosp Pharm. 1971; 28:326-35. [PubMed 4999686]

207. McRae MP, King JC. Compatibility of antineoplastic, antibiotic, and corticosteroid drugs in intravenous admixtures. Am J Hosp Pharm. 1976; 33:1010-3. [PubMed 973628]

208. Warren E, Synder RJ, Thompson CO et al. Stability of ampicillin in intravenous solutions. Mayo Clin Proc. 1972; 47:34-5. [PubMed 5008254]

209. Raffanti EF, King JC. Effect of pH on the stability of sodium ampicillin solutions. Am J Hosp Pharm. 1974; 31:745-51. [PubMed 4851691]

210. Savello DR, Shrangrav RF. Stability of sodium ampicillin solutions in the frozen and liquid states. Am J Hosp Pharm. 1971; 28:754-9. [PubMed 5125169]

211. Jacobs J, Nathan I, Superstine E et al. Ampicillin and carbenicillin stability in commonly used infusion solutions. Drug Intell Clin Pharm. 1970; 4:204-8. 212. Hiranaka P, Frazier AG. Stability of sodium ampicillin in aqueous solutions. Am J Hosp Pharm. 1972; 29:321-2. [PubMed 5025262]

213. Stratton M, Sandrin BJ. Stability studies of ampicillin sodium in intravenous fluids using optical activity. Bull Parenter Drug Assoc. 1975; 29:286-95. [PubMed 1131]

214. Pincok RE, Kiovsky TE. Kinetics of reactions in frozen solutions. J Chem Educ. 1966; 43:358-60. 215. Hou JP, Poole JW. Kinetics and mechanism of degradation of ampicillin in solution. J Pharm Sci. 1969; 58:447-54. [PubMed 5787442]

216. Shils ME, Wright WL, Turnbull A et al. Long-term parenteral nutrition through an external arteriovenous shunt. N Engl J Med. 1970; 283:341-4. [PubMed 4987877]

217. Zia H, Tehrani M. Kinetics of carbenicillin degradation in aqueous solutions. Can J Pharm Sci. 1974; 9:112-7. 218. Riff LJ, Jackson GO. Laboratory and clinical conditions for gentamicin inactivation by carbenicillin. Arch Intern Med. 1972; 130:887-91. [PubMed 5082469]

219. McLaughlin JE, Reeves DS. Clinical and laboratory evidence for inactivation of gentamicin by carbenicillin. Lancet. 1971; 1:261-4. [PubMed 4100015]

220. Klastersky J. Carbenicillin plus gentamicin. Lancet. 1971; 1:653-4. [PubMed 4101264]

221. Levinson ME, Kaye D. Carbenicillin plus gentamicin. Lancet. 1971; 2:45-6. [PubMed 4103685]

222. Elykyn S, Phillips J. Gentamicin plus carbenicillin. Lancet. 1971; 1:545-6. [PubMed 4100453]

223. Riff L, Jackson GG. Gentamicin plus carbenicillin. Lancet. 1971; 1:592. [PubMed 4100919]

224. Zost ED, Yanchick VA. Stability of gentamicin in combination with carbenicillin. Am J Hosp Pharm. 1972; 29:388-90. [PubMed 5035580]

225. Jacoby GA. Carbenicillin and gentamicin. N Engl J Med. 1971; 284:1096-8. [PubMed 5205659]

226. Kleinberg ML (Professional Services, Immunex, Seattle, WA): Personal communication; 1993 Jun 14. 227. Baldini JT (Professional Services, Schering Laboratories, Kenilworth, NJ): Personal communication; 1972 Feb 11. 228. Koup JR, Gerbracht L. Combined use of heparin and gentamicin in peritoneal dialysis solutions. Drug Intell Clin Pharm. 1975; 9:388. 229. Reeves DS, Bywater MJ, Wise R et al. Availability of three antibiotics after intramuscular injection into thigh and buttock. Lancet. 1974; 2:1421-2. [PubMed 4140333]

231. Preskey D, Kayes JB. Stability of sulfadiazine sodium as used in admixture with intravenous infusion fluids. J Clin Pharm. 1976; 1:39-48. 232. Physicians' desk reference. 49th ed. Oradell, NJ: Medical Economics Company; 1995. 233. Larsen SS, Jensen VG. Studies on stability of drugs in frozen systems. II. The stabilities of hexobarbital sodium and phenobarbital sodium in frozen aqueous solutions. Dan Tidsskr Farm. 1970; 44:21-31. [PubMed 5440939]

234. NCI investigational drugs pharmaceutical data. Bethesda, MD: National Cancer Institute; 1988, 1990, 1994. 235. Halpern NA, Colucci RD, Alicea M et al. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Clin Pharmacol Ther Toxicol. 1989; 27:250-4. [PubMed 2737791]

236. Anon. Kidney toxicity—main source of methotrexate complications. Am J Hosp Pharm. 1975; 32:1036-7. 237. Baker MBC Hospital Products Division, Abbott Laboratories, Abbott Park, Illinois: Personal Communication; 2003 Aug 27. 238. Hoeprich PD, Huston AC. Stability of four antifungal antimicrobics in vitro. J Infect Dis. 1978; 137:87-93. [PubMed 624855]

239. Selam JL, Lord P, van Antwerp WP et al. Heparin addition to insulin in implantable pumps to prevent catheter obstruction. Diabetes Care. 1989; 12:38-9. [PubMed 2714165]

240. Wang DP. Stability of procaine in aqueous systems. Analyst. 1983; 108:851-6. 241. Lapidus B. Cautions regarding the preparation of high-dose methotrexate infusions. Am J Hosp Pharm. 1976; 33:760. 242. Pelsor FR. Cautions regarding the preparation of high-dose methotrexate infusions. Am J Hosp Pharm. 1976; 33:760. 243. Pritchard J. Stability of heparin solutions. J Pharm Pharmacol. 1964; 16:487-9. [PubMed 14207092]

244. Turco SJ. I.V. drug incompatibilities—heparin sodium USP. Am J IV Ther. 1976; 3:16-9. 245. Kakkav RV, Corrigan TP. Prevention of fatal postoperative pulmonary embolism by low doses of heparin: an international multicentre trial. Lancet. 1975; 2:45-51. [PubMed 49649]

246. Sherry S. Low-dose heparin prophylaxis for postoperative venous thromboembolism. N Engl J Med. 1975; 293:300-2. [PubMed 1138184]

247. Gallus AS, Hirsch J, O'Brien SE et al. Prevention of venous thrombosis with small, subcutaneous doses of heparin. JAMA. 1976; 235:1980-2. [PubMed 946507]

248. Hopell AW. Low-dose heparin for the prevention of venous thromboembolism. Hosp Pharm. 1976; 11:223. 249. Wessler S. Heparin as an antithrombotic agent. Low-dose prophylaxis. JAMA. 1976; 236:389-91. [PubMed 9470059]

250. Erdi A, Kakkav VV, Thomas DP et al. Effect of low-dose subcutaneous heparin on whole-blood viscosity. Lancet. 1976; 2:342-4. [PubMed 60572]

251. Hadgraft JW. Adding drugs to intravenous infusions. Lancet. 1970; 2:1254. [PubMed 4098681]

254. Mitchell JF, Barger RC. Heparin stability in 5% dextrose and 0.9% sodium chloride. Am J Hosp Pharm. 1976; 33:340-2. 255. Thomas BR, Salter FJ. Heparin locks: their advantages and disadvantages. Hosp Formul. 1975; 10:536-8. [PubMed 10237817]

256. Deeb EN, DiMattia PE. The key question: how much heparin in the lock? Am J IV Ther. 1976; 3:22-6. 257. DeFina E. How we use heparin locks. Am J IV Ther. 33 (Dec-Jan) 1976; 3:27. 258. Hanson RL, Grant AM. Heparin

Journal. 1967; 21:25-30, 281. Schwartz MA, Buckwalter PH. Pharmacokinetics of penicillin. *J Pharm Sci.* 1962; 51:1119-28. [PubMed 13987384] 282. Thur MP (Parental Products, Travenol Laboratories, Deerfield, IL: Personal communication; 1976 Sep 20. 283. Ziembra JL (Medical Information, ICI Pharmaceuticals Group, Wilmington, DE): Personal communication; 1976 Mar 15. 284. Yamaji R, Tsuji A. Comparative stability of cephalosporins in aqueous solution: kinetics and mechanisms of degradation. *J Pharm Sci.* 1976; 65:1563-74. [PubMed 113300] 285. Kleinman LM, Davignon JP, Cradock JC et al. Investigational drug information. *Drug Intell Clin Pharm.* 1976; 10:48-56. 286. Chang SY, Evans LT. The stability of melphalan in the presence of chloride ion. *J Pharm Pharmacol.* 1979; 31:853-4. [PubMed 433721] 287. Mitenko KA, Ogilvie RI. Rationale for the use of theophylline. *N Engl J Med.* 1973; 289:600-3. [PubMed 4723589] 288. Simons FER, Pierson WE. Current status of the use of intravenously administered aminophylline. *South Med J.* 1975; 68:802-4. [PubMed 11540669] 289. Weinberger MW, Matthey RA, Ginchansky EJ et al. Intravenous aminophylline dosage. Use of serum theophylline measurement for guidance. *JAMA.* 1976; 235:2110-3. [PubMed 946537] 290. Nedich RL. Vitamin A absorption from plastic IV bags. *JAMA.* 1973; 224:1531-2. [PubMed 4739965] 291. Kaplan MA, Coppola WP, Nunning BC et al. Pharmaceutical properties and stability of amikacin, part i. *Curr Ther Res Clin Exp.* 1976; 20:352-8. [PubMed 129161] 292. Nunning BC, Granatek AP. Physical compatibility and chemical stability of amikacin sulfate in large-volume parenteral solutions, part ii. *Curr Ther Res Clin Exp.* 1976; 20:359-68. [PubMed 12917] 293. Nunning BC, Granatek AP. Physical compatibility and chemical stability of amikacin sulfate in combination with non-antibiotic drugs in large-volume parenteral solutions, part iv. *Curr Ther Res Clin Exp.* 1976; 20:417-91. [PubMed 12918] 295. Koup JR, Gerbracht L. Reduction in heparin activity by gentamicin. *Drug Intell Clin Pharm.* 1975; 9:568. 296. McKinley JD (M.D. Anderson Hospital and Tumor Institute, Houston, TX): Personal communication; 1976 Aug 23. 297. Weiner B, McNeely DJ, Kluge RM et al. Stability of gentamicin sulfate injection following unit dose repackaging. *Am J Hosp Pharm.* 1977; 33:1254-9. [PubMed 998642] 298. Dinel BA, Ayotte DL, Behme RJ et al. Comparative stability of antibiotic admixtures in minibags and minibottles. *Drug Intell Clin Pharm.* 1977; 11:226-39. [PubMed 10304770] 299. Dinel BA, Ayotte DL, Behme RJ et al. Stability of antibiotic admixtures frozen in minibags. *Drug Intell Clin Pharm.* 1977; 11:542-8. 300. Lynn B. Pharmacuetics of the semi-synthetic penicillins. *Chem Drug.* 1967; 187:157-60. 301. Stanaszek WF, Pan IH. Analysis of hydroxyzine hydrochloride, mepherine hydrochloride and atropine sulfate in glass and plastic syringes. *Am J Hosp Pharm.* 1978; 35:1084-7. [PubMed 29485] 302. Fraser GL. Incompatibility of magnesium sulfate and hydrocortisone sodium succinate. *Am J Hosp Pharm.* 1978; 35:783. [PubMed 665692] 303. Kresel JJ, McDermott SJ, Huffer LM et al. Stability of carbenicillin and oxacillin frozen in syringes. *Am J Hosp Pharm.* 1978; 35:310-2. [PubMed 626211] 304. Manning RE. Predicted expiration times for penicillin G in combination with multivitamin injections. *Am J Hosp Pharm.* 1976; 33:870. [PubMed 984050] 305. Cloyd JC, Bosch DE. Concentration-time profile of phenytoin after admixture with small volumes of intravenous fluids. *Am J Hosp Pharm.* 1978; 35:45-8. [PubMed 623117] 306. Bauman LJ, Siepler JK. Phenytoin crystallization in intravenous fluids. *Drug Intell Clin Pharm.* 1977; 11:646-9. 307. Ashwin J, Lynn B. Ampicillin stability in saline or dextrose infusions. *Pharm J.* 1975; 214:487-9. 308. O'Brien MJ, Poon JF. Cefoxitin sodium compatibility with intravenous infusions and additives. *Am J Hosp Pharm.* 1979; 36:33-8. [PubMed 531790] 309. Stevens JS. Incompatibility of diphenhydramine hydrochloride (Benadryl) with multilume iodiampide (Cholegrafin). *Radiology.* 1975; 117:224-5. [PubMed 1162066] 310. Petrick RJ, Wolleben JE. Stability of frozen solutions of doxycycline hyclate for injection. *Am J Hosp Pharm.* 1978; 35:1386-7. [PubMed 707508] 311. Melberg SG, Havelund S, Villumsen J et al. Insulin compatibility with polymer materials used in external pump infusion systems. *Diabet Med.* 1988; 5:243-7. [PubMed 2967145] 312. Gardella LA, Kesler H, Amann A et al. Intropin (dopamine hydrochloride) intravenous admixture compatibility, part 3: stability with miscellaneous additives. *Am J Hosp Pharm.* 1978; 35:581-4. [PubMed 655182] 313. Schuetz DH, King JC. Compatibility and stability of electrolytes, vitamins and antibiotics in combination with 8% amino acids solution. *Am J Hosp Pharm.* 1978; 35:33-44. [PubMed 623116] 314. El-Nakeeb MA, Souccar N. Inactivation of various antibiotics by some vitamins. *Can J Pharm Sci.* 1976; 11:85-9. 315. Dixon FP, Weshalek J. Physical compatibility of nine drugs in various intravenous solutions. *Am J Hosp Pharm.* 1972; 29:822-3. [PubMed 5075118] 316. Earhart RH. Instability of cis-dichlorodiammineplatinum in dextrose solution. *Cancer Treat Rep.* 1978; 62:1105-6. [PubMed 688249] 317. Greene RF, Chatterji DC, Hiranaka PK et al. Stability of cisplatin in aqueous solution. *Am J Hosp Pharm.* 1979; 36:38-43. [PubMed 758783] 318. Morrison RA, Oseekey KB. 5-Fluorouracil and methotrexate sodium: an admixture? *Am J Hosp Pharm.* 1978; 35:15. [PubMed 623109] 319. King JC. 5-Fluorouracil and methotrexate sodium: an admixture incompatibility? *Am J Hosp Pharm.* 1978; 35:18. [PubMed 623103] 320. Rumsin S, DeLuca P et al. Effect of inline filtration on the potency of drugs administered intravenously. *Am J Hosp Pharm.* 1977; 34:1071-4. [PubMed 920741] 321. Morris ME. Compatibility and stability of diazepam injection following dilution with intravenous fluids. *Am J Hosp Pharm.* 1978; 35:669-72. [PubMed 665679] 322. Allen LV, Levinson RS. Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets. *Am J Hosp Pharm.* 1977; 34:939-43. [PubMed 20779] 323. Arnold TR, Eder J. Compatibility of primary-piggyback solution combinations. *Am J Hosp Pharm.* 1978; 35:249-50. [PubMed 626204] 324. Jansen JR. Volume control sets and incompatibilities. *Am J Hosp Pharm.* 1975; 32:1225. [PubMed 1211393] 325. Aisenstein A, Kahn S. Study of the stability of some frozen antibiotics. *Hosp Pharm.* 1969; 4:17-21. 326. Parker WA. Physical compatibilities of preanesthetic medications. *Can J Hosp Pharm.* 1976; 29:91-2. 327. Cradock JC, Kleinman LM. Evaluation of some pharmaceutical aspects of intrathecal methotrexate sodium, cytarabine and hydrocortisone sodium succinate. *Am J Hosp Pharm.* 1978; 35:402-6. [PubMed 25579] 328. Sarubbi FA, Wilson B, Lee M et al. Nosocomial meningitis and bacteremia due to contaminated amphotericin B. *JAMA.* 1978; 239:416-8. [PubMed 413939] 329. The Upjohn Company. Solu-Medrol IV admixture, dilution, and compatibility information. 1978 Aug. 330. Parker WA, Morris ME. Incompatibility of diazepam injection in plastic intravenous bags. *Am J Hosp Pharm.* 1979; 36:505-7. [PubMed 433936] 331. Ingallinera T, Kapadia AJ, Hagman D et al. Compatibility of glycopyrrolate injection with commonly used infusion solutions and additives. *Am J Hosp Pharm.* 1979; 36:508-10. [PubMed 433937] 332. Bateman NE, Graham MD. Solubility of an ephedrine-phenobarbitone complex in water. *Australas J Pharm.* 1967; 48:568-9. 333. Chang CH, Ashford WR, Ives DAJ et al. Stability of oxytocin in various infusion solutions. *Can J Hosp Pharm.* 1972; 25:152. 334. Lynn B. Administration of carbenicillin and ticarcillin—pharmaceutical aspects. *Eur J Cancer.* 1973; 9:425-33. [PubMed 421701] 336. Gupta VD, Stewart KR. Quantitation of carbenicillin disodium, cefazolin sodium, cephalothin sodium, nafcillin sodium, and ticarcillin disodium by high-pressure liquid chromatography. *J Pharm Sci.* 1980; 69:1264-7. [PubMed 7452453] 337. Anon. Label changes on albumin—a reminder. *FDA Drug Bull.* 1978; 8:32. 338. Knopp DC, Freeman D, Webb D. Stability of ceftriaxone in 5 percent dextrose and 0.9 percent sodium chloride. *Can J Hosp Pharm.* 1993; 46:13-6. 339. Koup JR, Schentag JJ, Vance JW et al. System for clinical pharmacokinetic monitoring of theophylline therapy. *Am J Hosp Pharm.* 1976; 33:949-52. [PubMed 790522] 340. Jusko WJ, Koup JR, Vance JW et al. Intravenous theophylline therapy: nomogram guidelines. *Ann Intern Med.* 1977; 86:400-4. [PubMed 88081] 341. Travenol Laboratories. Product information on Travenol. 1984 Jan. 342. McGraw Laboratories. Product information on FraAmine III. Irvine, CA: 1991 Sep. 343. Odne MAL, Lee SC. Rationale for adding trace elements to total parenteral nutrient solutions—a brief review. *Am J Hosp Pharm.* 1978; 35:1057-9. [PubMed 100008] 344. Jeejeebhoy KN, Langer B, Tsallas G et al. Total parenteral nutrition at home: studies in patients surviving 4 months to 5 years. *Gastroenterology.* 1976; (Dec):943-53. [PubMed 825411] 345. Hull RL, Cassidy D. Trace element deficiencies during total parenteral nutrition. *Drug Intell Clin Pharm.* 1977; 11:536-41. 346. Shils ME. More on trace elements in total parenteral nutrition solutions. *Am J Hosp Pharm.* 1975; 32:141-2. [PubMed 806226] 347. Okada A, Takagi Y, Itakura T et al. Skin lesions during intravenous hyperalimentation: zinc deficiency. *Surgery.* 1976; 80:629-35. [PubMed 824754] 348. Matoi JR, Jeffreys LP. Formulation of a trace element solution for long-term parenteral nutrition. *Am J Hosp Pharm.* 1978; 35:165-8. [PubMed 415604] 349. Athanikar N, Boyer B, Deamer R et al. Visual compatibility of 30 additives with a parenteral nutrient solution. *Am J Hosp Pharm.* 1979; 36:511-3. [PubMed 107797] 350. Finlayson JS. The birth and demise of "salt-poor" albumin. *Am J Hosp Pharm.* 1978; 35:898-900. [PubMed 677130] 351. Wynnnes M, Jeppsson R. Diazepam adsorption to infusion sets and plastic syringes. *Acta Anaesthesiol Scand.* 1981; 25:93-6. [PubMed 7324831] 352. Bonner DP, Mechlinski W, Schaffner CP. Stability studies with amphotericin B and amphotericin B methyl ester. *J Antibiot.* 1975; 20:32-5. [PubMed 1234414] 353. Shadomy S, Brumley DL. Light sensitivity of prepared solutions of amphotericin B. *Am Rev Resp Dis.* 1973; 107:303-4. [PubMed 4683593] 354. Fields BT Jr, Bates JH, Abernathy RS. Effect of rapid intravenous infusion on serum concentrations of amphotericin B. *Appl Microbiol.* 1971; 22:615-7. [PubMed 5130433] [Free Fulltext PMC] 355. Janekngt R, van den Berg T, de Jong M et al. Compatibility study with midazolam. *Ziekenhuisfarmacie.* 1986; 2:45-8. 356. Arbuthnot R, Dullea A. Controlling thrombophlebitis from amphotericin B. *Am J Hosp Pharm.* 1978; 35:129. [PubMed 626193] 357. Rosch JM, Pazin G. Mannitol and amphotericin B. *JAMA.* 1977; 237:27. [PubMed 576127] 358. Moore DE, Sithipitaks V. Photolytic degradation of frusemide. *J Pharm Pharmacol.* 1983; 35:489-93. [PubMed 6137532] 359. Roberts JR. Cutaneous and subcutaneous complications of calcium infusions. *JACEP.* 1977; 6:16-20. [PubMed 830982] 360. Smith Kline & French Laboratories. Product information on Tagamet. Philadelphia, PA: 1978 Oct. 361. Winters RE, Chow AW, Hecht RH et al. Combined use of gentamicin and carbenicillin. *Antimicrob Agents Chemother.* 1976; 9:1004-11. [PubMed 938018] [Free Fulltext PMC] 362. Waitz JA, Druhe CG, Moss EL et al. Biological aspects of the interaction between gentamicin and carbenicillin. *J Antibiot.* 1972; 25:219-25. [PubMed 4626239] 363. Ervin FR, Bullock WE. Inactivation of gentamicin by penicillins in patients with renal failure. *Antimicrob Agents Chemother.* 1976; 10:104-17. [PubMed 938018] [Free Fulltext PMC] 364. Peterson CD, Kaatz BL. Ticarcillin and carbenicillin. *Drug Intell Clin Pharm.* 1977; 11:482-6. 366. Weibert R, Keane W, Shapiro F. Carbenicillin inactivation of aminoglycosides in patients with severe renal failure. *Trans Am Soc Artif Int Organs.* 1976; 22:439-43. 367. Weibert RT, Keane WF. Carbenicillin-gentamicin interaction in acute renal failure. *Am J Hosp Pharm.* 1977; 34:1137-9. [PubMed 920745] 368. Bodey GP, Feld R. B-Lactam antibiotics alone or in combination with gentamicin for therapy of gram-negative bacillary infections in neutropenic patients. *Am J Med Sci.* 1976; 271:179-84. [PubMed 773180] 369. Schimpff S, Satterlee W, Young UM et al. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. *N Engl J Med.* 1971; 284:1061-5. [PubMed 4994878] 370. Hendeles L. Are carbenicillin and gentamicin synergists or antagonists? *Hosp Pharm.* 1972; (Sep):297-8. 371. Kole-James A. Electrolyte content of common intravenous solutions and antibiotics. *Hosp Pharm.* 1977; 12:394. 372. Donnelly RF, Tirona RG. Stability of citrated caffeine injectable solution in glass vials. *Am J Hosp Pharm.* 1994; 51:512-4. [PubMed 8017419] 373. Turco SJ, Hasan I. Comparison of features of Kefzol and Ancef. *Hosp Pharm.* 1976; 11:482-374. 374. Kovich RA. Sugerman AA. Effect of 2% procaine hydrochloride solution on the bioavailability of cephadrine after intramuscular injection. *Curr Ther Res Clin Exp.* 1975; 18:711-9. [PubMed 812649] 375. Stennett DJ, Simonson W. Effect of membrane filtration on 10-mg/ml cefazolin admixtures. *Am J Hosp Pharm.* 1979; 36:657-60. [PubMed 453218] 376. Klink PR, Frable RA, Bornstein M. Stability of mandol in parenteral fluids, frozen solutions and admixtures containing other drugs. Presented at 13th annual ASHP midyear clinical meeting. San Antonio, TX: 1978 Dec. 377. Henney JE, Von Hoff DD, Rozenecwieg M et al. Thrombophlebitic potential of intravenous cytotoxic agents. *Drug Intell Clin Pharm.* 1977; 11:266-7. 378. Sillers BR. Irritant properties of diazepam. *Br Dent J.* 1968; 124:295. [PubMed 5238618] 379. Roche Products Ltd. Irritant properties of diazepam—reply. *Br Dent J.* 1968; 124:295. [PubMed 5238618] 380. Friedenberg W, Barker JD Jr. Intravenous diazepam administration. *JAMA.* 1973; 224:901-2. [PubMed 4739691] 381. Jusko WJ, Gretch M, Gassett R. Precipitation of diazepam from intravenous preparations. *JAMA.* 1973; 225:176. 382. Kortilla K, Sothman A. Polyethylene glycol as a solvent for diazepam: bioavailability and clinical effects after intramuscular administration, comparison of oral, intramuscular and rectal administration, and precipitation from intravenous solutions. *Acta Pharmacol Toxicol (Copenh).* 1976; 39:104-17. [PubMed 782123] 383. Hillelson DE, Weissman H. Serum concentrations and clinical effects after intravenous, intramuscular and oral administration. *Clin Pharmacol Ther.* 1974; 16:479-84. [PubMed 4412803] 384. Assaf RA, Dundee JW, Gamble JA. The influence of the route of administration on the clinical action of diazepam. *Anaesthesia.* 1975; 30:152-8. [PubMed 1093426] 385. Baxter MT, McKenzie DD. Dilution of diazepam in intravenous fluids. *Am J Hosp Pharm.* 1977; 34:124. [PubMed 842538] 386. Thong YH, Abramson DC. Continuous infusion of diazepam in infants with severe recurrent convulsions. *Med Ann DC.* 1974; 43:63-5. [PubMed 4521743] 387. Khalid MS, Schultz H. Treatment and management of emergency status epilepticus. *Epilepsia.* 1976; 17:73-6. [PubMed 817894] 389. Kawathekar P, Anusuya SR, Srinivas P et al. Diazepam (Calmpose) in eclampsia: a preliminary report of 16 cases. *Curr Ther Res Clin Exp.* 1973; 15:845-55. [PubMed 4201598] 391. Prensly AL, Raff MC, Moore MJ et al. Intravenous diazepam in the treatment of prolonged seizure activity. *N Engl J Med.* 1967; 276:779-84. [PubMed 4960697] 392. Tehrani JB, Cavanaugh A. Diazepam infusion in the treatment of tetanus. *Drug Intell Clin Pharm.* 1977; 11:491. 393. McLean WN. Safety of diazepam infusion questioned. *Drug Intell Clin Pharm.* 1977; 11:690. 394. Trissel LA, Kleinman LM, Davignon JP et al. Investigational drug information—daunorubicin hydrochloride and streptozotocin. *Drug Intell Clin Pharm.* 1978; 12:404-6. 395. Elsberry VA, Grangeia JM, Giorgianni SJ et al. The lipid phase in TPN. *Am J IV Ther.* 1977; 4:22-8. 396. Belin RP, Bivins BA, Jona JZ et al. Fat overload with a 10% soybean oil emulsion. *Arch Surg.* 1976; 111:391-3. [PubMed 826237] 397. McNiff BL. Clinical use of 10% soybean oil emulsion. *Am J Hosp Pharm.* 1977; 34:1080-6. [PubMed 411372] 398. Roche Laboratories, Nutley, NJ: Personal communication. 399. McGaw Laboratories. McGaw compatibility studies: a preliminary report. Irvine, CA: 1978. 400. Bundgaard H, Norgaard T, Nielsen NM. Photodegradation and hydrolysis of furosemide and furosemide esters in aqueous solutions. *Int J Pharm.* 1988; 42:217-24. 401. Kresel JJ, Smith AL. Stability of gentamicin in plastic syringes. *Am J Hosp Pharm.* 1977; 34:570. [PubMed 879174] 402. McNeely DJ, Weiner B, Stewart RB et al. Stability of gentamicin in plastic syringes. *Am J Hosp Pharm.* 1977; 34:570. [PubMed 879174] 403. Chrai SS, Ambrosio TJ. Gentamicin sulfate injection repackaging in syringes. *Am J Hosp Pharm.* 1977; 34:920. [PubMed 920741] 404. McNeely DJ, Weiner B, Stewart RB et al. Stability of gentamicin in plastic syringes. *Am J Hosp Pharm.* 1977; 34:570. [PubMed 879174] 405. Scharf C, Cupti G. Concentration of heparin in heparin locks. *Drug Intell Clin Pharm.* 1977; 11:646-9. 307. Ashwin J, Lynn B. Ampicillin stability in saline or dextrose infusions. *Pharm J.* 1975; 214:487-9. 308. O'Brien MJ, Poon JF. Cefoxitin sodium compatibility with intravenous infusions and additives. *Am J Hosp Pharm.* 1979; 36:33-8. [PubMed 531790] 309. Stevens JS. Incompatibility of diphenhydramine hydrochloride (Benadryl) with multilume iodiampide (Cholegrafin). *Radiology.* 1975; 117:224-5. [PubMed 1162066] 310. Petrick RJ, Wolleben JE. Stability of frozen solutions of doxycycline hyclate for injection. *Am J Hosp Pharm.* 1978; 35:1386-7. [PubMed 707508] 311. Melberg SG, Havelund S, Villumsen J et al. Insulin compatibility with polymer materials used in external pump infusion systems. *Diabet Med.* 1988; 5:243-7. [PubMed 2967145] 312. Gardella LA, Kesler H, Amann A et al. Intropin (dopamine hydrochloride) intravenous admixture compatibility, part 3: stability with miscellaneous additives. *Am J Hosp Pharm.* 1978; 35:581-4. [PubMed 655182] 313. Schuetz DH, King JC. Compatibility and stability of electrolytes, vitamins and antibiotics in combination with 8% amino acids solution. *Am J Hosp Pharm.* 1978; 35:33-44. [PubMed 623116] 314. El-Nakeeb MA, Souccar N. Inactivation of various antibiotics by some vitamins. *Can J Pharm Sci.* 1976; 11:85-9. 315. Dixon FP, Weshalek J. Physical compatibility of nine drugs in various intravenous solutions. *Am J Hosp Pharm.* 1972; 29:822-3. [PubMed 5075118] 316. Earhart RH. Instability of cis-dichlorodiammineplatinum in dextrose solution. *Cancer Treat Rep.* 1978; 62:1105-6. [PubMed 688249] 317. Greene RF, Chatterji DC, Hiranaka PK et al. Stability of cisplatin in aqueous solution. *Am J Hosp Pharm.* 1979; 36:38-43. [PubMed 758783] 318. Morrison RA, Oseekey KB. 5-Fluorouracil and methotrexate sodium: an admixture? *Am J Hosp Pharm.* 1978; 35:15. [PubMed 623109] 319. King JC. 5-Fluorouracil and methotrexate sodium: an admixture incompatibility? *Am J Hosp Pharm.* 1978; 35:18. [PubMed 623103] 320. Rumsin S, DeLuca P et al. Effect of inline filtration on the potency of drugs administered intravenously. *Am J Hosp Pharm.* 1977; 34:1071-4. [PubMed 920741] 321. Morris ME. Compatibility and stability of diazepam injection following dilution with intravenous fluids. *Am J Hosp Pharm.* 1978; 35:669-72. [PubMed 665679] 322. Allen LV, Levinson RS. Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets. *Am J Hosp Pharm.* 1977; 34:939-43. [PubMed 20779] 323. Arnold TR, Eder J. Compatibility of primary-piggyback solution combinations. *Am J Hosp Pharm.* 1978; 35:249-50. [PubMed 626204] 324. Jansen JR. Volume control sets and incompatibilities. *Am J Hosp Pharm.* 1975; 32:1225. [PubMed 1211393] 325. Aisenstein A, Kahn S. Study of the stability of some frozen antibiotics. *Hosp Pharm.* 1969; 4:17-21. 326. Parker WA. Physical compatibilities of preanesthetic medications. *Can J Hosp Pharm.* 1976; 29:91-2. 327. Cradock JC, Kleinman LM. Evaluation of some pharmaceutical aspects of intrathecal methotrexate sodium, cytarabine and hydrocortisone sodium succinate. *Am J Hosp Pharm.* 1978; 35:402-6. [PubMed 25579] 328. Sarubbi FA, Wilson B, Lee M et al. Nosocomial meningitis and bacteremia due to contaminated amphotericin B. *JAMA.* 1978; 239:416-8. [PubMed 413939] 329. The Upjohn Company. Solu-Medrol IV admixture, dilution, and compatibility information. 1978 Aug. 330. Parker WA, Morris ME. Incompatibility of diazepam injection in plastic intravenous bags. *Am J Hosp Pharm.* 1979; 36:505-7. [PubMed 433936] 331. Ingallinera T, Kapadia AJ, Hagman D et al. Compatibility of glycopyrrolate injection with commonly used infusion solutions and additives. *Am J Hosp Pharm.* 1979; 36:508-10. [PubMed 433937] 332. Bateman NE, Graham MD. Solubility of an ephedrine-phenobarbitone complex in water. *Australas J Pharm.* 1967; 48:568-9. 333. Chang CH, Ashford WR, Ives DAJ et al. Stability of oxytocin in various infusion solutions. *Can J Hosp Pharm.* 1972; 25:152. 334. Lynn B. Administration of carbenicillin and ticarcillin—pharmaceutical aspects. *Eur J Cancer.* 1973; 9:425-33. [PubMed 421701] 336. Gupta VD, Stewart KR. Quantitation of carbenicillin disodium, cefazolin sodium, cephalothin sodium, nafcillin sodium, and ticarcillin disodium by high-pressure liquid chromatography. *J Pharm Sci.* 1980; 69:1264-7. [PubMed 7452453] 337. Anon. Label changes on albumin—a reminder. *FDA Drug Bull.* 1978; 8:32. 338. Knopp DC, Freeman D, Webb D. Stability of ceftriaxone in 5 percent dextrose and 0.9 percent sodium chloride. *Can J Hosp Pharm.* 1993; 46:13-6. 339. Koup JR, Schentag JJ, Vance JW et al. System for clinical pharmacokinetic monitoring of theophylline therapy. *Am J Hosp Pharm.* 1976; 33:949-52. [PubMed 790522] 340. Jusko WJ, Koup JR, Vance JW et al. Intravenous theophylline therapy: nomogram guidelines. *Ann Intern Med.* 1977; 86:400-4. [PubMed 88081] 341. Travenol Laboratories. Product information on Travenol. 1984 Jan. 342. McGraw Laboratories. Product information on FraAmine III. Irvine, CA: 1991 Sep. 343. Odne MAL, Lee SC. Rationale for adding trace elements to total parenteral nutrient solutions—a brief review. *Am J Hosp Pharm.* 1978; 35:1057-9. [PubMed 100008] 344. Jeejeebhoy KN, Langer B, Tsallas G et al. Total parenteral nutrition at home: studies in patients surviving 4 months to 5 years. *Gastroenterology.* 1976; (Dec):943-53. [PubMed 825411] 345. Hull RL, Cassidy D. Trace element deficiencies during total parenteral nutrition. *Drug Intell Clin Pharm.* 1977; 11:536-41. 346. Shils ME. More on trace elements in total parenteral nutrition solutions. *Am J Hosp Pharm.* 1975; 32:141-2. [PubMed 806226] 347. Okada A, Takagi Y, Itakura T et al. Skin lesions during intravenous hyperalimentation: zinc deficiency. *Surgery.* 1976; 80:629-35. [PubMed 824754] 348. Matoi JR, Jeffreys LP. Formulation of a trace element solution for long-term parenteral nutrition. *Am J Hosp Pharm.* 1978; 35:165-8. [PubMed 415604] 349. Athanikar N, Boyer B, Deamer R et al. Visual compatibility of 30 additives with a parenteral nutrient solution. *Am J Hosp Pharm.* 1979; 36:511-3. [PubMed 107797] 350. Finlayson JS. The birth and demise of "salt-poor" albumin. *Am J Hosp Pharm.* 1978; 35:898-900. [PubMed 677130] 351. Wynnnes M, Jeppsson R. Diazepam adsorption to infusion sets and plastic syringes. *Acta Anaesthesiol Scand.* 1981; 25:93-6. [PubMed 7324831] 352. Bonner DP, Mechlinski W, Schaffner CP. Stability studies with amphotericin B and amphotericin B methyl ester. *J Antibiot.* 1975; 20:32-5. [PubMed 1234414] 353. Shadomy S, Brumley DL. Light sensitivity of prepared solutions of amphotericin B. *Am Rev Resp Dis.* 1973; 107:303-4. [PubMed 4683593] 354. Fields BT Jr, Bates JH, Abernathy RS. Effect of rapid intravenous infusion on serum concentrations of amphotericin B. *Appl Microbiol.* 1971; 22:615-7. [PubMed 5130433] [Free Fulltext PMC] 355. Janekngt R, van den Berg T, de Jong M et al. Compatibility study with midazolam. *Ziekenhuisfarmacie.* 1986; 2:45-8. 356. Arbuthnot R, Dullea A. Controlling thrombophlebitis from amphotericin B. *Am J Hosp Pharm.* 1978; 35:129. [PubMed 626193] 357. Rosch JM, Pazin G. Mannitol and amphotericin B. *JAMA.* 1977; 237:27. [PubMed 576127] 358. Moore DE, Sithipitaks V. Photolytic degradation of frusemide. *J Pharm Pharmacol.* 1983; 35:489-93. [PubMed 6137532] 359. Roberts JR. Cutaneous and subcutaneous complications of calcium infusions. *JACEP.* 1977; 6:16-20. [PubMed 830982] 360. Smith Kline & French Laboratories. Product information on Tagamet. Philadelphia, PA: 1978 Oct. 361. Winters RE, Chow AW, Hecht RH et al. Combined use of gentamicin and carbenicillin. *Antimicrob Agents Chemother.* 1976; 9:1004-11. [PubMed 938018] [Free Fulltext PMC] 362. Waitz JA, Druhe CG, Moss EL et al. Biological aspects of the interaction between gentamicin and carbenicillin. *J Antibiot.* 1972; 25:219-25. [PubMed 4626239] 363. Ervin FR, Bullock WE. Inactivation of gentamicin by penicillins in patients with renal failure. *Antimicrob Agents Chemother.* 1976; 10:104-17. [PubMed 938018] [Free Fulltext PMC] 364. Peterson CD, Kaatz BL. Ticarcillin and carbenicillin. *Drug Intell Clin Pharm.* 1977; 11:482-6. 366. Weibert R, Keane W, Shapiro F. Carbenicillin inactivation of aminoglycosides in patients with severe renal failure. *Trans Am Soc Artif Int Organs.* 1976; 22:439-43. 367. Weibert RT, Keane WF. Carbenicillin-gentamicin interaction in acute renal failure. *Am J Hosp Pharm.* 1977; 34:1137-9. [PubMed 920745] 368. Bodey GP, Feld R. B-Lactam antibiotics alone or in combination with gentamicin for therapy of gram-negative bacillary infections in neutropenic patients. *Am J Med Sci.* 1976; 271:179-84. [PubMed 773180] 369. Schimpff S, Satterlee W, Young UM et al. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. *N Engl J Med.* 1971; 284:1061-5. [PubMed 4994878] 370. Hendeles L. Are carbenicillin and gentamicin synergists or antagonists? *Hosp Pharm.* 1972; (Sep):297-8. 371. Kole-James A. Electrolyte content of common intravenous solutions and antibiotics. *Hosp Pharm.* 1977; 12:394. 372. Donnelly RF, Tirona RG. Stability of citrated caffeine injectable solution in glass vials. *Am J Hosp Pharm.* 1994; 51:512-4. [PubMed 8017419] 373. Turco SJ, Hasan I. Comparison of features of Kefzol and Ancef. *Hosp Pharm.* 1976; 11:482-374. 374. Kovich RA, Sugerman AA. Effect of 2% procaine hydrochloride solution on the bioavailability of cephadrine after intramuscular injection. *Curr Ther Res Clin Exp.* 1975; 18:711-9. [PubMed 812649] 375. Stennett DJ, Simonson W. Effect of membrane filtration on 10-mg/ml cefazolin admixtures. *Am J Hosp Pharm.* 1979; 36:657-60. [PubMed 453218] 376. Klink PR, Frable RA, Bornstein M. Stability of mandol in parenteral fluids, frozen solutions and admixtures containing other drugs. Presented at 13th annual ASHP midyear clinical meeting. San Antonio, TX: 1978 Dec. 377. Henney JE, Von Hoff DD, Rozenecwieg M et al. Thrombophlebitic potential of intravenous cytotoxic agents. *Drug Intell Clin Pharm.* 1977; 11:266-7. 378. Sillers BR. Irritant properties of diazepam. *Br Dent J.* 1968; 124:295. [PubMed 5238618] 379. Roche Products Ltd. Irritant properties of diazepam—reply. *Br Dent J.* 1968; 124:295. [PubMed 5238618] 380. Friedenberg W, Barker JD Jr. Intravenous diazepam administration. *JAMA.* 1973; 224:901-2. [PubMed 4739691] 381. Jusko WJ, Gretch M, Gassett R. Precipitation of diazepam from intravenous preparations. *JAMA.* 1973; 225:176. 382. Kortilla K, Sothman A. Polyethylene glycol as a solvent for diazepam: bioavailability and clinical effects after intramuscular administration, comparison of oral, intramuscular and rectal administration, and precipitation from intravenous solutions. *Acta Pharmacol Toxicol (Copenh).* 1976; 39:104-17. [PubMed 782123] 383. Hillelson DE, Weissman H. Serum concentrations and clinical effects after intravenous, intramuscular and oral administration. *Clin Pharmacol Ther.* 1974; 16:479-84. [PubMed 4412803] 384. Assaf RA, Dundee JW, Gamble JA. The influence of the route of administration on the clinical action of diazepam. *Anaesthesia.* 1975; 30:152-8. [PubMed 1093426] 385. Baxter MT, McKenzie DD. Dilution of diazepam in intravenous fluids. *Am J Hosp Pharm.* 1977; 34:124. [PubMed 842538] 386. Thong YH, Abramson DC. Continuous infusion of diazepam in infants with severe recurrent convulsions. *Med Ann DC.* 1974; 43:63-5. [PubMed 4521743] 387. Khalid MS, Schultz H. Treatment and management of emergency status epilepticus. *Epilepsia.* 1976; 17:73-6. [PubMed 817894] 389. Kawathekar P, Anusuya SR, Srinivas P et al. Diazepam (Calmpose) in eclampsia: a preliminary report of 16 cases. *Curr Ther Res Clin Exp.* 1973; 15:845-55. [PubMed 4201598] 391. Prensly AL, Raff MC, Moore MJ et al. Intravenous diazepam in the treatment of prolonged seizure activity. *N Engl J Med.* 1967; 276:779-84. [PubMed 4960697] 392. Tehrani JB, Cavanaugh A. Diazepam infusion in the treatment of tetanus. *Drug Intell Clin Pharm.* 1977; 11:491. 393. McLean WN. Safety of diazepam infusion questioned.

1984; 37:137-9. [PubMed 10269318] 612. Stewart P, Lourwood D. Guidelines for the administration of a phenytoin loading dose via IVPB. *Hosp Pharm*. 1986; 21:1003-4. 613.

Goldschmid S. An evaluation of the stability and safety of phenytoin infusion. *NY State J Pharm*. 1987; 7:45-7. 614. Kradjan WA, Burger R. In vivo inactivation of gentamicin by carbenicillin and ticarcillin. *Arch Intern Med*. 1980; 140:1668-70. [PubMed 7458498] 615. Young LS, Decker G. Inactivation of gentamicin by carbenicillin in the urinary tract. *Chemotherapy*. 1974; 20:212-20. [PubMed 4413818] 616. Henderson JL, Polk RE. In vitro inactivation of gentamicin, tobramycin, and netilmicin by carbenicillin, azlocillin, or mezlocillin. *Am J Hosp Pharm*. 1981; 38:1167-70. [PubMed 6455916] 617. Flournoy DJ. Inactivation of netilmicin by carbenicillin. *Infection*. 1978; 6:241. [PubMed 730393] 618. Russo ME. Penicillin-aminoglycoside inactivation: another possible mechanism of interaction. *Am J Hosp Pharm*. 1980; 37:702-4. [PubMed 7386483] 619. Laskar PA, Ayres JW. Degradation of carmustine in aqueous media. *J Pharm Sci*. 1977; 66:1073-6. [PubMed 19612] 620. Cardi V, Wilcox GS. Reconstituting cefamandole and protecting from light. *Am J Hosp Pharm*. 1980; 37:334. [PubMed 7369213] 621. Kaiser GV, Gorman M. Cefamandole—a review of chemistry and microbiology. *J Infect Dis*. 1978; 137:510-516. [PubMed 565798] 622. Wold JS, Joost RR, Black HR et al. Hydrolysis of cefamandole nafate to cefamandole in vivo. *J Infect Dis*.

1980; 137:510-516. [PubMed 565798] 623. Palmer MA, Frateropio CC. Clarification of "explosive-like" reaction occurring when reconstituted cefamandole nafate was stored in syringes. *Am J Hosp Pharm*. 1979; 36:1025. [PubMed 484557] 624. Fites AL. Reconstituting cefamandole and protecting from light. *Am J Hosp Pharm*. 1980; 37:334. [PubMed 7369213] 625. Foster TS, Shrewsbury RF, Coonrod JD. Bioavailability and pain study of cefamandole nafate. *J Clin Pharmacol*. 1980; 20:526-33. [PubMed 7000857] 626. Indelicato JM, Stewart BA. Formylation of glucose by cefamandole nafate at alkaline pH. *J Pharm Sci*. 1980; 69:1183-8. [PubMed 7420288] 627. Tomecko GW, Kleinberg ML, Latolaia CL et al. Stability of cefazolin sodium admixtures in plastic bags after thawing by microwave radiation. *Am J Hosp Pharm*. 1980; 37:211-5. [PubMed 7361792] 628. Janousek JP, Minisci MP. An evaluation of cefazolin sodium injection in an IV piggyback bottle. *Infection*. 1978; 2:67-73. 629. Stiles ML. Effect of microwave radiation on the stability of frozen cefotaxim sodium solution in plastic bags. *Am J Hosp Pharm*. 1981; 38:1743-5. [PubMed 7304629] 630. Oberholzer ER, Brenner GS. Cefotaxim sodium: solution and solid state chemical stability studies. *J Pharm Sci*. 1979; 68:863-6. [PubMed 458604] 631. Bray RJ, Davies PA. The stability of preservative-free morphine in plastic syringes. *Anaesthesia*. 1986; 41:294-5. [PubMed 3963333] 632. Walker SE, Paton TW, Fabian TM et al. Stability and sterility of cimetidine admixtures frozen in minibags. *Am J Hosp Pharm*. 1981; 38:881-3. [PubMed 7246565] 633. Cohen MR. Error 148—More on cisplatin solution. *Hosp Pharm*. 1980; 15:158-9. 634. LeRoy AF. Some quantitative data on cis-dichlorodiamminoplatinum (II) species in solution. *Cancer Treat Rep*. 1979; 63:231-3. [PubMed 362628] 635. Hincal AP, Long DF. Cis-platin stability in aqueous parenteral vehicles. *J Parenter Drug Assoc*. 1979; 33:107-16. [PubMed 256991] 636. Mariani EP, Southard BJ, Woevelier JT, et al. Physical compatibility and chemical stability of cisplatin in various diluents and in large-volume parenteral solutions. In: *Cisplatin current status and new developments*. New York, NY: Academic Press; 1980:305-16. 637. Repta AJ, Long DF. cis-Dichlorodiamminoplatinum (II) stability in aqueous vehicles. *Cancer Treat Rep*. 1979; 63:231-3. [PubMed 44101] 638. Gamble JA, Dunne IV, Assal RA. Plasma diazepam levels after single dose oral and intramuscular administration. *Anaesthesia*. 1975; 30:164-9. [PubMed 1093427] 639. Langdon DE, Harlan JR, Bailey RL. Thrombophlebitis with diazepam used intravenously. *JAMA*. 1973; 223:184-5. [PubMed 4569819] 640. Dam M, Christiansen J. Diazepam: intravenous infusion in the treatment of status epilepticus. *Acta Neurol Scand*. 1976; 54:278-80. [PubMed 961379] 641.

Huber JW, Raymond GG. Additional conclusions on diazepam injectable precipitate: GC-MS confirmation. *Clin Toxicol*. 1979; 14:439-44. [PubMed 466985] 642.

Raymond G, Huber JW. Identification of injectable Valium precipitate. *Drug Intell Clin Pharm*. 1979; 13:612. 643. Newton DW, Driscoll DF, Goudreau JL, et al. Solubility characteristics of diazepam in aqueous admixture solutions: theory and practice. *Am J Hosp Pharm*. 1981; 38:179-82. [PubMed 7211883] 644. Mason NA, Cline S, Hyneck ML et al. Factors affecting diazepam infusion: solubility, administration-set composition, and flow rate. *Am J Hosp Pharm*. 1981; 38:1449-54. [PubMed 7294034] 645. MacKichan J, Duffner PK. Adsorption of diazepam to plastic tubing. *N Engl J Med*. 1979; 301:332-3. [PubMed 450030] 646. Parker WA, MacCara ME. Compatibility of diazepam with intravenous fluid containers and administration sets. *Am J Hosp Pharm*. 1980; 37:496-500. [PubMed 7377212] 647. Cloyd JC, Vezeau C. Availability of diazepam from plastic containers. *Am J Hosp Pharm*. 1980; 37:492-6. [PubMed 7377211] 648. Cloyd JC. Diluting diazepam injection. *Am J Hosp Pharm*. 1981; 38:32. 649. Dasta JF, Brier K. Loss of diazepam to drug delivery systems. *Am J Hosp Pharm*. 1980; 37:1176. [PubMed 7416168] 650. Boatman JA, Johnson JB. A four-stage approach to new-drug development. *Pharm Tech*. 1981; 5:46-56. 651. Martin CM. Chemical incompatibility of Renografin 76 and protamine sulfate. *Am Heart J*. 1976; 91:675-7. [PubMed 1266726] 652. Hoffman DM, Grossano DD, Danin I, et al. Stability of refrigerated and frozen solutions of doxorubicin hydrochloride. *Am J Hosp Pharm*. 1979; 36:1536-8. [PubMed 517541] 653. Gardiner WA. Possible incompatibility of doxorubicin hydrochloride with aluminum. *Am J Hosp Pharm*. 1981; 38:1276. [PubMed 7282707] 654. Pfaller MA, Granich GS, Valdes R et al. Comparative study of the ability of four aminoglycoside assay techniques to detect the inactivation of aminoglycosides by beta-lactam antibiotics. *Diagn Microbiol Infect Dis*. 1984; 2:93-100. [PubMed 6370573] 655. Hospira Inc. Product information on Liposyn III 10%, 20%, and 30%. Lake Forest, IL; 2005 AUG/SEP. 656. Black CD, Popovich NG. Study of intravenous emulsion compatibility: effects of dextrose, amino acids and selected electrolytes. *Drug Intell Clin Pharm*. 1981; 15:184-93. [PubMed 7274033] 657. Black CD, Popovich NG. Comment on intravenous emulsion compatibility. *Drug Intell Clin Pharm*. 1981; 15:908-9. [PubMed 7297424] 658. Pelham LD. Rational use of intravenous fat emulsions. *Am J Hosp Pharm*. 1981; 38:198-208. [PubMed 6782871] 659. Solussol C. Long-term parenteral nutrition: an artificial gut. *Int Surg*. 1976; 61:266-70. [PubMed 819387] 660. Wretling A. Current status of intralipid and other fat emulsions. In: *Fat emulsion in parenteral nutrition*. Chicago, IL: American Medical Association; 1975:109-19. 661. Higbee KC, Lamy PP. Use of Intralipid in neonates and infants. *Hosp Formul*. (Feb) 1980; 15:117-9, 122, 127. 662. Kleinberg ML, Stauffer GL. Effect of microwave radiation on redissolving precipitated matter in fluorouracil injection. *Am J Hosp Pharm*. 1980; 37:678-9. [PubMed 7386478] 663. Driessen O, deVos T. Adsorption of fluorouracil on glass. *J Pharm Sci*. 1978; 67:1494-5. [PubMed 702318] 664. Ghanekar AG, Das Gupta V. Stability of furosemide in aqueous systems. *J Pharm Sci*. 1978; 67:808-11. [PubMed 660463] 665. McLaughlin JE, Reeves DS. Gentamicin plus carbenicillin. *Lancet*. 1971; 1:868-9. [PubMed 410217] 666. Young LS, Walker G. Inactivation of gentamicin by carbenicillin in the urinary tract. *Chemotherapy*. 1974; 20:212-20. [PubMed 4413818] 667. Murillo J, Standiford HC, Schimpff SC et al. Gentamicin and ticarcillin serum levels. *JAMA*. 1979; 241:2401-3. [PubMed 439317] 668. Storey P, Hill HH, St. Louis RH, et al. Sustained control of cancer pain with TPN. *Am J Hosp Pharm*. 1980; 37:533-41. 669. Edwards ND, Fletcher A, Cole JR et al. Combined infusions of morphine and ketamine for postoperative pain in elderly patients. *Anaesthesia*. 1993; 48:124-7. [PubMed 8460758] 670. Dornarum CG (Associate Medical Information Scientist, Medical and Drug Information, Pharmacia Corp., Kalamazoo, MI). Personal communication; 2002 Mar 21. 671. Liles S (Department of Pharmacy, Christ Hospital, Cincinnati, OH). Personal communication; 2002 Feb 20. 672. Hayes DM, Reilly RM. The pharmaceutical stability of deferaxamine mesylate. *Can J Hosp Pharm*. 1994; 47:9-14. 673. Downie G, McRae N. Leaching of plasticizers by fat emulsion from polyvinyl chloride. *Br J Parenter Ther*. 1985; 6:162-4. 674. Anderson W, Harthill JE, Couper IA et al. Heparin stability in dextrose solutions [proceedings]. *J Pharm Pharmacol*. 1977; 29:31P. [PubMed 22661] 675. Bowie HM, Haylor V. Stability of heparin in sodium chloride solution. *J Clin Pharm*. 1978; 3:211-4. 676.

Tunbridge LJ, Lloyd JV, Penhall RK et al. Stability of diluted heparin sodium stored in plastic syringes. *Am J Hosp Pharm*. 1981; 38:1001-4. [PubMed 7258195] 677. Deeb EN, DiMattia PE. Standardization of heparin-locks maintenance solution. *N Engl J Med*. 1976; 294:448. [PubMed 1246325] 678. Holford NHG, Vozeh S, Coates P et al. More on heparin-locks. *N Engl J Med*. 1977; 296:1300-1. [PubMed 859528] 679. Lynch CL, Linder GE. Frequently asked questions about insulin. *Hosp Pharm*. 1980; 15:213-4. 680. Graham DT, Pomeroy AR. Effects of freezing on commercial insulin suspensions. *Int J Pharm*. 1978; 1:315-22. 681. Hill JB. Adsorption of insulin to glass. *Proc Soc Exp Biol Med*. 1959; 65:515. [PubMed 1385237] 682. Wiseman R, Baltz BE. Prevention of insulin-1131 adsorption to glass. *Endocrinology*. 1961; 68:354-6. [PubMed 13786004] 684. Sonksen PH, Ellis JP, Lowy C et al. Quantitative evaluation of the relative efficiency of gelatine and albumin in preventing insulin adsorption to glass. *Diabetologia*. 1965; 1:208-10. 685. Suess V, Froesch ER. Zur therapie des coma diabeticum: quantitative bedeutung des insulinverlusts am infusionsbesteck. *Schweizer Med Wochenschr*. 1975; 105:1315-8. 686. Okamoto H, Kikuchi T. Adsorption of insulin to infusion bottles and plastic intravenous tubing. *Yakuzaigaku*. 1979; 39:107-11. 687. Wingert TD, Levin SR. Insulin adsorption to an air-eliminating inline filter. *Am J Hosp Pharm*. 1981; 38:382-3. [PubMed 7013477] 688. Hirsch JP, Wood HJ. Insulin adsorption to polyolefin infusion bottles and polyvinyl chloride administration sets. *Am J Hosp Pharm*. 1981; 38:995-7. [PubMed 7020415] 689. Kerchner J, Coculaci DM. Effect of whole blood on insulin adsorption onto intravenous infusion systems. *Am J Hosp Pharm*. 1980; 37:1323-5. [PubMed 6998986] 690. Galloway JA, Bressler R. Insulin treatment in diabetes. *Med Clin N Am*. 1978; 62:663-80. [PubMed 98674] 691. Anon. Letter: Carrier solutions for low-level intravenous insulin infusion. *Br Med J*. 1976; 1:151-2. 692. Wan KK, Tsailias G. Dilute iron dextran formulation for addition to parenteral nutrient solutions. *Am J Hosp Pharm*. 1980; 37:206-10. [PubMed 6767401] 693. Bornstein M, Lo AY, Thomas PN et al. Moxalactam disodium compatibility with intramuscular and intravenous diluents. *Am J Hosp Pharm*. 1982; 39:1495-8. [PubMed 6215859] 694. Kleinberg ML, Latolaia CJ. Use of a microwave oven to redissolve crystallized mannitol injection (25%) in ampuls. *Hosp Pharm*. 1979; 14:391-2. 695.

Hanson GG. Microwave oven explosion. *Hosp Pharm*. 1979; 14:612. 696. Kleinberg ML, Latolaia CJ. Microwave oven explosion. *Hosp Pharm*. 1979; 14:612. 697. Kana MJ. Microwave oven explosion. *Hosp Pharm*. 1980; 15:694. 698. Post RE, Stephen SP. A warming cabinet for storing mannitol ampuls. *Hosp Pharm*. 1975; 10:102-3. [PubMed 10237869] 699. Scott KR, Bell AF, Thomas AJ. Warming kettle for storing mannitol injection. *Am J Hosp Pharm*. 1980; 37:16. 700. Herring P. Keeping mannitol in solution. *Hosp Pharm*. 1980; 15:530-1. 702. Townsend RJ, Puchala AH. Stability of methylprednisolone sodium succinate in small volumes of 5% dextrose and 0.9% sodium chloride injections. *Am J Hosp Pharm*. 1981; 38:1319-22. [PubMed 7025616] 703. Knutsen CV, Epps DR, McCormick DC et al. Total nutrient admixture guidelines. *Drug Intell Clin Pharm*. 1984; 18:253-4. [PubMed 6421559] 704. Ruggle MA, Brandt RB. Decomposition of TPN solutions. *J Pediatr*. 1982; 100:670. [PubMed 7062224] 705. Krumholz H, Garguilo M, Al. Stability of total parenteral nutrition (TPN) solutions. *J Parenter Enter Nutr*. 1980; 4:101-2. [PubMed 6823978] 706. Kowalik EA. Plastic syringes and intravenous infusions. *Med J Aust*. 1982; 186:102-3. [PubMed 6823978] 707. Little GB, Boylston JC. I.V. Flagyl reacts with aluminum. *Hosp Pharm*. 1981; 16:627. 708. Carmichael RR, Mahoney CD. Solubility and stability of phenytoin sodium when mixed with intravenous solutions. *Am J Hosp Pharm*. 1980; 37:95-8. [PubMed 7361779] 709. Salem RB, Yost RL, Torosian G et al. Investigation of the crystallization of phenytoin in normal saline. *Drug Intell Clin Pharm*. 1980; 14:605-8. 710. Pfeifle CE, Adler DS. Phenytoin sodium solubility in three intravenous solutions. *Am J Hosp Pharm*. 1981; 38:358-2. [PubMed 7223749] 712. Gupta VD, Stewart KR. Stability of cefuroxime sodium in some aqueous buffered solutions and intravenous admixtures. *J Clin Hosp Pharm*. 1986; 11:47-54. [PubMed 3958213] 713. Newton DW, Kluz RB. Prediction of phenytoin solubility in intravenous admixtures: physicochemical theory. *Am J Hosp Pharm*. 1980; 37:1647-51. [PubMed 7446539] 714. Cohen MR. Make sure your nurses mix drug additions to infusing I.V. solutions. *Hosp Pharm*. 1981; 16:164. 715. Schuna A, Nappi J, Kolstad J. Potassium pooling in non-rigid parenteral fluid containers. *J Parenter Drug Assoc*. 1979; 33:184-6. [PubMed 260935] 716. McCloskey WV, Jeffrey LP. Rational ordering of phosphatidyl supplements. *Hosp Pharm*. 1979; 14:486-7. 717. Herman JH. Phosphate: its valence and methods of quantification in parenteral solutions. *Drug Intell Clin Pharm*. 1979; 13:579-85. 718. Benderer K. Hypophosphatemia and phosphorus supplementation. *Hosp Pharm*. 1980; 15:611-3. 719. Swerling R. Use and preparation of cardioplegic solutions in cardiac surgery. *Hosp Pharm*. 1980; 15:497-503. 720. Loucas SP, Mehl B, Maager P et al. Stability of procaine HCl in a buffered cardioplegia formulation. *Am J Hosp Pharm*. 1981; 38:1924-8. [PubMed 7325175] 721. Amann AH, Baaske DM. Plastic iv. container for nitroglycerin. *Am J Hosp Pharm*. 1980; 37:618. [PubMed 6770680] 722. Cacace LG, Harralson A, Clougherty T. Stability of NTG. *Am Heart J*. 1979; 97:817-8. [PubMed 107777] 723. Yuen PH, Denman SL, Sokoloski DL et al. Loss of nitroglycerin from aqueous solution into plastic intravenous delivery systems. *J Pharm Sci*. 1979; 68:1163-6. [PubMed 115988] 724. Baaske DM, Amann AH, Wagenknecht DM et al. Nitroglycerin compatibility with intravenous fluid filters, containers, and administration sets. *Am J Hosp Pharm*. 1980; 37:201-5. [PubMed 6767400] 725. Roberts MS, Cossum PA, Galbraith AJ et al. Availability of nitroglycerin from parenteral solutions. *J Pharm Pharmacol*. 1980; 32:237-44. [PubMed 6103051] 726.

Amann AH, Baaske DM, Amann AH. Nitroglycerin infusion—factors influencing the concentration of nitroglycerin available to the patient. *J Clin Hosp Pharm*. 1980; 5:209-15. 727. Sokoloski DL, Wu CC. Rapid adsorptive loss of nitroglycerin from aqueous solution to plastic. *Int J Pharm*. 1980; 6:63-76. 728. Baaske DM, Amann AH, Karnatz NN et al. Administration set for use with intravenous nitroglycerin. *Am J Hosp Pharm*. 1982; 39:121-2. [PubMed 6798867] 729. Little LA, Hatheway GP. Problems with administration devices for commercially available nitroglycerin injection. *Am J Hosp Pharm*. 1982; 39:400. [PubMed 6803587] 730. Turco SJ. Problems with administration devices for commercially available nitroglycerin injection. *Am J Hosp Pharm*. 1982; 39:977. [PubMed 6808836] 732. Vesey CJ, Batistoni GA. Determination and stability of sodium nitroprusside in aqueous solutions (determination and stability of SNP). *J Clin Pharm*. 1977; 2:105-7. 733. Milewski B, Jones D. Photodecomposition. *Hosp Pharm*. 1981; 16:178. 734.

Nolly RJ, Staeh PE, Latolaia CJ et al. Stability of thiamine hydrochloride repackaged in disposable syringes. *Am J Hosp Pharm*. 1982; 39:471-4. [PubMed 7072734] 735. Polk RE, Kline BJ. Mail order tobramycin serum levels: low values caused by ticarcillin. *Am J Hosp Pharm*. 1980; 37:920. [PubMed 7395883] 736. Seitz DJ, Archambault JR, Kresel JJ et al. Stability of tobramycin in plastic syringes. *Am J Hosp Pharm*. 1980; 37:1614-5. [PubMed 7446535] 738. Svensson LA. Stressed oxidative degradation of terbutaline in aqueous solution. *Acta Pharm Suec*. 1972; 9:141-6. [PubMed 5030542] 739. Cutie MR. Compatibility of verapamil with other additives. *Am J Hosp Pharm*. 1981; 38:231. [PubMed 7211888] 740. Lederle Laboratories. Hospital formulary monograph—Pipracil. Wayne, NJ; 1981 Nov. 741. Chan KK, Giannini DD, Staroski J et al. 5-Azacytidine hydrolysis kinetics measured by high-pressure liquid chromatography and 13C-NMR spectroscopy. *J Pharm Sci*. 1979; 68:807-12. [PubMed 88514] 742. Rubin M, Bilik R, Aserin A et al. Catheter obstruction: analysis of filter content of total nutrient admixture. *J Parenter Enter Nutr*. 1989; 13:641-3. 743. Flora PK, Smith SL. Application of a simple high-performance liquid chromatographic method for the determination of melphalan in the presence of its hydrolysis products. *J Chromatogr*. 1979; 177:91-7. [PubMed 536450] 744. Palmer AJ, Sewell GJ, Rowland CG. Qualitative studies on :ga-interferon-2b in prolonged continuous infusion regimes using gradient elution high-performance liquid chromatography. *J Clin Pharm Ther*. 1988; 13:225-31. [PubMed 3209630] 745. Morris ME, Parker WA. Compatibility of chlorthalidose HCl injection following dilution. *Can J Pharm Sci*. 1981; 16:43-5. 746. Cummings DS, Park MK. Compatibility of propranolol hydrochloride injection with intravenous infusion fluids in plastic containers. *Am J Hosp Pharm*. 1982; 39:1685-7. [PubMed 7148843] 747. Deans KW, Lang JR. Stability of trimethoprim-sulfamethoxazole injection in five infusion fluids. *Am J Hosp Pharm*. 1982; 39:1681-4. [PubMed 6983297] 748. Munson JW, Kubiak EJ. The arabinoside stability in intravenous admixtures with sodium bicarbonate and in plastic syringes. *Drug Intell Clin Pharm*. 1982; 16:765-7. [PubMed 6291888] 749. Kirschenbaum HL, Aronoff W, Perentesis GP et al. Stability of dobutamine hydrochloride in selected large-volume parenterals. *Am J Hosp Pharm*. 1982; 39:1923-5. [PubMed 7148861] 750. Ray BJ, Newton DW, Nye MT et al. Droperidol stability in intravenous admixtures. *Am J Hosp Pharm*. 1983; 40:94-7. [PubMed 6823997] 751. Das Gupta V, Stewart KR. Stability of cefotaxime sodium and moxalactam disodium in 5% dextrose and 0.9% sodium chloride injections. *Am J Hosp Pharm*. 1980; 37:29-30 (Jan) 1983; 10:20. 752. Jett S, Eng SS. Prochlorperazine edisylate incompatibility. *Am J Hosp Pharm*. 1983; 40:210. [PubMed 6829573] 753. Porter WR, Johnson CA, Cohon MS et al. Compatibility and stability of clindamycin phosphate with intravenous fluids. *Am J Hosp Pharm*. 1983; 40:91-4. [PubMed 6823996] 754. Hittel WP, Iafraite RP, Karnes HT et al. Stability of pentobarbital sodium in 5% dextrose injection and 0.9% sodium chloride injection. *Am J Hosp Pharm*. 1983; 40:294-6. [PubMed 6829585] 755. Niemiec PW, Vanderveen TW, Hohenwarter MW et al. Stability of aminophylline injection in three parenteral nutrition solutions. *Am J Hosp Pharm*. 1983; 40:428-32. [PubMed 6405614] 756. Perentesis GP, Piltz GW, Kirschenbaum HL et al. Stability and visual compatibility of bretylium tosylate with selected large-volume parenterals and additives. *Am J Hosp Pharm*. 1983; 40:1010-2. [PubMed 6869385] 757. Hsu K, Taddesio GA, Ka BE et al. Compatibility and stability of labetalol hydrochloride in commonly used intravenous solutions. *Am J Hosp Pharm*. 1983; 40:1007-9. [PubMed 6869384] 758. Pyter RA, Hsu LCC. Stability of methylprednisolone sodium succinate in 5% dextrose and 0.9% sodium chloride injection. *Am J Hosp Pharm*. 1983; 40:1329-33. [PubMed 6351604] 759.

Gannon PM, Sesin GP. Stability of cytarabine following repackaging in plastic syringes and glass containers. *Am J IV Ther Clin Nutr*. 1983; 10:11-6. 760. Sesin GP, Millette LA. Stability study of 5-fluorouracil following repackaging in plastic disposable syringes and multidosed vials. *Am J IV Ther Clin Nutr*. 29-30 (Sep) 1982; 9:23-5. 761. Parker WA. Compatibility of perphenazine and butorphanol admixtures. *Can J Hosp Pharm*. 1981; 34:38. 762. Jung GW, Plaza VM. Compatibility of nalbuphine hydrochloride with other preoperative medications. *Am J Hosp Pharm*. 1982; 39:841-3. [PubMed 7081259] 673. Dorr RT, Peng YM, Alberts DS. Bleomycin compatibility with selected intravenous medications. *J Med*. 1982; 13(1-2):121-30. 764. Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. *Am J Hosp Pharm*. 1983; 40:1205-7. [PubMed 6881161] 765. Shively CD, Redford A, Flagyl IV., drug-drug physical compatibility. *Am J IV Ther Clin Nutr*. 1981; 8:9-16. 766. Souney PF, Steele L. Effect of vitamin B complex and ascorbic acid on the antimicrobial activity of cefazolin sodium. *Am J Hosp Pharm*. 1982; 39:840-1. [PubMed 7081258] 767. Keller JH, Ensminger WD. Stability of cancer chemotherapeutic agents in a totally implanted drug delivery system. *Am J Hosp Pharm*. 1982; 39:1321-3. [PubMed 6214944] 768. Rodanelli R, Comelli M, Pascale V et al. Clinical pharmacology of some antibiotics: problems relating to their intravenous use in hospitals. *Farmacoe Ed Prat*. 1982; 37:185-8. 769. Kowalik EA, Roberts MS. Drug loss in polyolefin infusion systems. *Am J Hosp Pharm*. 1983; 40:118-9. [PubMed 6823983] 770. Ihara L, Bundasara H. Sorption of drugs by plastic infusion bags. *Int J Pharm*. 1982; 10:339-51. 771. Pfizer Laboratories. Vistaril IM, table of physical compatibilities. New York, NY; 1979 Jul. 772. Abbott Laboratories. Package insert on Neut. North Chicago, IL; 1988 Oct. 773. Jhunjhuwala PV, Bhalla HL. Sodium ampicillin: its stability in some large volume parenteral solutions. *Indian J Hosp Pharm*. 1981; 8:55-7. 774. Scheiner JM, Araujo MM. Thiamine destruction by sodium bisulfite in infusion solutions. *Am J Hosp Pharm*. 1981; 38:1911-3. [PubMed 7325171] 775. Kirschenbaum HL, Aronoff W, Perentesis GP et al. Stability and compatibility of lidocaine hydrochloride with selected large-volume parenterals and drug additives. *Am J Hosp Pharm*. 1982; 39:1013-5. [PubMed 7102682] 776. Lackner TE, Baldus D, Butler CD et al. Lidocaine stability in cardioplegic solution stored in glass bottles and polyvinyl chloride bags. *Am J Hosp Pharm*. 1983; 40:97-101. [PubMed 6823998] 777. Russell WJ, Meyer-Witting M. The stability of atracurium in clinical practice. *Anaesth Inten Care*. 1980; 18:550-2. 778. Shank WA, Coupal JF. Stability of digoxin in common large-volume injections. *Am J Hosp Pharm*. 1982; 39:844-6. [PubMed 7081261] 779. Solomon DA, Nasinyk KK. Compatibility of haloperidol lactate and heparin sodium. *Am J Hosp Pharm*. 1982; 39:843-4. [PubMed 7081260] 780. Elliott GT, McKenzie MW, Curry SH et al. Stability of cimetidine hydrochloride in admixtures after microwave thawing. *Am J Hosp Pharm*. 1983; 40:1002-6. [PubMed 6869383] 781. Tsailias G, Allen LC. Stability of cimetidine hydrochloride in parenteral nutrition solutions. *Am J Hosp Pharm*. 1982; 39:434-5. [PubMed 6803587] 782. Roberts MS, Cossum PA, Kowalik EA et al. Plastic syringes and intravenous infusions. *Med J Aust*. 1981; 2:580-1. [PubMed 6801447] 783. Das Gupta V, Stewart KR. Effect of tobramycin on the stability of carbenicillin disodium. *Am J Hosp Pharm*. 1983; 40:1013-6. [PubMed 6869386] 784.

Simmons A, Allwood MC. Sorption to plastic syringes of drugs administered by syringe pump. *J Clin Hosp Pharm*. 1981; 6:71-3. [PubMed 7345099] 785. Nicholas E, Hess G. Degradation of penicillin, ticarcillin and carbenicillin resulting from storage of unit doses. *N Engl J Med*. 1982; 306:547-8. [PubMed 7057866] 786. Carpenter JP, Gomez EA. Administration of lorazepam injection through intravenous tubing. *Am J Hosp Pharm*. 1981; 38:1514-6. [PubMed 6117200] 787. Newton DW, Narducci WA, Leet WA et al. Lorazepam solubility in and sorption from intravenous admixture solutions. *Am J Hosp Pharm*. 1983; 40:424-7. [PubMed 6133447] 788. Frable RA, Klink RP, Engel GL et al. Stability of cefamandole nafate injection with parenteral solutions and additives. *Am J Hosp Pharm*. 1982; 39:622-7. [PubMed 7082453] 789. Kirschenbaum HL, Aronoff W, Piltz GW et al. Compatibility and stability of dobutamine hydrochloride with large-volume parenterals and selected additives. *Am J Hosp Pharm*. 1983; 40:1690-1. [PubMed 6638033] 790. Bosch EH, van Doorne H, Brouwers [RBJ] et al. Verminderung van het sufentanilgehalte bij de bereiding en tijdens het gebruik van een epidurale toedieningsvorm. Een oriënterend onderzoek. *Ziekenhuisfarmacie*. 1993; 9:97-101. 791. Cairns CJ. Incompatibility of amiodarone. *Pharm J*. 1986; 236:68. 792. Roney JV (Scientific Services, Hoechst-Roussel Pharmaceuticals, Somerville, NJ): Personal communication; 1983 Dec 4. 793. Berge SM, Henderson NL. Kinetics and mechanism of degradation of cefotaxime sodium in aqueous solution. *J Pharm Sci*. 1983; 72:59-63. [PubMed 6298400] 794. Smith PH, Nuesse NO. Stability of digoxin injection packaged in glass unit-dose syringes. *Am J Hosp Pharm*. 1982; 39:1687-90. [PubMed 7148844] 795. Cossum PA, Roberts MS. Availability of isoribidite dinitrate, diazepam and chlormethazine from I.V. delivery systems. *Eur J Clin Pharmacol*. 1981; 19:181-5. [PubMed 7215415] 796. Smith A, Bird G. Compatibility of diazepam with infusion fluids and their containers. *J Clin Hosp Pharm*. 1982; 7:181-6. [PubMed 7174833] 797. Yirru LI, Sothmann AG, Laine RH et al. Sorptive loss of diazepam and nitroglycerin from solutions to three types of containers. *Am J Hosp Pharm*. 1982; 39:1018-21. [PubMed 6808834] 798.

Kubish J, Ashagen U. Cleavage of glycosidic bonds of digoxin and derivatives as function of pH and time. *Naunyn Schmiedeberg Arch Pharmacol*. 1973; 276:149-56. [PubMed 4268465] 799. Gault MH, Charles JD, Sugden DL et al. Hydrolysis of digoxin by acid. *J Pharm Pharmacol*. 1977; 29:27-32. [PubMed 131718] 800. Sternson LA, Shaffer RD. Kinetics of digoxin stability in aqueous solution. *J Pharm Sci*. 1978; 67:327-30. [PubMed 25324] 801. Khalil SA, El-Masry S. Instability of digoxin in acid medium using a nonisotopic method. *J Pharm Sci*. 1978; 67:1358-60. [PubMed 29955] 802. Fagerman KE, Dean RE. Daily digoxin administration in parenteral nutrition solution. *Am J Hosp Pharm*. 1981; 38:1955. [PubMed 6798864] 803. Patterson MJ, Tjokroeste R. Stability of adrenaline injection BP following sterilization. *Aust J Hosp Pharm*. 1981; 11:21-2. 804. Nazeravich DR, Otlen NHH. Effect of inline filtration on delivery of gentamicin at a slow infusion rate. *Am J Hosp Pharm*. 1983; 40:1961-4. [PubMed 6650527] 805. Zell M, Paone RP. Stability of insulin in plastic syringes. *Am J Hosp Pharm*. 1983; 40:637-8. [PubMed 6342381] 806. Benveniste JA. Errors in oncologic agent stability study. *Am J Hosp Pharm*. 1983; 40:1628. [PubMed 6638024] 807. Bisailon S, Sarrazin R. Compatibility of several antibiotics or hydrocortisone when added to metronidazole solution for intravenous infusion. *J Parenter Sci Technol*. 1983; 37:129-132. [PubMed 6620045] 808. Gove L. Antibiotic interactions. *Pharm J*. 1983; 231:233. 809. Ennis CE, Merritt RJ, Neff DN. In vitro study of in line filtration of medications commonly administered to pediatric cancer patients. *JPEN J Parenter Enter Nutr*. 1983; 7:156-8. [PubMed 6406704] 810. Buxton PC, Conduit SM. Stability of parentivrite in infusion fluids. *Br J IV Ther*. 1983; 4:5. 811. Das Gupta V, Stewart KR. Stability of dobutamine hydrochloride and verapamil hydrochloride in 0.9% sodium chloride and 5% dextrose injections. *Am J Hosp Pharm*. 1984; 41:686-9. [PubMed 6720710] 812. Hasegawa GR, Eder JF. Visual compatibility of dobutamine hydrochloride with other injectable drugs. *Am J Hosp Pharm*. 1984; 41:949-51. [PubMed 6731457] 813. Souney PF, Colucci RD, Mariani G et al. Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection. *Am J Hosp Pharm*. 1984; 41:323-4. [PubMed 6702842] 814.

Lundergan FS, Lombardi TP, Neilan GE et al. Stability of tobramycin sulfate mixed with oxacillin sodium and nafcillin sodium in human serum. *Am J Hosp Pharm*. 1984; 41:144-5. [PubMed 6659530] 815. Kubiak EJ. Physical compatibility of solutions of preoperative medications. *Hosp Pharm*. 1984; 19:475-8

Arzneimittelforschung. 1983; 33:595-7.

PubMed 64091291 935. Rock CM, Gull J. Reducing IV-nitroglycerin loss to an intravenous administration set by preliminary preparation.

Am J IV Ther Clin Nutr. 40:42 (Oct) 1982; 9:36. Nix DE, Tharpe WN. Effects of pressurization on nitroglycerin delivery by polyvinyl chloride infusion sets. Am J Hosp Pharm. 1984; 41:1835-7. [PubMed 6437222] 937. Jacoby J, Dasta JF, Reilly TE et al.

Loss of nitroglycerin to pulmonary artery catheters. Crit Care Med. 1983; 11:50-2. [PubMed 6401237] 940. Dasta JF, Jacoby J, Sokolowski TD et al. Extraction of nitroglycerin by a membrane oxygenator. J Extra-Corp Technol. 1983; 15:101-3. 941. St. Peter JV, Cochran TG. Nitroglycerin loss from intravenous solutions administered with a volumetric infusion pump. Am J Hosp Pharm. 1982; 39:1328-30. [PubMed 6812416] 942. Hala ET. Loss of nitroglycerin during microinfusion. Am J Hosp Pharm. 1984; 41:142-4. [PubMed 6421154] 943. Yacobi A, Amann AH. Pharmaceutical considerations of nitroglycerin. Drug Intell Clin Pharm. 1983; 17:255-63.

PubMed 64046191 944. Malick AW, Amann AH, Baaske DM, et al. Loss of nitroglycerin from solutions to intravenous plastic containers: a theoretical treatment. J Pharm Sci. 1981; 70:798-800. [PubMed 6790697] 945. Amann AH, Baaske DM. Loss of nitroglycerin from intravenous administration sets during infusion: a theoretical treatment. J Pharm Sci. 1981; 70:798-800. [PubMed 6790697] 946. Amann AH, Baaske DM. Loss of nitroglycerin from intravenous administration sets during infusion: a theoretical treatment. J Pharm Sci. 1981; 70:798-800. [PubMed 6790697] 947. Salem RB, Wilder BJ, Yost RL et al. Rapid infusion of phenytoin sodium loading doses. Am J Hosp Pharm. 1981; 38:354-7. [PubMed 7223748] 948. Gannaway WL, Wilking DC, Slepner JK et al. Clinical use of intravenous phenytoin sodium infusions. Clin Pharm. 1983; 2:135-8. [PubMed 6883941] 949. Boike SC, Rybak MJ, Tintinalli JE et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 950. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 951. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 952. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 953. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 954. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 955. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 956. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 957. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 958. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 959. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 960. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 961. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 962. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 963. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 964. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 965. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 966. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 967. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 968. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 969. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 970. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 971. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 972. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 973. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 974. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 975. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 976. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 977. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 978. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 979. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 980. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 981. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 982. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 983. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 984. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 985. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 986. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 987. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 988. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 989. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 990. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 991. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 992. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 993. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 994. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 995. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 996. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 997. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 998. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 999. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 1000. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 1001. Gannaway WL, Wilking DC, Slepner JK et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:144-6. [PubMed 6627872] 1002. Gannaway WL, Wilking DC, Slepner JK et

Anticancer Nutr. 1987; 11:23-7.

1220. Plonkiewicz M, Van Wyk CJ. The stability of parenteral fat emulsions in nutrition admixtures. J Clin Pharm Ther. 1987; 12:307-18. [PubMed 3119608] 1222. Sayeed FA, Tripp MG, Sukumaran KB et al. Stability of total nutrient admixtures using various intravenous fat emulsions. Am J Hosp Pharm. 1987; 44:2271-80. [PubMed 3687967] 1223. Sayeed FA, Tripp MG, Sukumaran KB et al. Stability of total nutrient admixture formulations using Liposyn II and Amniosyn II. Am J Hosp Pharm. 1987; 44:2280-6. [PubMed 3687968] 1224. McGee CD, Mascarenhas MG, Ostro MJ et al. Selenium and vitamin E stability in parenteral solutions. JPN J Parenter Enteral Nutr. 1985; 9:568-70. [PubMed 3930763] 1225. Dahl GB, Jeppsson RI. Vitamin stability in a TPN mixture stored in an EVA plastic bag. J Clin Hosp Pharm. 1986; 11:271-9. [PubMed 3093563] 1226.

Shenkin A, Fraser WD, McLelland AJ et al. Maintenance of vitamin and trace element status in intravenous nutrition using a complete nutritive mixture. JPN J Parenter Enteral Nutr. 1987; 11:238-42. [PubMed 3110439] 1227. Yamaoka K, Nakajima Y, Okinaga S et al. Variation by combination of hyperalimentation with fat emulsion. Jap J Hosp Pharm. 1987; 13:211-5.

1228. Sewell DL, Golper TA, Brown SD et al.

Stability of single and combined antimicrobial agents in various parenteral dialysates in the presence of insulin and heparin. Am J Kidney Dis. 1983; 3:209-12. [PubMed 6356893] 1229. Nance KS, Matzke GR. Stability of gentamicin and tobramycin in concentrate solutions for automated peritoneal dialysis. Am J Nephrol. 1984; 4:240-3. [PubMed 6476012] 1230. Das Gupta V, Pararasmpuria J. Quantitation of acetazolamide in pharmaceutical dosage forms using high-performance liquid chromatography. Drug Dev Ind Pharm. 1987; 13:147-57. 1231. Boak LR. Aminophylline stability. Can J Hosp Pharm. 1987; 40:155. 1232. Moore BR, Tindula R. Incompatibility between amphotericin B and evacuated i.v. containers. Am J Hosp Pharm. 1987; 44:1312. [PubMed 3618605] 1233.

Bretschneider H. Osmolalities of commercially supplied drugs often used in anesthesia. Anaesth Analg. 1987; 66:361-2. 1234. Odgers C. Drug/nutrient interactions and incompatibilities complicating TPN. N.Z. Pharm. 1986; 6:64-8. 1235. Kedzierewicz F, Finance C, Nicolas A et al. Etude comparative de la stabilité de solutions de carbenicilline en fonction de la température. Interet du cycle congélation-décongélation au four a micro-ondes. Pharm Acta Helv. 1987; 62:109-15. [PubMed 3602011] 1236. Arbus MH. Room temperature stability guidelines for carmustine. Am J Hosp Pharm. 1988; 45:531. [PubMed 3369454] 1237. Frederiksson K, Lundgren P. Stability of carmustine—kinetics and compatibility during administration. Acta Pharm Scand. 1986; 23:115-24. [PubMed 3739737] 1238. Sewell GJ, Riley CM. The stability of carboplatin in ambulatory continuous infusion regimes. J Clin Pharm Ther. 1987; 12:427-32. [PubMed 3326888] 1239.

Ross MB.

Additive stability guidelines for routinely refrigerated drug products. Am J Hosp Pharm. 1988; 45:1498-9. [PubMed 3414714] 1240. Goodell JA, Harry DJ, Low JR. More on production of a carbon dioxide gas after reconstitution of ceftazidime. Am J Hosp Pharm. 1987; 44:510. [PubMed 3105308] 1241. Savello DR. More on production of carbon dioxide gas after reconstitution of ceftazidime. Am J Hosp Pharm. 1987; 44:512.

1242. Rovers JP, Menielly G, Souney PF et al. The use of stability-indicating assays to determine the in vitro compatibility and stability of metronidazole/gentamicin admixtures. Can J Hosp Pharm. 1989; 42:143-6. 1243. Walker SE, Dranitsaris G. Stability of reconstituted ceftriaxone in dextrose and saline solutions. Can J Hosp Pharm. 1987; 40:161-6. 1244. Martinez-Pancheo R, Vila-Jeto JL. Effect of different factors on stability of ceftriaxone in solution. Farmaco Ed Prat. 1987; 42:131-7. 1245. Kedzierewicz F, Finance C, Nicolas A et al. Stability of parenteral ceftriaxone disodium solutions in frozen and liquid states: effect of freezing and microwave thawing. J Pharm Sci. 1989; 78:73-7. [PubMed 2709324] 1246. Kristjansson P, Stjernson LA. An investigation on possible oligomer formation in pharmaceutical formulations of cisplatin. Int J Pharm. 1988; 41:67-74.

1247. Anon.

High-dose Maxolon mixes with cisplatin. Pharm J. 1985; 234:593. 1248. Kirk B. The evaluation of a light-protective giving set. The photosensitivity of intravenous dacarbazine solutions. Br J Parenter Ther. (May-June) 1987; 8:78, 81-2, 85-6. 1249. Bosanquet AG. Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. General considerations, the nitroreosares and alkylating agents. Cancer Chemother Pharmacol. 1985; 14:83-95. [PubMed 3882257] 1250. Beijnen JH, Potman RP, van Ooijen RD et al. Structure elucidation and characterization of daunorubicin degradation products. Int J Pharm. 1987; 34:247-57. 1251. Haronikova K, Pikulikova Z, Kral L et al. Sorption of diazepam on the surface of the plastic infusion unit, part 2. Farm Obz. 1986; 55:485-94. 1252. Mathot F, Bonnard J, Paris P et al. Influence des materiaux de perfusion sur les solutions de diazepam. J Pharm Belg. 1982; 37:153-6. [PubMed 7108734] 1253. Murphy A, Maltby S. Dissolution time, on reconstitution, of a new parenteral formulation of doxorubicin (Doxorubicin Rapid Dissolution). Int J Pharm. 1987; 38:257-9. 1254. Baumann TJ, Smythe MA, Kaufmann K et al. Dissolution times of Adriamycin and Adriamycin RDF. Am J Hosp Pharm. 1988; 45:1607. [PubMed 3218641] 1255. Vogelzang NJ, Ruane M. Phase I trial of an implanted battery-powered, programmable drug delivery system for continuous doxorubicin administration. J Clin Oncol. 1985; 3:407-14. 1256. Keusters L, Stolk LML, Umans R et al. Stability of solutions of doxorubicin and epirubicin in plastic minibags for intravesical use after storage at -20 °C and thawing by microwave radiation. Pharm Weekbl [Sci]. 1986; 8:194-7. 1257.

Williamson M, Luce JK. Microwave thawing of doxorubicin hydrochloride admixtures not recommended. Am J Hosp Pharm. 1987; 44:505. [PubMed 3365405] 1258. Adams S, Fernandez F. Intravenous use of haloperidol. Hosp Pharm. 1987; 22:306-7. 1259.

Thoma K, Struve M. Untersuchungen zur photo- und thermostabilität von adrenalin-lösungen. Pharm Acta Helv. 1986; 61:2-9. [PubMed 3952103] 1260. David LM. Phlebitis with intravenous erythromycin. Am J Hosp Pharm. 1987; 44:732. [PubMed 3578303] 1261. Schwinghammer TL, Reilly M. Cracking of ABS plastic devices used to infuse undiluted etoposide injection. Am J Hosp Pharm. 1988; 45:1277. [PubMed 3414692] 1262. Beijnen JH, Holthuis JIM, Kerkdijk HG et al. Degradation kinetics of etoposide in aqueous solution. Int J Pharm. 1988; 41:169-78. 1263. Brown DH, Simkover RA. Maximum hang times for i.v. fat emulsions. Am J Hosp Pharm. 1987; 44:282. [PubMed 3565382] 1264. Allwood MC. The release of phthalate ester plasticizer from intravenous administration sets into fat emulsion. Int J Pharm. 1986; 29:233-6. 1265. Nahata MC, Hipple TF. Stability of gentamicin diluted in 0.9% sodium chloride injection in glass syringes. Hosp Pharm. 1987; 22:1131-2. 1266. Dunn DL, Lenihan SF. The case for the saline flush. J Clin Pharm Ther. 1987; 12:395-7.

1267. Nahata MC, Hipple TF, Hearn J.

Normal saline flush dilutes heparin flush. A study of peripheral intratective I.V. devices. NITA. 1987; 10:425-7. [PubMed 3696458] 1268. Hamilton RA, Plis JM, Clay C et al. Heparin sodium versus 0.9% sodium chloride injection for maintaining patency of indwelling intermittent infusion devices. Clin Pharm. 1988; 7:439-43. [PubMed 3402178] 1269. Lombardi TP, Gundersen B, Zammett LO et al. Efficacy of 0.9% sodium chloride injection with or without heparin sodium for maintaining patency of intravenous catheters in children. Clin Pharm. 1988; 7:832-6. [PubMed 3197384] 1270. Cyganski JM, Donahue JM. The case for the heparin flush. Am J Nurs. 1987; 87:796-7. [PubMed 3647723] 1271. Bullock LS, Fitzgerald JF, Glick MR. Stability of famotidine in minibags refrigerated and/or frozen. DICP. 1989; 23:132-5. [PubMed 2728502] 1272. Swanson DJ, DeAngelis C, Smith IL et al. Degradation kinetics of imipenem in normal saline and human serum. Antimicrob Agents Chemother. 1986; 29:936-7. [PubMed 3460525][Free Fulltext PMC] 1273. Smith GB, Schoenewaldt EF. Stability of N-formimidoethylthiamycin in aqueous solution. J Pharm Sci. 1981; 70:272-6. [PubMed 6943333] 1274. McElnay JC, Elliott DS. Binding of human insulin to burette administration sets. Int J Pharm. 1987; 36:199-203. 1275.

Adams PS, Haines-Nutt RF. Stability of insulin mixtures in disposable plastic insulin syringes. J Pharm Pharmacol. 1987; 38:158-63. [PubMed 2883277] 1276. Mozzi C, Conzatti B, Lotti R et al. Stabilità del calcio folinato in soluzioni acquose in funzione del pH e della temperatura. Boll Chim Farm. 1986; 125:424-8. 1277. Powell MF.

Stability of lidocaine in aqueous solution: effect of temperature, pH, buffer, and metal ions on amide hydrolysis. Pharm Res. 1987; 4:42-5. [PubMed 3505282] 1278. Das Gupta V, Stewart KR. Chemical stabilities of lignocaine hydrochloride and phenylephrine hydrochloride in aqueous solution. J Clin Hosp Pharm. 1986; 11:449-52. [PubMed 3818967] 1279. Kirk B. Stability of reconstituted mustine injection BP during storage. Br J Parenter Ther. (July-Aug) 1986; 7:86-7, 90-2. 1280. Wright MP, Newton JM. Stability of methotrexate injection in prefilled, plastic disposable syringes. Int J Pharm. 1988; 45:237-44. 1281. Dyvik O, Grisingaas AL, Tonnesen HH et al. Methotrexate in infusion solutions—a stability test for the hospital pharmacy. J Clin Hosp Pharm. 1986; 11:343-8. [PubMed 3782479] 1282. Cabeza Barrera J, Bautista Paloma J, Garcia de Pesquera F et al. Disminución de la adsorción de insulina a los envases de nutrición parenteral. Rev Assoc Esp Farm Hosp. 1988; 12:251-4. 1283. Beijnen JH, Fokkens RH, Rosing H et al. Degradation of mitomycin C in acid phosphate and acetate buffer solutions. Int J Pharm. 1986; 32:111-21. 1284. Beijnen JH, Lingeman H, Van Munster HA et al. Mitomycin antitumor agents: a review of their physico-chemical and analytical properties and stability. J Pharm Biomed Anal. 1986; 4:275-95. [PubMed 18867564] 1285. Stolk LML, Frujtier A. Stability after freezing and thawing of solutions of mitomycin C in plastic minibags for intravenous use. Pharm Weekbl [Sci]. 1986; 8:286-8.

1286.

Depiero D, Rekhi GS, Souney PF et al. Stability of morphine sulfate solutions frozen in polyvinyl chloride intravenous bags. Pharm Pract News. (Oct) 1987; 14:1, 39-40. 1287. Hung CT, Young M. Stability of morphine solutions in plastic syringes determined by reversed-phase ion-pair liquid chromatography. J Pharm Sci. 1988; 77:719-23. [PubMed 3210163] 1288. Visor GC, Lin LH, Jackson SE et al. Stability of ganciclovir sodium (DHPG sodium) in 5% dextrose or 0.9% sodium chloride injections. Am J Hosp Pharm. 1986; 43:2810-2. [PubMed 3492139] 1289. Behme RJ, Brooke D, Kensler TT et al. Incompatibility of ifosfamide with benzyl-alcohol-preserved bacteriostatic water for injection. Am J Hosp Pharm. 1988; 45:627-8. [PubMed 3369469] 1290. Rowland CG, Bradford E, Adams P et al. Infusion of ifosfamide plus mesna. Lancet. 1984; 2:468. [PubMed 6147537] 1291.

Bristol-Myers Oncology Division. Product information on Mesnex (Mesna). Evansville, IN; 1989 Jun. 1292.

Dort RT. Mesnex dosing and administration guide. Evansville, IN: Bristol-Myers Company; 1989. 1293. Lederle Laboratories, American Cyanamid Company. Product information on Novantrone. Pearl River, NY; 1988. 1294. Nahata MC, Hipple TF. Stability of phenobarbital sodium diluted in 0.9% sodium chloride injection. Am J Hosp Pharm. 1986; 43:384-5. [PubMed 3953601] 1295. Dela Cruz FG, Kanter MG, Fischer JH et al. Efficacy of individualized phenytoin sodium loading doses administered by intravenous infusion. Clin Pharm. 1988; 7:219-24. [PubMed 3356118] 1296. Davidson SW, Lyall D. Sodium nitroprusside stability in light-protective administration sets. Am J Hosp Pharm. 1987; 44:2291-3. [PubMed 3687970] 1299. Raymond GG.

Stability of terbutaline sulfate injection stored in plastic tuberculin syringes. Drug Intell Clin Pharm. 1988; 22:303-5. [PubMed 3371191] 1300. Das Gupta V, Gardner SN, Jalowsky CM et al. Chemical stability of theophylline sodium injection in disposable plastic syringes. J Clin Pharm Ther. 1987; 12:339-42. [PubMed 3680403] 1301. Nahata MC, Miller MA. Stability of vancomycin hydrochloride in various concentrations of dextrose injection. Am J Hosp Pharm. 1987; 44:802-4. [PubMed 3578315] 1302. Greenberg RN, Saeed AMK, Kennedy DJ et al. Instability of vancomycin in Infusaid drug pump model 100. Antimicrob Agents Chemother. 1987; 31:610-1. [PubMed 3606065][Free Fulltext PMC] 1303.

Tucker R, Gentile JF. Precipitation of verapamil in an intravenous line. Ann Intern Med. 1984; 101:880. [PubMed 6497208] 1304. Patel SD, Yalkowsky SH. Development of an intravenous formulation for the antiviral drug 9-(beta-D-arabinofuranosyl)-adenine. J Parenter Sci Technol. 1987; 41:15-20. [PubMed 3559829] 1305. Stolk LML, Huisman W, Nordeemann HD et al. Formulation of a stable vidarabine infusion fluid. Pharm Weekbl [Sci]. 1983; 5:57-60. 1306. Back J, Buechter DD. Stability of vinblastine sulfate when exposed to light. Drug Intell Clin Pharm. 1988; 22:634-6. [PubMed 3416757] 1307. Vendrig DEMM, Smeets BPGH, Beijnen JH et al. Degradation kinetics of vinblastine sulphate in aqueous solutions. Int J Pharm. 1988; 43:131-8. 1308. Cartwright-Shamoon JM, McElnay JC. Examination of sorption and photodegradation of amarsine during storage in intravenous burette administration sets. Int J Pharm. 1988; 42:41-6. 1309. Milano G, Etienne MC, Cassuto-Viguer E et al. Long-term stability of 5-fluorouracil and folic acid admixtures. Eur J Cancer. 1987; 23:109-12. [PubMed 3324252] 1329. Stewart CF, Hampton EM. Stability of cisplatin and etoposide in intravenous admixtures. Am J Hosp Pharm. 1989; 46:1400-4. [PubMed 2757048] 1330.

Shea BF, Pischinski RJ, O'Neill S et al. Stability of cyclosporine in 5% dextrose injection. Am J Hosp Pharm. 1989; 46:2053-5. [PubMed 2816962] 1331. Bullock L, Fitzgerald JF, Glick MR et al. Stability of famotidine 20 and 40 mg/L and amino acids in total parenteral nutrient solutions. Am J Hosp Pharm. 1989; 46:2321-5. [PubMed 2511752] 1332. Bullock L, Fitzgerald JF. Stability of famotidine 20 and 50 mg/L in total nutrient admixtures. Am J Hosp Pharm. 1989; 46:2326-9. [PubMed 2511753] 1333. Montoro JB, Pot L, Salvador P et al. Stability of famotidine 20 and 40 mg/L in total nutrient admixtures. Am J Hosp Pharm. 1989; 46:2329-32. [PubMed 2511754] 1334. DiStefano JE, Mitranoff JP, Baptista RJ et al. Long-term stability of famotidine 20 mg/L in a total parenteral nutrient solution. Am J Hosp Pharm. 1989; 46:2333-5. [PubMed 2511755] 1335.

Lor E, Takagi J. Visual compatibility of foscanet with other injectable drugs. Am J Hosp Pharm. 1990; 47:157-9. [PubMed 2137288] 1336. Scott SM. Incompatibility of cefepazone and promethazine. Am J Hosp Pharm. 1990; 47:519. [PubMed 2316532] 1337. Savitsky ME. Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm. 1990; 47:820-1. [PubMed 1969713] 1338. Smythe MA, Patel MA.

Visual compatibility of narcotic analgesics with selected intravenous admixtures. Am J Hosp Pharm. 1990; 47:819-20. [PubMed 1969712] 1339. Stewart CF, Fleming RA. Compatibility of cisplatin and fluorouracil in 0.9% sodium chloride injection. Am J Hosp Pharm. 1990; 47:1373-7. [PubMed 2368735] 1340. Lee CY, Mauro VF. Visual and spectrophotometric determination of compatibility of alteplase and streptokinase with other injectable drugs. Am J Hosp Pharm. 1990; 47:606-8. [PubMed 2107741] 1341. Gupta VD, Bethea C. Chemical stabilities of cefepazone sodium and ceftazidime in 5% dextrose and 0.9% sodium chloride injections. J Clin Pharm Ther. 1989; 13:199-205. [PubMed 3062012] 1342.

Gupta VD, Pararasmpuria J. Chemical stabilities of famotidine and ranitidine hydrochloride in intravenous admixtures. J Clin Pharm Ther. 1988; 13:329-34. [PubMed 3230097] 1343. Gupta VD, Pramar Y. Stability of acyclovir sodium in dextrose and sodium chloride injections. J Clin Pharm Ther. 1989; 14:451-6. [PubMed 2613771] 1344. Underberg WJM, Koomen JM. Stability of famotidine in commonly used nutritional infusion fluids. J Parenter Sci Technol. 1988; 42:94-7. [PubMed 2905734] 1345.

Messerschmidt W. Pharmazeutische kompatibilität von ceftazidim und metronidazol. Pharm Ztg. 1990; 135:36-8. 1346. Messerschmidt W. Kompatibilität von ciprofloxacin und metronidazol in mischinfusionen. Pharm Ztg. 1988; 133:26-6. 1347. Murdoch JM, Garner ST. Calcium gluconate compatibility. Pharm J. 1989; 242:634. 1348. Stoberski P, Zakrzewski S. Bąndanie stabilności furosemidu i soli sodowej hemibursztynianu hydrochloridu z wybranych płynach infuzyjnych. Farm Pol. 1988; 44:398-401. 1349. Veechho M, Walker SE, Iazzetta J et al. The stability of morphine intravenous infusion solutions. Can J Hosp Pharm. 1988; 41:5-9. 1350. Walker SE, Kirby K.

Stability of ranitidine hydrochloride admixtures refrigerated in polyvinyl chloride minibags. Can J Hosp Pharm. 1988; 41:105-8. 1351. Gupta VD, Pararasmpuria J, Bethea C et al. Stability of clindamycin phosphate in dextrose and saline solutions. Can J Hosp Pharm. 1989; 42:109-12. 1352. Walker SE, Iazzetta J, Lau DWC et al. Famotidine stability in total parenteral nutrient solutions. Can J Hosp Pharm. 1989; 42:97-103. 1353. Walker SE, Dranitsaris G. Ceftazidime stability in normal saline and dextrose 5% in water. Can J Hosp Pharm. 1988; 41:65-71. 1354. Walker SE, Birkhans B. Stability of intravenous vancomycin. Can J Hosp Pharm. 1989; 41:233-8. 1355.

Halpern NA, Colucci RD, Allice M et al. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Clin Pharmacol Ther Toxicol. 1989; 27:294-7. [PubMed 2544533] 1356. Allen LV Jr, Stiles ML. Stability of fentanyl citrate in 0.9% sodium chloride solution in portable infusion pumps. Am J Hosp Pharm. 1990; 47:1572-4. [PubMed 2368750] 1357. Kowalski SR, Goulay G. Stability of fentanyl citrate in glass and plastic containers and in a patient-controlled delivery system. Am J Hosp Pharm. 1990; 47:1584-7. [PubMed 2368752] 1358. Schaff LJ, Robinson DH, Vogel GJ et al. Stability of esmolol hydrochloride in the presence of aminophylline, brytilum tosylate, heparin sodium, and procainamide hydrochloride. Am J Hosp Pharm. 1990; 47:1567-71. [PubMed 2368749] 1359. Rosenberg LS, Hostetler CG, Wagenknecht DM et al. An accurate prediction of the pH change due to degradation: correction for a "produced" secondary buffering system. Pharm Res. 1988; 5:514-7. [PubMed 2344660] 1360. Williams MF, Hak LJ. In vitro evaluation of the stability of ranitidine hydrochloride in total parenteral nutrient mixtures. Am J Hosp Pharm. 1990; 47:1574-9. [PubMed 2141791] 1361. Galante LJ, Stewart JT, Warren FW et al. Stability of ranitidine hydrochloride with eight medications in intravenous admixtures. Am J Hosp Pharm. 1990; 47:1606-10. [PubMed 2368759] 1362. Galante LJ, Stewart JT, Warren FW et al. Stability of ranitidine hydrochloride at dilute concentration in intravenous infusion fluids at room temperature. Am J Hosp Pharm. 1990; 47:1580-4. [PubMed 2368751] 1363. Marquardt ED. Visual compatibility of talozoline hydrochloride with various intravenous admixtures. Am J Hosp Pharm. 1990; 47:1802-3. [PubMed 2369789] 1364. Chandler SW, Felstad J. Aztreonam-vancomycin incompatibility. Am J Hosp Pharm. 1990; 47:1970. [PubMed 2220842] 1365. Trissel LA, Frumante SM. Visual compatibility of ondansetron hydrochloride with other selected drugs during simulated Y-site injection. Am J Hosp Pharm. 1991; 48:988-92. [PubMed 1830190] 1366. Leak RE, Woodford JD. Pharmaceutical development of ondansetron injection. Eur J Cancer Clin Oncol. 1989; 25(Suppl 1):S67-S69. 1367.

Mackinnon JW, Collin DT. The chemistry of ondansetron. Eur J Cancer Clin Oncol. 1989; 25(Suppl 1):S61. [PubMed 2533900] 1368. Adria Laboratories.

Idamycin—hospital formulary product information form. Columbus, OH; 1990 Oct 19. 1369. Allwood M, Stanley A, Wright P. The cytotoxics handbook. 4th ed. Oxford, England: Radcliffe Medical Press; 2002. 1370. Genentech, Inc.

Avastin® (bevacizumab) injection prescribing information. South San Francisco, CA; 2019 Jun. 1371. Sandoz Laboratories. Sandostatin—compatibility between octreotide in the infusion and the giving set/container. Basle, Switzerland; 1986 Apr 3. 1372. Bakri SJ, Snyder MR, Pulido JS et al. Six-month stability of bevacizumab (Avastin) binding to various plastic containers. Am J Hosp Pharm. 1990; 47:1572-4. [PubMed 2368750] 1373. Marchianilo M. Stability of octreotide in various infusion supplies. East Hanover, NJ: Sandoz Pharmaceuticals Corporation; 1990 Mar 20. 1374. Beijnen JH, Beijnen-Bandhoe AU, Dubbelman AC et al. Chemical and physical stability of etoposide and teniposide in commonly used infusion fluids. J Parenter Sci Technol. 1991; 45:108-12. [PubMed 2051255] 1375. Santiero ML, Sagraves R.

Osmolality of small-volume i.v. admixtures for pediatric patients. Am J Hosp Pharm. 1990; 47:1359-64. [PubMed 2368732] 1376. Messerschmidt W. Kompatibilität von cefuroxim mit metronidazole. Krankenhauspharmazie. 1987; 8:45-7. 1377.

Rosen GH. Potential incompatibility of insulin and octreotide in total parenteral nutrient solutions. Am J Hosp Pharm. 1989; 46:1128. [PubMed 2502011] 1378. McElnay JC, Elliott DS, Cartwright-Shamoon J et al. Stability of methotrexate and vinblastine in burette administration sets. Int J Pharm. 1988; 47:239-47.

1379. Williams DA. Stability and compatibility of admixtures of antineoplastic drugs.

En: Lokich JJ, ed. Cancer chemotherapy by infusion. 2nd ed. Chicago, IL: Precept Press; 1990:52-73. 1380. Baaske DM, DeMay JF, Latona CA et al. Stability of nicardipine hydrochloride in intravenous solutions. Am J Health-Syst Pharm. 1996; 53:1701-5. [PubMed 8827237] 1381. Trissel LA, Chandler SW. Visual compatibility of amarsine with selected drugs during simulated Y-site injection. Am J Hosp Pharm. 1990; 47:2525-8. [PubMed 2728268] 1382. Townsend RS. In vitro inactivation of gentamicin by ampicillin. Am J Hosp Pharm. 1989; 46:2250-1. [PubMed 2589333] 1383. Vaughn LM, Small C. Incompatibility of iron dextran and a total nutrient admixture. Am J Hosp Pharm. 1990; 47:1745-6. [PubMed 2117854] 1384. Cutie MR. Verapamil precipitation. Ann Intern Med. 1983; 98:672. [PubMed 6303173] 1385. Garner SS, Wiest DB. Compatibility of drugs separated by a fluid barrier in a retrograde intravenous infusion system. Am J Hosp Pharm. 1990; 47:604-6. [PubMed 2107740] 1386. Lokich J, Anderson N, Bern M et al. Combined fluorouridine and cisplatin in a 14-day infusion. Cancer. 1988; 62:2309-12. [PubMed 2972354] 1387. Anderson N, Lokich J, Bern M et al. A phase I clinical trial of combined fluoropyrimidines with leucovorin in a 14-day infusion. Cancer. 1989; 63:233-7. [PubMed 2521296] 1388. Lokich J, Anderson N, Bern M et al. Etoposide admixed with cisplatin. Cancer. 1989; 63:818-21. [PubMed 2914288] 1389. Lokich J, Bern M, Anderson N et al. Cyclophosphamide, methotrexate, and 5-fluorouracil in a three-drug admixture. Cancer. 1989; 63:822-4. [PubMed 2914289] 1390. Anderson N, Lokich J, Bern M et al. Combined 5-fluorouracil and fluorouridine administered as a 14-day infusion. Cancer. 1989; 63:825-7. [PubMed 2521571] 1391. Stiles ML, Tu YH. Stability of cefazolin sodium, cefoxitin sodium, ceftazidime, and penicillin G sodium in portable pump reservoirs. Am J Hosp Pharm. 1989; 46:1408-12. [PubMed 2667354] 1392. Martens JH, De Goede PN. Sorption of various drugs in polyvinyl chloride, glass, and polyethylene-lined infusion containers. Am J Hosp Pharm. 1990; 47:369-73. [PubMed 2309728] 1393. Baltz JK, Kennedy P, Minor JR et al. Visual compatibility of foscanet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm. 1990; 47:2075-7. [PubMed 2145761] 1394. Walker SE, Coons C, Matte D et al. Hydromorphone and morphine stability in portable infusion pump cassettes and minibags. Can J Hosp Pharm. 1988; 41:177-82. 1395. Smythe M, Malouf E. Visual compatibility of insulin with secondary intravenous drugs in admixtures. Am J Hosp Pharm. 1989; 48:125-6. [PubMed 2000872] 1396. Tu YH, Stiles ML. Stability of fentanyl citrate and bupivacaine hydrochloride in portable pump reservoirs. Am J Hosp Pharm. 1990; 47:2037-40. [PubMed 2220858] 1397. Pugh CB, Pabis DJ. Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection. Am J Hosp Pharm. 1990; 47:123-5. [PubMed 2000871] 1398. Pritts D, Hancock D. Incompatibility of ceftriaxone with vancomycin. Am J Hosp Pharm. 1991; 48:77. [PubMed 2000880] 1399. DeMuyneck C, De Vroe C, Remon JP et al. Binding of drugs to end-line filters: a study of four commonly administered drugs in intensive care units. J Clin Pharm Ther. 1989; 14:335-40. [PubMed 3230098] 1400. Aki H, Sawai N, Yamamoto K et al. Structural confirmation of ampicillin polymers formed in aqueous solution. Pharm Res. 1991; 8:119-22. [PubMed 2014199] 1401. Bonhomme L, Postaire E, Touratier S et al. Chemical stability of lignocaine (lidocaine) and adrenaline (epinephrine) in pH-adjusted parenteral solutions. J Clin Pharm Ther. 1988; 13:257-61. [PubMed 3235475] 1402. Lee DKT. See 1408 A.

Compatibility of cefepazone sodium and furosemide in 5% dextrose injection. Am J Hosp Pharm. 1991; 48:100-10. [PubMed 2000865] 1403. Lee DK, Wang DP. Compatibility of cefepazone sodium and cimetidine hydrochloride in 5% dextrose injection. Am J Hosp Pharm. 1991; 48:111-3. [PubMed 2000866] 1404. Kirkpatrick AE, Holcombe BJ. Effect of retrograde aminophylline administration on calcium and phosphate solubility in neonatal total parenteral nutrient solutions. Am J Hosp Pharm. 1989; 46:2496-500. [PubMed 2513716] 1405.

Seay R, Bostrom B. Apparent compatibility of methotrexate and vancomycin. Am J Hosp Pharm. 1990; 47:2656. [PubMed 2782787] 1406. Johnson OL, Washington C, Davis SS et al. The destabilization of parenteral feeding emulsions by heparin. Int J Pharm. 1989; 53:237-40. 1407. Lor E, Sheybani T. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm. 1991; 48:744-6. [PubMed 2226787] 1408. Tol A, Quik RF. Sorption of human and porcine insulins to intravenous administration sets. Pharm Weekbl [Sci]. 1989; 10:213-6. 1409.

Cartwright-Shamoon DF, Allen LV Jr. Visual compatibility with selected intravenous medications during simulated Y-site injection. Am J Hosp Pharm. 1990; 47:2530-1. [PubMed 2177585] 1410. Wilson TD, Forde MD. Stability of milrinone and epinephrine, atropine sulfate, lidocaine hydrochloride, or morphine sulfate injection. Am J Hosp Pharm. 1990; 47:2504-7. [PubMed 2728621] 1411. Lam NP, Kennedy PE, Jarosinski PF et al. Stability of zidovudine in 5% dextrose injection and 0.9% sodium chloride injection. Am J Hosp Pharm. 1991; 48:280-2. [PubMed 2003500] 1412. Horrow JC, Digregorio GJ, Barbieri EJ et al. Intravenous infusions of nitroprusside, dobutamine, and nitroglycerin are compatible. Crit Care Med. 1990; 18:858-61. [PubMed 1116261] 1413. Halstead CD, Guzzo J, Giardina JA et al. In vitro bactericidal activities of gentamicin, ceftazolin, and imipenem in peritoneal dialysis fluids. Antimicrob Agents Chemother. 1989; 33:1553-6. [PubMed 2510594][Free Fulltext PMC] 1414. Drake JM, Myre SA, Stanekc JL et al. Antimicrobial activity of vancomycin, gentamicin, and tobramycin in peritoneal dialysis solution. Am J Hosp Pharm. 1990; 47:1604-6. [PubMed 2368758] 1415.

Pavlik EJ, van Nagel JH, Hanson MB et al. Sensitivity to anticancer agents in vitro: standardizing the cytotoxic response and characterizing the sensitivities of a reference cell line. Gynecol Oncol. 1982; 14:243-61. [PubMed 7129221] 1416.

Pavlik EJ, Kenady DE, van Nagel JR et al. Properties of anticancer agents relevant to in vitro determinations of human tumor cell sensitivity. Cancer Chemother Pharmacol. 1983; 11:8-15. [PubMed 6883628] 1417. Gora ML, Seth S, Visconti JA et al. Stability of dobutamine hydrochloride in peritoneal dialysis solutions. Am J Hosp Pharm. 1991; 48:1234-7. [PubMed 1858802] 1418. Strom JG Jr, Miller SW. Stability and compatibility of methylprednisolone sodium succinate and cimetidine hydrochloride in 5% dextrose injection. Am J Hosp Pharm. 1991; 48:1237-41. [PubMed 1858803] 1419. Riley CM, Junkin P. Stability of amnionine and digoxin, procainamide hydrochloride, propranolol hydrochloride, sodium bicarbonate, potassium chloride, or verapamil hydrochloride in intravenous admixtures. Am J Hosp Pharm. 1991; 48:1245-52. [PubMed 1650135] 1420. Pennell AT, Allington DR. Effect of ceftazidime, cefotaxime, and cefepazone on serum tobramycin concentrations. Am J Hosp Pharm. 1991; 48:520-2. [PubMed 2029001] 1421. Collins LJ, Lutz RJ. In vitro study of simultaneous infusion of chemotherapeutic drugs in multilumen catheters. Heart Lung. 1991; 20:271-7. [PubMed 1903369] 1422. Gupta VD. Complexation of procainamide with dextrose. J Pharm Sci. 1982; 71:994-6. [PubMed 7131286] 1423. Gupta VD. Complexation of procainamide with hydroxide-containing compounds. J Pharm Sci. 1983; 72:205-7. [PubMed 6834262] 1424. Pararasmpuria J, Gupta VD. Preformulation studies of acetazolamide: effect of pH, two buffer systems, ionic strength, and temperature on its stability. J Pharm Sci. 1989; 78:855-7. [PubMed 2600793] 1425. Frazin BS. Maximal dilution of activase. Am J Hosp Pharm. 1990; 47:1016. [PubMed 2107737] 1426. Tripp MG. Automated 3-in-1 admixture compounding: a comparative study of simultaneous versus sequential pumping of core substrates on admixture stability. Hosp Pharm. 1990; 25:1090-3. 1427. Knowles JB, Cusson G, Smith M et al. Pulmonary deposition of calcium phosphate crystals as a complication of home total parenteral nutrition. JPN J Parenter Enteral Nutr. 1989; 13:209-13. [PubMed 2496525] 1428. Knight PJ, Buchanan S. Calcium and phosphate requirements of preterm infants who require prolonged hyperalimentation. J Am Med Assoc. 1980; 243:1244-6. 1429. Stennett DJ, Gerwick WH, Egging PK et al. Precipitate analysis from an indwelling total parenteral nutrition catheter. JPN J Parenter Enteral Nutr. 1988; 12:88-92. [PubMed 3125364] 1430. Mazur RH, Stennett DJ, Egging PK. Extraction of diethylhexylphthalate from total nutrient solution-containing polyvinyl chloride bags. J Parenter Enteral Nutr. 1989; 13:426. [PubMed 2496525] 1431. Smith IL, Canham JE, Kirkland WD et al. Effect of intralipid, amino acids, calcium, temperature, and duration of storage on vitamin stability in total parenteral nutrition admixtures. JPN J Parenter Enteral Nutr. 1988; 12:478-83. [PubMed 3141645] 1432. Tripp MG, Menon SK. Stability of total nutrient admixtures in a dual-chamber flexible container. Am J Hosp Pharm. 1990; 47:2496-503. [PubMed 21216163] 1433. Dalton-Bunnow MF, Halvaks RJ. Update on room-temperature stability of drug products labeled for refrigerated storage. Am J Hosp Pharm. 1990; 47:2522-4. [PubMed 2728267] 1434. Kintzel PE, Kennedy PE. Stability of amphotericin B in 5% dextrose injection at concentrations used for administration through a central venous line. Am J Hosp Pharm. 1991; 48:283-5. [PubMed 2003501] 1435.

Rice JK.

Visual compatibility of am

Am J Hosp Pharm. 1990; 47:1516. Stewart JT, Warren FW, Johnson SM et al. Stability of ranitidine in intravenous admixtures stored frozen, refrigerated, and at room temperature. Am J Hosp Pharm. 1990; 47:2043-6. [PubMed 2208660] 1517. Thibault L. Streptokinase flocculation in evacuated glass bottles. Am J Hosp Pharm. 1985; 42:278.

[PubMed 3976669] 1518. Lerebours E, Ducable G, Franceschi A, et al. Catheter obstruction during prolonged parenteral alimentation. Are lipids responsible? Clin Nutr. 1985; 4:135-8. 1519. Den Hartigh J, Brandenburg HCR. Stability of azacitidine in lactated Ringers's injection frozen in polypropylene syringes. Am J Hosp Pharm. 1989; 46:2500-5. [PubMed 2481397] 1520. Waugh WN, Trissel LA. Stability, compatibility, and plasticizer extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers. Am J Hosp Pharm. 1991; 48:1520-4. [PubMed 1679294] 1521. Strong K, Morris LA. Precipitation of teniposide during infusion. Am J Hosp Pharm. 1990; 47:512. [PubMed 2316530] 1522. Outman WR, Mitrano FP. Visual compatibility of ganciclovir sodium and total parenteral nutrient solution during simulated Y-site injection. Am J Hosp Pharm. 1991; 48:1538-9. [PubMed 1909095] 1523. Outman WR, Monolakis J. Visual compatibility of haloperidol lactate with 0.9% sodium chloride injection or injectable critical-care drugs during simulated Y-site injection. Am J Hosp Pharm. 1991; 48:1539-41. [PubMed 1882889] 1524.

Neels JC. Compatibility of hydromorphone hydrochloride and tetracaine hydrochloride. Am J Hosp Pharm. 1991; 48:1682-83. [PubMed 1716855] 1525. Trowers RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm. 1991; 48:2181-4. [PubMed 1781476] 1526. Woloschuk DMM, Wermeling JR. Stability and compatibility of fluorouracil and mannitol during simulated Y-site administration. Am J Hosp Pharm. 1991; 48:2158-60. [PubMed 1781472] 1527. Ishisaka DY, van Fleet J. Visual compatibility of idomethacin sodium trihydrate with drugs given to neonates by continuous infusion. Am J Hosp Pharm. 1991; 48:2442-3. [PubMed 1746582] 1528. Trissel LA, Bready BB. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm. 1992; 49:1716-9. [PubMed 1352424] 1529. DiStefano JE, Outman WR. Additional data on visual compatibility of foscarnet sodium with morphine sulfate. Am J Hosp Pharm. 1992; 49:1672. [PubMed 1535751] 1530. Zanetti LA. Visual compatibility of diltiazem with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm. 1992; 49:1911. [PubMed 1442831] 1531. Martin KM. (Product Information Services, Lederle Laboratories, Pearl River, NY): Personal communication; 1992 Jan 14. 1532. Walker SE, DeAngelis C. Stability and compatibility of combinations of hydromorphone and a second drug. Can J Hosp Pharm. 1991; 44:289-95. 1533. Raineri DL, Cwik MJ, Rodvold KA et al. Stability of nizatidine in commonly used intravenous fluids and containers. Am J Hosp Pharm. 1988; 45:1523-9. [PubMed 3137816] 1534.

Hatton J, Holstad SG, Rosenblum AD et al. Stability of nizatidine in total nutrient admixtures. Am J Hosp Pharm. 1991; 48:1507-10. [PubMed 1679293] 1535. Wade CS, Lampasona V, Mullins RE et al. Stability of cefazidime and amino acids in parenteral nutrient solutions. Am J Hosp Pharm. 1991; 48:1515-9. [PubMed 1909093] 1536. Patel JP, Tran LT, Sinaï WJ et al. Activity of urokinase diluted in 0.9% sodium chloride injection or 5% dextrose injection and stored in glass or plastic syringes. Am J Hosp Pharm. 1991; 48:1511-4. [PubMed 1882883] 1537. Kintzel PE, Kennedy PE. Stability of amphotericin B in 5% dextrose injection at 25 °C. Am J Hosp Pharm. 1991; 48:1681. [PubMed 1897539] 1538. Stiles ML, Allen LV. Stability of doxorubicin hydrochloride in portable pump reservoirs. Am J Hosp Pharm. 1991; 48:1976-7. [PubMed 1928146] 1539. Sarkar MA, Rogers E, Reinhard M et al. Stability of clindamycin phosphate, ranitidine hydrochloride, and piperacillin sodium in polyolefin containers. Am J Hosp Pharm. 1991; 48:2184-6.

[PubMed 1781477] 1540. Ritchie DJ, Holstad SG, Westrich TJ et al. Activity of octreotide acetate in a total nutrient admixture. Am J Hosp Pharm. 1991; 48:2172-5. [PubMed 1781474] 1541. Goodwin SD, Nix DE, Heyd A et al. Compatibility of intravenous fluids with selected drugs and solutions. Am J Hosp Pharm. 1991; 48:2166-71. [PubMed 1781473] 1542. Walker SE, DeAngelis C, Iazzetta J et al. Compatibility of dexamethasone sodium phosphate with hydromorphone hydrochloride or diphenhydramine hydrochloride. Am J Hosp Pharm. 1991; 48:2161-6. [PubMed 1723578] 1543. Harkness BJ, Williams D, Stewart MC et al. Change needed for i.v. rifampin preparation instructions. Am J Hosp Pharm. 1991; 48:2127-8. [PubMed 1781461] 1544. Wiest DB, Maish WA, Garner SS et al. Stability of amphotericin B in four concentrations of dextrose injection. Am J Hosp Pharm. 1991; 48:2430-3. [PubMed 1746578] 1545. Silvestri AP, Mitrano FP, Baptista RJ et al. Stability and compatibility of ganciclovir sodium in 5% dextrose injection over 35 days. Am J Hosp Pharm. 1991; 48:2641-3. [PubMed 1814209] 1546. Mitrano FP, Outman WR, Baptista RJ et al. Chemical and visual stability of amphotericin B in 5% dextrose injection stored at 4 °C for 35 days. Am J Hosp Pharm. 1991; 48:2635-7. [PubMed 1814207] 1547. Rivers TE, McBride HA. Stability of cefotaxime sodium and metronidazole in an i.v. admixture at 8 °C. Am J Hosp Pharm. 1991; 48:2638-40. [PubMed 1814208] 1548. Rochard EB, Barthes DMC. Stability of fluorouracil, cytarabine, or doxorubicin hydrochloride in ethylene vinyl acetate portable infusion-pump reservoirs. Am J Hosp Pharm. 1992; 49:619-23. [PubMed 1598939] 1549. Letourneau M, Milot L. Visual compatibility of magnesium sulfate with narcotic analgesics. Am J Hosp Pharm. 1992; 49:838-9. [PubMed 1595718] 1550. Thompson DF, Hefflin NR. Incompatibility of injectable indomethacin with gentamicin sulfate or tobramycin sulfate. Am J Hosp Pharm. 1992; 49:836. [PubMed 1595717] 1551. Munoz M, Girona V, Pujol M et al. Stability of ifosfamide in 0.9% sodium chloride solution or water for injection in a portable i.v. pump cassette. Am J Hosp Pharm. 1992; 49:1137-9. [PubMed 1595743] 1552. Anderson PM, Rogosheske JR, Ramsay NKC et al. Biological activity of recombinant interleukin-2 in intravenous admixtures containing antibiotic, morphine sulfate, or total parenteral nutrient solution. Am J Hosp Pharm. 1992; 49:608-12. [PubMed 1598936] 1553. Stiles ML, Allen LV. Stability of ondansetron hydrochloride in portable infusion-pump reservoirs. Am J Hosp Pharm. 1992; 49:1471-3. [PubMed 1388331] 1554. Couch P, Jacobson P. Stability of fluconazole and amino acids in parenteral nutrient solutions. Am J Hosp Pharm. 1992; 49:1459-62. [PubMed 1529990] 1555. McDonald C, Faridah. Solubilities of trimethoprim and sulfamethoxazole at various pH values and crystallization of trimethoprim from infusion fluids. J Parenter Sci Technol. 1991; 45:147-51. [PubMed 1886043] 1556. Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 drugs during simulated Y-site injection. Am J Hosp Pharm. 1993; 50:300-4. [PubMed 8097617] 1557. Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm. 1993; 50:2359-63. [PubMed 8266963] 1558. Trissel LA, Martinez JF. Visual, turbidimetric, and particle-count assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm. 1994; 51:495-9. [PubMed 8017415] 1559. Pearson SD, Trissel LA. Stability and compatibility of minocycline hydrochloride and rifampin in intravenous solutions at various temperatures. Am J Hosp Pharm. 1993; 50:698-702. [PubMed 8470688] 1560. Graham CL, Dukes GE, Kao CF et al. Stability of cefazolin sodium and metronidazole in plastic syringes. Am J Hosp Pharm. 1992; 49:1672-4. [PubMed 1535751] 1561. Halasi S, Naim JG. Stability of hydralazine hydrochloride in parenteral solutions. Can J Hosp Pharm. 1990; 43:237-41. 1562.

Speaker TJ, Turco SJ, Nardone DA et al. A study of the interaction of selected drugs and plastic syringes. J Parenter Sci Technol. 1991; 45:212-7. [PubMed 1753310] 1564. Adams PS, Haines-Nutt RF, Bradford E et al. Pharmaceutical aspects of home infusion therapy for cancer patients. Pharm J. 1987; 238:476-8. 1565. Barnes AR. Chemical stabilities of cefuroxime sodium and metronidazole in an admixture for intravenous infusion. J Clin Pharm Ther. 1990; 15:187-96. [PubMed 2365756] 1566. Weir PJ, Ireland DS. Chemical stability of cytarabine and vinblastine injections. Br J Pharm Pract. (Feb) 1990; 12:53, 54, 60.

1567. Vincke BJ, Verstraeten AE, El Eini DID et al. Extended stability of 5-fluorouracil and methotrexate solutions in PVC containers. Int J Pharm. 1989; 54:181-9. 1568. Stevens RF, Wilkins KM. Use of cytotoxic drugs with an end-line filter—a study of four drugs commonly administered to paediatric patients. J Clin Pharm Ther. 1989; 14:475-9. [PubMed 2613773] 1569. Garner ST, Murdoch JM. Dopamine dilutions. Pharm J. 1990; 244:218. 1570.

Schroder F, Schutz H. Kompatibilitat von heparin und gentamicin sulfat. Pharm Ztg. 1989; 134:24-6. 1571. Adams PS, Haines-Nutt RF. The stability of aminophylline intravenous infusion solutions. Proc Guild. 1988; 25:41-4. 1572. Schaaf LJ, Tremel LC, Wulf BG et al. Compatibility of enalaprilat with dobutamine, dopamine, heparin, nitroglycerin, potassium chloride, and nitroprusside. J Clin Pharm Ther. 1990; 15:371-6. [PubMed 1963175] 1573. Kern JW, Lee KJ, Martinoff JT et al. The in vivo availability of gentamicin when admixed with total nutrient solutions: a comparative study. JPEN J Parenter Enteral Nutr. 1990; 14:523-6. [PubMed 2122026] 1574. Montoro JB, Galard R, Catalan R et al. Stability of somatostatin in the total parenteral nutrition. Pharm Weekbl [Sci]. 1990; 12:240-2. 1575. Sauer H. Aufbewahrung von zytostatika-lösungen. Krankenhauspharmazie. 1990; 11:373-5. 1576. Shea BF, Souney PF, Dukes GE, Amato JG. Stability of amphotericin B in 5% dextrose injection over 35 days. Am J Hosp Pharm. 1991; 48:2641-3. [PubMed 1814209] 1577. De Vroe C, De Mynck C, Remon JP et al. A study on the stability of three antineoplastic drugs and on their sorption by i.v. delivery systems and end-line filters. Int J Pharm. 1990; 65:49-56. 1578. Reymond JC, Davis NL. Physical compatibility and chemical stability of amphotericin B admixture with magnesium sulfate in 5% dextrose injection. DICP. 1991; 25:123-6. [PubMed 1554924] 1579. Pramay Y, Gupta VD, Gardner SN et al. Stabilities of dobutamine, dopamine, nitroglycerin, and sodium nitroprusside in disposable plastic syringes. J Clin Pharm Ther. 1991; 16:203-7. [PubMed 1907977] 1580. Stewart JT, Warren FW, Johnson SM et al. Stability of cefazidime in plastic syringes and glass vials under various storage conditions. Am J Hosp Pharm. 1992; 49:2765-8. [PubMed 1471643] 1581.

Stiles ML, Allen LV Jr. Stability of cefazidime (with arginine) and cefuroxime sodium in infusion-pump reservoirs. Am J Hosp Pharm. 1992; 49:2761-4. [PubMed 1471642] 1582. Kaufman MB, Scavone JM. Stability of undiluted trimethoprim-sulfamethoxazole for injection in plastic syringes. Am J Hosp Pharm. 1992; 49:2782-3. [PubMed 1471648] 1583. Nahata MC, Morosco RS. Stability of morphine sulfate in bacteriostatic 0.9% sodium chloride injection stored in glass vials at two temperatures. Am J Hosp Pharm. 1992; 49:2785-6. [PubMed 1471650] 1584. Nahata MC, Morosco RS. Stability of cefazidime (with arginine) stored in plastic syringes at three temperatures. Am J Hosp Pharm. 1992; 49:2954-6. [PubMed 1481801] 1585. Mawhinney WM, Adair CG, Gorman SP et al. Stability of ciprofloxacin in peritoneal dialysis solutions. Am J Hosp Pharm. 1992; 49:2956-9. [PubMed 1481801] 1586. Nahata MC, Morosco RS. Stability of aminophylline in bacteriostatic water for injection stored in plastic syringes at two temperatures. Am J Hosp Pharm. 1992; 49:2962-3. [PubMed 1481803] 1587. Allwood MC. The influence of buffering on the stability of erythromycin injection in small-volume infusions. Int J Pharm. 1992; 80:R7-9. 1588. Toki N. Glass adsorption of highly purified urokinase. Tromb Haemost. 1980; 43:67. [PubMed 6996206] 1589. Zimmerman R, Schoffel G. Urokinase therapy: dose reduction by administration in plastic material. Tromb Haemost. 1981; 45:296. [PubMed 7025343] 1590. Walker SE, Iazzetta J. Compatibility and stability of pentobarbital infusions. Anesthesiology. 1991; 55:487-9. [PubMed 7294399] 1591. Walker SE, Iazzetta J. Cefotetan stability in normal saline and five percent dextrose in water. Can J Hosp Pharm. (1) 1992; 45:9-13, 37. 1592. Nahata MC. Stability of ceftriaxone sodium in peritoneal dialysis solutions. DICP. 1991; 25:741-2. [PubMed 1949930] 1593. Walker SE, Lau DWC, DeAngelis C et al. Mitoxantrone stability in syringes and glass vials and evaluation of chemical contamination. Can J Hosp Pharm. 1991; 44:143-51. 1594. Walker S, Lau D, DeAngelis C et al. Doxorubicin stability in syringes and glass vials and evaluation of chemical contamination. Can J Hosp Pharm. 1991; 44:71-78. 1595. Peterson GM, Khoo BHC, Galloway JC et al. A preliminary study of the stability of midazolam in polypropylene syringes. Aust J Hosp Pharm. 1991; 21:115-8. 1596. Lecompte D, Bousselet M, Gayraud D et al. Stability study of reconstituted and diluted solutions of calcium folinate. Pharm Ind. 1991; 53:90-4. 1597. Allwood MC. The stability of erythromycin injection in small-volume infusions. Int J Pharm. 1990; 62:R1-R3. 1598. Gupta VD, Pramay Y, Odom C et al. Chemical stability of cefotetan disodium in 5% dextrose and 0.9% sodium chloride injections. J Clin Pharm Ther. 1990; 15:109-14. [PubMed 2341489] 1599. Poggi GL. Compatibility of morphine tartrate admixtures in polypropylene syringes. Aust J Hosp Pharm. 1991; 21:316.

McLaughlin JP, Simpson C. The stability of reconstituted aztreonam. Br J Pharm Pract. (Oct) 1990; 12:328. 330, 334. 1601. Beijnen JH, van Gijn R, Horenblas S et al. Chemical stability of suramin in commonly used infusion fluids. DICP. 1990; 24:1056-8. [PubMed 2752277] 1602. Patel JP. Urokinase: stability studies in solution and lyophilized formulations. Drug Dev Ind Pharm. 1990; 16:2613-26. 1603. Driver AG, Worden JP Jr. Intravenous streptomycin. DICP. 1990; 24:826-8. [PubMed 2260337] 1605. Theuer H, Scherbel G, Distler F et al. Cisplatin-injektionslösung. Krankenhauspharmazie. 1990; 16:2613-26. 1606. Blumh DP, Summers RS, Lowes MMJ et al. Influence of container on vitamin A stability in TPN admixtures. Int J Pharm. 1991; 68:281-3. 1607. Blumh DP, Summers RS, Lowes MMJ et al. Lipid emulsion content and vitamin A stability in TPN admixtures. Int J Pharm. 1991; 68:277-80. 1608. Beijnen J, Koks CHW. Visual compatibility of ondansetron and dexamethasone. DICP. 1991; 25:869. 1609. Lawson WA, Longmore RB, McDonald C et al. Stability of hyoscine in mixtures with morphine for continuous subcutaneous administration. Aust J Hosp Pharm. 1991; 21:395-6. 1610. Allwood MC. The stability of four catecholamines in 5% glucose infusions. J Clin Pharm Ther. 1991; 16:337-40. [PubMed 1752912] 1611. Van Asten P, Glerum JH, Spaanderman ER et al. Compatibility of bupivacaine and iohexol in two mixtures for paediatric regional anaesthesia. Pharm Weekbl Sci. 1991; 13:254-6. [IDIS 293188] [PubMed 1795936] 1612. Sewell GJ, Palmer AJ. The chemical and physical stability of three intravenous infusions subjected to frozen storage and microwave thawing. Int J Pharm. 1991; 72:57-63.

1613. Jankegt R, Stratermans T, Clissen J et al. Ofloxacin intravenous—compatibility with other antibacterial agents. Pharm Weekbl Sci. 1991; 13:207-9. 1614. Dunham B, Marcuard S, Khazanie PG et al. The solubility of calcium and phosphorus in neonatal total parenteral nutrient solutions. JPEN J Parenter Enteral Nutr. 1991; 15:608-11. [PubMed 1766049] 1615. Delaney RA, Mikkelsen SL. Effects of heat treatment on selected plasma therapeutic drug concentrations. Ann Pharmacother. 1992; 26:338-40. [PubMed 1554952] 1616.

McLeod HL, McGuire TR. Stability of cyclosporine in dextrose 5%, NaCl 0.9%, dextrose/amino acid solution, and lipid emulsion. Ann Pharmacother. 1992; 26:172-5. [PubMed 1554924] 1617. Andreu A, Cardona D, Pastor C et al. Intravenous aminophylline: in vitro stability in fat-containing TPN. Ann Pharmacother. 1992; 26:127-8. [PubMed 1606335] 1618. Matsuura G. Visual compatibility of sargramostim (GM-CSF) during simulated Y-site administration with selected agents. Hosp Pharm. (Mar) 1992; 27:200. 202, 209. 1619. De Mynck C, Colardyn F, Remon JP. Influence of intravenous administration set composition on the sorption of isosorbide dinitrate. J Pharm Pharmacol. 1991; 43:601-4. [PubMed 1685515] 1620. Bullock L, Fitzgerald JF, Walter WV. Emulsion stability in total nutrient admixtures containing a pediatric amino acid formulation. JPEN J Parenter Enteral Nutr. 1992; 16:64-8. [PubMed 1738223] 1621. Ollrich A. Weichmacher als problematische bestandteile von mischinfusionen. Krankenhauspharmazie. 1991; 12:192-4. 1622. Cano SM, Montoro JB, Pastor C et al. Stability of cimetidine in total parenteral nutrition. J Clin Nutr Gastroenter. 1987; 2:40-3. 1623. Loeppky C, Tarka E. Compatibility of cephalosporins and aminoglycosides in peritoneal dialysis fluid. Perit Dial Bull. 1983; 3:128-9. 1624. Bhatt-Mehta V, Rosen DA, King RS et al. Stability of midazolam hydrochloride in parenteral nutrient solutions. Am J Hosp Pharm. 1993; 50:285-8. [PubMed 8480785] 1625. Jacobson PA, Maksym CJ, Landvay A et al. Compatibility of cyclosporine with fat emulsion. Am J Hosp Pharm. 1993; 50:687-90. [PubMed 8470685] 1626. Johnson CE, Jacobson PA, Pillen HA et al. Stability and compatibility of fluconazole and aminophylline in intravenous admixtures. Am J Hosp Pharm. 1993; 50:703-6. [PubMed 8470689] 1627. Allen LV Jr, Stiles ML, Wang DP et al. Stability of bupivacaine hydrochloride, epinephrine hydrochloride, and fentanyl citrate in portable infusion-pump reservoirs. Am J Hosp Pharm. 1993; 50:714-5. [PubMed 8470692] 1628.

Pearl LA, Rho JP. Visual compatibility of ciprofloxacin with selected components of total parenteral nutrient solutions during simulated Y-site injection. Am J Hosp Pharm. 1993; 50:715-6. [PubMed 8470693] 1629. Nieforth KA, Shea BF, Souney PF et al. Stability of cyclosporine with magnesium sulfate in 5% dextrose injection. Am J Hosp Pharm. 1993; 50:470-2. [PubMed 8442464] 1630. Min DI, Brown T. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm. 1992; 49:2964-6. [PubMed 1282779] 1631.

Dine T, Luyckx M, Cazin JC et al. Stability and compatibility studies of vinblastine, vincristine, vindesine and vinorelbine with PVC infusion bags. Int J Pharm. 1991; 77:279-85. 1632. Inagaki K, Gill MA, Okamoto MP et al. Stability of ranitidine hydrochloride with aztreonam, ceftazidime, or piperacillin sodium during simulated Y-site administration. Am J Hosp Pharm. 1992; 49:2769-72. [PubMed 1471644] 1633. Mitra AK, Narurkar MM. Kinetics of azathioprine degradation in aqueous solution. Int J Pharm. 1986; 35:165-71. 1634.

Snyder RL. Filter clogging caused by albumin in i.v. nutrient solution. Am J Hosp Pharm. 1993; 50:63-4. [PubMed 8427280] 1635. Feldman F, Bergman G. Filter clogging caused by albumin in i.v. nutrient solution. Am J Hosp Pharm. 1993; 50:63. [PubMed 8427281] 1636. Bornstein M, Kao SH, Mercorelli M et al. Stability of an ofloxacin injection in various infusion fluids. Am J Hosp Pharm. 1992; 49:2756-60. [PubMed 1335226] 1637. Heni J. Rekonstituierte ganciclovirlösung. Krankenhauspharmazie. 1991; 12:342-4. 1638. Theuer H, Scherbel G. Stabilitätsuntersuchungen von Gentamicin in TPN. Krankenhauspharmazie. 1991; 12:233-45. 1639. Burger DM, Brandjes DP, Koks CH, et al. Heparine in het heparineslot? Pharm Weekbl. 1991; 126:624-7. 1640. Witmer DR. Heparin lock flush solution versus 0.9% sodium chloride injection for maintaining patency. Am J Hosp Pharm. 1993; 50:241. [PubMed 8480774] 1641. Weber DR. Is heparin really necessary in the lock and, if so, how much? DICP. 1991; 25:399-407. 1642. Bosso JA, Prince RA. Stability of ondansetron hydrochloride in injectable solutions at -20, 5, and 25 °C. Am J Hosp Pharm. 1992; 49:2223-5. [PubMed 1388000] 1643. Pararasamuria J, Li LC, Stelmach AH et al. Stability of ganciclovir sodium in 5% dextrose injection and in 0.9% sodium chloride injection over 35 days. Am J Hosp Pharm. 1992; 49:116-8. [PubMed 1570851] 1644. Guo-jie LJ. Compatibility of bumetanide injection and dextrose injection. Yaoxue Tongbao. 1989; 24:86-7. 1645. Buck GW, Wolfe KR. Interaction of sodium ascorbate with stainless steel particulate-filter needles. Am J Hosp Pharm. 1991; 48:1191. [PubMed 1907909] 1646. Floy BJ, Royko CG. Compatibility of ketorolac tromethamine injection with common infusion fluids and administration sets. Am J Hosp Pharm. 1990; 47:1097-100. [PubMed 2337102] 1647. Zieske PA, Koberda M, Hines JL et al. Characterization of cisplatin degradation as affected by pH and light. Am J Hosp Pharm. 1991; 48:1500-6. [PubMed 1882882] 1648. Tu YH, Knox NL, Biringer JM et al. Compatibility of iron dextran with total nutrient admixtures. Am J Hosp Pharm. 1992; 49:2233-5. [PubMed 1524069] 1649. Rivers TE, McBride HA, Trang JM. Stability of cefazolin sodium and metronidazole at 8 °C for use as an i.v. admixture. J Parenter Sci Technol. 1992; 47:15-17. [PubMed 1685515] 1650. Helbock HW, Motchnik PA. Toxic hydroperoxides in intravenous lipid emulsions used in preterm infants. Pediatrics. 1993; 91:83-7. [PubMed 8416510] 1651. Washington C, Sizer T. Stability of TPN mixtures compounded from Lipofundin S and Aminoplex amino-acid solutions: comparison of laser diffraction and Coulter counter droplet size analysis. Int J Pharm. 1992; 83:227-31. 1652. Mason NA, Johnson CE. Stability of cefazidime and tobramycin injection in peritoneal dialysis solution. Am J Hosp Pharm. 1992; 49:1139-42. 1653. Brawley V, Bhatia J. Hydrogen peroxide generation in a model paediatric parenteral amino acid solution. Clin Sci. 1993; 85:709-12. [PubMed 8287663] 1654. Mawhinney WM, Adair CG, Gorman SP et al. Stability of vancomycin hydrochloride in peritoneal dialysis solution. Am J Hosp Pharm. 1992; 49:137-9. [PubMed 1570857] 1655. Cervenka P, Dejong DJ, Butler BL et al. Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration. Hosp Pharm. (Nov) 1992; 27:957-8. 961-2. 1656. Garretts JC, LaRocca J, Ast D et al. Comparison of heparin and 0.9% sodium chloride injection in the maintenance of indwelling intermittent i.v. devices. Clin Pharm. 1989; 8:34-9. [PubMed 2643500] 1657. Lewis JS. Justification for use of 1.2 micron end-line filters on total nutrient admixtures. Hosp Pharm. 1993; 28:656-8. 1658.

Benvenuto JA, Adams SC, Vyas HM, et al. Pharmaceutical issues in infusion chemotherapy stability and compatibility. In: Lokich JJ, ed. Cancer chemotherapy by infusion. Chicago, IL: Precept Press; 1987:100-13. 1659. Briceland LL, Fudin J. Evaluation of microbial growth in select inoculated antineoplastic solutions. Hosp Pharm. 1990; 25:338-40. 1660. Nields JT. Compatibility of bupivacaine hydrochloride with hydromorphone hydrochloride or morphine sulfate. Am J Hosp Pharm. 1992; 49:2149. [PubMed 1381871] 1661. Hauser AR, Trissel LA. Ondansetron compatible with sodium acetate. J Clin Oncol. 1993; 11:42-8. [PubMed 8418236] 1662.

Pecosity DA, Pararasamuria J, Li LC et al. Stability and sorption of calcitriol in plastic tuberculin syringes. Am J Hosp Pharm. 1992; 49:1463-6. [PubMed 1529991] 1663. Gregory R, Edwards S. Demonstration of insulin transformation products in insulin vials with high-performance liquid chromatography. Diabetes Care. 1991; 14:42-8. [PubMed 1991434] 1664. Seres DS. Insulin adsorption to parenteral infusion systems: case report and review of the literature. Nutr Clin Pract. 1990; 5:111-7. [PubMed 2114520] 1665. Lazorova L, Haronikova K. Studium sorpcie inulinu v priebehu infuznej terapie. Farm Obz. 1990; 59:157-64. 1666. Stolk LML, Chandi LS. Stabiliteit van fluorouracil (0,55 mg) in polypropylen spuiten bij -20 °C. Ziekenhuisfarmacie. 1991; 7:12-3. 1667. de Vogel EM, Hendrik MMP, van Dellen RT et al. Adsorptie van sulfentail aan bacteriefilters. Ziekenhuisfarmacie. 1991; 7:65-70. 1668. Hehenberger H. Fettemulsionen kompatibel mit während der bypass-infusion. Krankenhauspharmazie. 1989; 10:513-8. 1669. Carstens G. Calcium-foliatn überlegungen zur stabilität und zum einatz verschiedener zubereitungen. Krankenhauspharmazie. 1989; 10:478-82. 1670. Washington C.

Stability of total parenteral nutrient solutions. Int J Pharm. 1990; 66:1-21. 1671. Allwood MC, Brown PW. The effect of buffering on the stability of reconstituted benzylpenicillin injection. Int J Pharm Pract. 1992; 1:242-4. 1672. Allwood MC. The stability of diamorphine alone and in combination with anti-emetics in plastic syringes. Palliative Med. 1991; 5:330-3. 1673. Lober AC, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm. 1993; 50:1208-10. [PubMed 8517464] 1674. Jahns BE, Bakst CM. Extension of expiration time for lorazepam injection at room temperature. Am J Hosp Pharm. 1993; 50:1134. [PubMed 8517447] 1675. Trissel LA, Martinez JF. Idarubicin hydrochloride turbidity versus incompatibility. Am J Hosp Pharm. 1993; 50:1134. [PubMed 8517448] 1676. Hunt-Fugate AK, Hennessey CK. Stability of fluconazole injectable solutions. Am J Hosp Pharm. 1993; 50:1186-7. [PubMed 8517459] 1677.

Inagaki K, Takagi J, Lor E et al. Stability of fluconazole in commonly used intravenous antibiotic solutions. Am J Hosp Pharm. 1993; 50:1206-8. [PubMed 8517463] 1678. Liao E, Fox JL. In-line filtration of ondansetron hydrochloride during simulated i.v. administration. Am J Hosp Pharm. 1993; 50:906. [PubMed 8506862] 1679. Bellevue PP, Shea BF. Stability of metoprolol tartrate in 5% dextrose injection or 0.9% sodium chloride injection. Am J Hosp Pharm. 1993; 50:950-2. [PubMed 8506875] 1680.

Ringwood MA. Stability of cefepime for injection for IM or IV use following constitution/dilution. Syracuse, NY: Bristol-Myers Company; 1990 Aug 16. 1681. Ringwood MA, Vance VH. Cefepime IM, IV, and compatibility studies for U.S. registration filing. Syracuse, NY: Bristol-Myers Company; 1992 May 13. 1682. Vance VH. Stability of cefepime admixed with vancomycin, metronidazole, ampicillin, clindamycin, tobramycin, netilmicin, TPN solution, and PD solution. Syracuse, NY: Bristol-Myers Company; 1992 Oct 14. 1683. Pearson SD, Trissel LA. Leaching of diethylethyl phthalate from polyvinyl chloride containers by selected drugs and formulation components. Am J Hosp Pharm. 1993; 50:1405-9. [PubMed 8362871] 1684. Trissel LA, Pearson SD. Storage of lorazepam in three injectable solutions in polyvinyl chloride and polyolefin bags. Am J Hosp Pharm. 1994; 51:368-72. [PubMed 8160690] 1686. Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm. 1994; 51:1792-9. [PubMed 7942908] 1687. Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm. 1994; 51:1907-13. [PubMed 7524319] 1688. Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam sodium with selected drugs during simulated Y-site injection. Am J Hosp Pharm. 1994; 51:672-8. [PubMed 8203388] 1690. Trissel LA, Xu Q, Martinez JF et al. Compatibility and stability of ondansetron hydrochloride with morphine sulfate and hydromorphone hydrochloride in 0.9% sodium chloride injection at various temperatures. Am J Hosp Pharm. 1994; 51:2138-42. [PubMed 7527184] 1691. Bellevue PP, Nightingale CH. Stability of aztreonam and ampicillin/sulbactam in 0.9% saline for injection. Am J Hosp Pharm. 1994; 51:901-4. [PubMed 8017440] 1692. Fisher DM, Canfel C. Stability of atracurium administered by infusion. Anesthesiology. 1984; 61:347-8. [PubMed 6548098] 1693. Harper NJ, Pollard BJ, Edwards D et al. Stability of atracurium in dilute solutions. Br J Anaesth. 1988; 60:344P-345P.

1694. Talton MA (Drug Information, Burroughs Wellcome Company, Research Triangle Park, NC): Personal communication; 1993 Jun 11. 1695. Perrone RK, Kaplan MA. Extent of cisplatin formation in carbolpinat admixtures. Am J Hosp Pharm. 1989; 46:258-9. [PubMed 2653024] 1696. Northcott M, Allsopp MA, Powell H et al. The stability of carbolpinat, diamorphine, 5-fluorouracil and mitoxantrone infusions in an ambulatory pump under storage and prolonged "in-use" conditions. J Clin Pharm Ther. 1991; 16:123-9. [PubMed 1856250] 1697. Ahmed ST, Parkinson R. The stability of drugs in pre-filled syringes: fluoxacinil, ampicillin, cefuroxime, cefotaxime, and ceftazidime. Hosp Pharm Pract. 1992; 2:285-9. 1698. Faouzi A, Dine T, Luyckx M et al. Stability and compatibility studies of pefloxacin, ofloxacin and ciprofloxacin with PVC infusion bags. Int J Pharm. 1993; 89:125-31. 1699. Stiles ML, Allen LV Jr. Gas production of three brands of ceftazidime. Am J Hosp Pharm. 1991; 48:1727-9. [PubMed 1910261] 1700. Dine T, Cazin JC, Gressier B et al. Stability and compatibility of four anthracyclines: doxorubicin, epirubicin, daunorubicin, and pirarubicin with PVC infusion bags. Pharm Weekbl [Sci]. 1992; 14:365-9. 1701. Trissel LA, Martinez JF. Sargramostim incompatibility. Hosp Pharm. 1992; 27:929. 1702.

Trissel LA. Alternative interpretation for data. Am J Hosp Pharm. 1992; 49:570. [PubMed 1598927] 1703. Knapp AJ, Mauro VF. Incompatibility of ketorolac tromethamine with selected postoperative drugs. Am J Hosp Pharm. 1992; 49:2960-2. [PubMed 14851402] 1705. Colon MS (Clinical Development and Medical Affairs, The Upjohn Company, Kalamazoo, MI): Personal communication; 1993 Dec 6. 1706. Chandler SW, Trissel LA, Weinstein SM. Combined administration of opioids with selected drugs to manage pain and other cancer symptoms: initial safety screening for compatibility. J Pain Symptom Manage. 1993; 12:147-51. [PubMed 8803380] 1707.

Nation RL, Hackett LP. Uptake of clonazepam for plastic intravenous infusion bags and administration sets. Am J Hosp Pharm. 1983; 40:1692-3. [PubMed 6386034] 1708. Hooymans PM, Janknegt R. Comparison of clonazepam sorption to polyvinyl chloride-coated and polyethylene-coated tubings. Pharm Weekbl [Sci]. 1990; 12:188-9. 1709. McLaughlin JP, Simpson C. The stability of reconstituted diethanolamine fusidate in a 5% dextrose infusion. Hosp Pharm Pract. 1992; 2:59-62. 1710. Olsen KM, Gurley BJ, Davis GA et al. Stability of flumazenil with selected drugs in 5% dextrose injection. Am J Hosp Pharm. 1993; 50:1907-12. [PubMed 8135238] 1711. Food and Drug Administration. Center for Drug Evaluation and Research. Application number: 20-9401Orig1s8000: Multi-Discipline Review. From FDA website. 1712. Larson PO, Ragi G, Swandby M et al. Stability of buffered lidocaine and epinephrine used for local anesthesia. J Dermatol Surg Oncol. 1991; 17:411-4. [PubMed 2302021] 1713. Stewart JH, Cole GW. Neutralized lidocaine with epinephrine for local anesthesia. J Dermatol Surg Oncol. 1989; 15:1081-3. [PubMed 2794204] 1714.

Nahata MC, Morosco RS. Stability of cimetidine hydrochloride and clindamycin phosphate in water for injection stored in glass vials at two temperatures. Am J Hosp Pharm. 1993; 50:2559-61. [PubMed 8122695] 1715.

1995; 17:87-92. [PubMed 7550055] 2071. Grassby PF, Hutchings L. Drug combinations in syringe drivers: the compatibility and stability of diamorphine with cyclizine and haloperidol. *Palliat Med*. 1997; 11:217-24. [PubMed 9205655] 2072. Cohen MR. Volume limitations for IV drug infusions when sterile water for injection is used as a diluent. *Hosp Pharm*. 1988; 33:274-73. 2073. Pierce LR, Gaines A, Varricchio F et al. Hemolysis and renal failure associated with use of sterile water for injection to dilute 25% human albumin solution.

Am J Health-Syst Pharm. 1998; 55(10):1057, 1062, 1062, 1070. [PubMed 96064559] 2074. Trissel LA, Martinez JF. Compatibility of cistatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm. 1999; 54:921-926. [PubMed 9314339] 2076. Ennis RD, Dahl TC. Stability of cidofovir in 0.9% sodium chloride injection for five days. Am J Health-Syst Pharm. 1997; 54(19):2204-6. [PubMed 9331442] 2077. Murray KM, Ertella D, Gomborze WR et al. Stability of thehep in 0.9% sodium chloride injection. Am J Health-Syst Pharm. 1997; 54(25):2588-91. [PubMed 9397270] 2078. Babal SM, Lee TJ, McGinnes M et al. Visual compatibility of warfarin sodium injection with selected medications and solutions. Am J Health-Syst Pharm. 1997; 54:2599-600. [PubMed 9397223] 2079. Ndaun PE, Hoyer GL, LeDoux JH et al. Stability of ranitidine hydrochloride and human insulin in 0.9% sodium chloride injection. Am J Health-Syst Pharm. 1997; 54:1304-6. [PubMed 9179353] 2080. Stiles ML, Allen LV. Stability of nafcillin sodium, oxacillin sodium, penicillin G potassium, penicillin G sodium, and tobramycin sulfate in polyvinyl chloride drug reservoirs. Am J Health-Syst Pharm. 1997; 54:1068-70. [PubMed 9143657] 2081. Pujol M, Munoz M, Prat J et al. Stability study of epirubicin in NaCl 0.9% injection. Ann Pharmacother. 1997; 31:992-5. [PubMed 9296237] 2082. Walker SE, DeAngelis C. Stability and compatibility of combinations of hydromorphone and a second drug. Can J Hosp Pharm. 1991; 44:289-95. 2083. Fischer JH, Cwik MJ, Luer MS et al. Stability of fosphenytoin sodium with intravenous solutions in glass bottles, polyvinyl chloride bags, and polypropylene syringes. Ann Pharmacother. 1997; 31:553-9. [PubMed 9161647] 2084. Ervard B, Ceccato A, Gaspario O et al. Stability of ondansetron hydrochloride and dexamethasone sodium phosphate in 0.9% sodium chloride injection and in 5% dextrose injection. Am J Health-Syst Pharm. 1997; 54:1065-8. [PubMed 9143656] 2085. Peddicord TE, Olsen KM, ZumBrunnen TL et al. Stability of high-concentration dopamine hydrochloride, norepinephrine bitartrate, epinephrine hydrochloride, and nitroglycerin in 5% dextrose injection. Am J Health-Syst Pharm. 1997; 54:1065-8. [PubMed 9143656] 2086. Trissel LA, Gilbert DL. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm. 1997; 54:2708-13. [PubMed 94008515] 2088. Pramur YV, Loucas VA. Stability of midazolam hydrochloride in syringes and i.v. fluids. Am J Health-Syst Pharm. 1997; 54:913-5. [PubMed 9114923] 2089. Patel PH, Cook SE. Stability of meropenem in intravenous solutions. Am J Health-Syst Pharm. 1997; 54:412-21. [PubMed 9043564] 2090. Cornish LA, Montgomery PA. Stability of bumetanide in 5% dextrose injection. Am J Health-Syst Pharm. 1997; 54:422-3. [PubMed 9043565] 2091. Bailey LC, Orosz ST. Stability of ceftriaxone sodium and metronidazole hydrochloride. Am J Health-Syst Pharm. 1997; 54:424-7. [PubMed 9043566] 2092. Stewart JT, Warren FW, King DT et al. Stability of ondansetron hydrochloride, doxorubicin hydrochloride, and dacarbazine or vincristine solution in elastomeric portable infusion devices and polyvinyl chloride bags. Am J Health-Syst Pharm. 1997; 54:915-20. [PubMed 9114924] 2093. Owens D, Fleming RA, Restino MS et al. Stability of amphotericin B 0.05 and 0.5 mg/mL in 20% fat emulsion. Am J Health-Syst Pharm. 1997; 54:683-6. [PubMed 9075499] 2094. Zhang Y, Xu QA, Trissel LA et al. Compatibility and stability of paclitaxel combined with cisplatin and with carboplatin in infusion solutions. Ann Pharmacother. 1997; 31:1465-70. 2095. Gupta VD, Maswoswe J. Stability of ketorolac tromethamine in 5% dextrose injection and 0.9% sodium chloride injections. Int J Pharm Compound. 1997; 1:206-7. 2096. Zhang YP, Trissel LA. Stability of aminocaproic acid injection admixtures in 5% dextrose injection and 0.9% sodium chloride injection. Int J Pharm Compound. 1997; 1:132-4. 2097. Allen LV, Stiles ML. Stability of vancomycin hydrochloride in medication cassette reservoirs. Int J Pharm Compound. 1997; 1:123-4. 2098. Zhang YP, Trissel LA, Martinez JF et al. Stability of acyclovir sodium 1, 7, and 10 mg/mL in 5% dextrose injection and 0.9% sodium chloride injection. Am J Health-Syst Pharm. 1998; 55:74-7. [PubMed 9544334] 2099. Amador DF, Azzati ES. Stability of carboplatin in polyvinyl chloride bags. Am J Health-Syst Pharm. 1998; 55:602. [PubMed 9544339] 2100. Gupta VD, Maswoswe J. Stability of cefmetazole sodium in 5% dextrose injection and 0.9% sodium chloride injection. Int J Pharm Compound. 1997; 1:208-9. 2101. Gupta VD, Maswoswe J. Stability of cefepime hydrochloride in 5% dextrose injection and 0.9% sodium chloride injection. Int J Pharm Compound. 1997; 1:435-6. 2103. Mayhew SL, Quick MW. Compatibility of iron dextran with neonatal parenteral nutrient solutions. Am J Health-Syst Pharm. 1997; 54:570-1. [PubMed 9066869] 2104. Moshfeghi M, Ciuffo JD. Visual compatibility of fentanyl citrate with parenteral nutrient solutions. Am J Health-Syst Pharm. 1998; 55:1194. [PubMed 9626384] 2105. Gupta VD, Maswoswe J. Stability of indomethacin in 0.9% sodium chloride injection. Int J Pharm Compound. 1998; 2:168-9. 2107. Nguyen D, Gill MA. Stability of milrinone lactate in 5% dextrose injection and 0.9% sodium chloride injection. Int J Pharm Compound. 1997; 1:280-1. 2102. Gupta VD, Maswoswe J. Stability of cefepime hydrochloride in 5% dextrose injection and 0.9% sodium chloride injection. Int J Pharm Compound. 1998; 2:246-8. 2108. Montgomery PA, Cornish LA, Johnson CE et al. Stability of fentanyl in 5% dextrose injection. Am J Health-Syst Pharm. 1998; 55:1042-3. [PubMed 9606457] 2109. Trissel LA, Gilbert DL, Martinez JF et al. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm. 1997; 54:1295-1300. [PubMed 9179351] 2110. Pramur YV. Chemical stability of amiodarone hydrochloride in intravenous fluids. Int J Pharm Compound. 1997; 1:347-8. 2111. Wang DP, Wang MT, Wong CY et al. Compatibility of vancomycin hydrochloride and famotidine in 5% dextrose injection. Int J Pharm Compound. 1997; 1:354-5. 2112. Bhatt-Mehta V, Hirata S. Physical compatibility and chemical stability of atracurium besylate and midazolam hydrochloride during intravenous infusion. Int J Pharm Compound. 1998; 2:79-82. 2113. Stendal TL, Klem W, Tonnesen HH et al. Drug stability and pyridine generation in ceftazidime injection stored in an elastomeric infusion device. Am J Health-Syst Pharm. 1998; 55:683-5. [PubMed 9558424] 2114. Ketkar VA, Kolling WM, Nardviriyakul N et al. Stability of undiluted and diluted adenosine at three temperatures in syringes and bags. Am J Health-Syst Pharm. 1998; 55:466-0. [PubMed 9522931] 2115. Naud C, Marti B, Fernandez C et al. Stability of adenosine 6 mcg/mL in 0.9% sodium chloride solution. Am J Health-Syst Pharm. 1998; 55:1161-4. [PubMed 9626381] 2116. Xu QA, Zhang YP, Trissel LA et al. Stability of cistatracurium besylate in vials, syringes, and infusion admixtures. Am J Health-Syst Pharm. 1998; 55:1037-41. [PubMed 9606456] 2117. Das T, Volety S, Ahsan SM et al. Safety, sterility and stability of direct-from-vial multiple dosing intravitreal injection of bevacizumab. Clin Exp Ophthalmol. 2015; 43:466-73. [PubMed 25545882] 2118. Allwood MC, Martin J. How does storage affect propofol? The stability of propofol in plastic syringes. Pharm Pract. 1997; 7:15-6. 2119. Harris MC, Como JA. Heparin flush solutions: how much is enough? South J Health-Syst Pharm. 1997; 2:10-4. 2120. Meyer BA, Little CJ, Thorp JA et al. Heparin versus normal saline as a peripheral line flush in maintenance of intermittent intravenous lines in obstetric patients. Obstet Gynecol. 1995; 85:433-6. [PubMed 7862386] 2121. Danek GD, Norris EM. Pediatric i.v. catheters: efficacy of saline flush. Pediatr Nurs. 1992; 18:111-3. [PubMed 1574361] 2122. Hook ML, Reuling J, Luettgens ML et al. Comparison of the patency of arterial lines maintained with heparinized and nonheparinized infusions. The Cardiovascular Intensive Care Unit Nursing Research Committee of St. Luke's Hospital. Heart Lung. 1987; 16:693-9. [PubMed 3679863] 2123. Kulkarni M, Elsnser C, Chellett D et al. Heparinized saline versus normal saline in maintaining patency of the radial artery catheter. Can J Surg. 1994; 37:37-42. [PubMed 8306218] 2124. Clifton GD, Branson P, Kelly HJ et al. Comparison of normal saline and heparin solutions for maintenance of arterial catheter patency. Heart Lung. 1991; 20:115-8. [PubMed 13409125] 2125. Ward C, Wack J, Shanks G et al. Effect of heparin concentration and infusion rate on the patency of arterial catheters. Crit Care Med. 1987; 15:230-2. [PubMed 3455674] 2126. Smith S, Dawson S, Hennessey R, et al. Maintenance of the patency of indwelling central venous catheters: is heparin necessary? Am J Pediatr Hematol Oncol. 1991; 13(2):141-3. 2127. O'Neill TJ, Tierney LM Jr, Proulx RJ. Heparin lock-induced alterations in the activated partial thromboplastin time. JAMA. 1974; 227:1297-8. [PubMed 4405979] 2128. Passanante A, Macik BG. Case report: the heparin flush syndrome: a cause of iatrogenic hemorrhage. Am J Med Sci. 1988; 296:71-3. [PubMed 3407682] 2129. Heeger PS, Backstrom JT. Heparin flushes and thrombocytopenia. Ann Intern Med. 1986; 105:143. [PubMed 3717797] 2130. Laster J, Cikrit D, Walker N et al. The heparin-induced thrombocytopenia syndrome: an update. Surgery. 1987; 102:763-70. [PubMed 2958948] 2131. Rizzoni WE, Miller K, Rick M et al. Heparin-induced thrombocytopenia and thromboembolism in the postoperative period. Surgery. 1988; 103:470-6. [PubMed 3353858] 2132. Doty JR, Alving BM, McDonnell DE et al. Heparin-associated thrombocytopenia in the neurosurgical patient. Neurosurgery. 1986; 19:69-72. [PubMed 3748340] 2133. Mehta AC, Kay EA. Storage time can be extended. Pharm Pract. (June) 1997; 7:305, 306, 308. 2134. Brittain HG, Lafferty L, Bouserski P et al. Stability of Revex, nalmeferine hydrochloride injection. PDA J Pharm Sci Technol. 1996; 50:35-9. [PubMed 8846056] 2135. McKinnon BT. FDA Safety Alert: hazards of precipitation associated with parenteral nutrition. Nutr Clin Pract. 1996; 11:59-65. [PubMed 8788339] 2136. Seidner DL, Speerhas R. Can octreotide be added to parenteral nutrition? Point-counterpoint. Nutr Clin Pract. 1998; 13:84-8. 2137. Dodds HM, Craik DJ. Photodegradation of irinotecan (CPT-11) in aqueous solutions: identification of fluorescent products and influence of solution composition. J Pharm Sci. 1997; 86:1410-6. [PubMed 9423156] 2138. Gremeau I, Sautou-miranda V, Picq F et al. Influence de la nature de la membrane sur le passage du nitrate d'isossorbidie et de son metabolite actif au cours d'une dialyse. J Pharm Clin. 1997; 16:19-23. 2139. Graham AE, Speicher E. Analysis of gentamicin sulfate and a study of its degradation in dextrose solution. J Pharm Biomed Anal. 1997; 15:537-43. [PubMed 8953497] 2140. Craig SB, Hattah J. Stability and compatibility of topecatan hydrochloride for injection with common infusion solutions and containers. J Pharm Biomed Anal. 1997; 16:199-205. [PubMed 9408034] 2141. Pramur YV, Loucas VA. Chemical stability and adsorption of atracurium besylate injections in disposable plastic syringes. J Clin Pharm Ther. 1996; 21:173-5. [PubMed 89351] 2142. Galanti LM, Hecq JD, Vanbecckbergen D et al. Long-term stability of cefuroxime and cefazolin sodium in intravenous infusions. J Clin Pharm Ther. 1996; 21:185-9. [PubMed 8873853] 2143. Kawano K, Takamatsu S, Mochizuku C et al. Loss of isosorbide dinitrate or nitroglycerin solution content in practice injection or precision continuous drip infusion. Jpn J Hosp Pharm. 1996; 22:167-72. 2144. Yoshida H, Takaba D, Uchida Y et al. Research for the crystal material produced in the continuous infusion line of midazolam (Dormicum) and butorphanol (Stadol). Jpn J Hosp Pharm. 1997; 23:531-8. 2145. Mahwinney WM, Adair CG, Gorman SP et al. Long-term stability of teicoplanin in dialysis fluid: implications for the home-treatment of CAPD peritonitis. Int J Pharm Pract. 1991; 1:90-3. 2146. Allwood MC, Martin H. The extraction of diethyhexylphthalate (DEHP) from polyvinyl chloride components of intravenous infusion containers and administration sets by paclitaxel injection. Int J Pharm. 1996; 127:65-71. 2147. Valiere C, Arnaud P, Caroff E et al. Stability and compatibility study of a carboplatin solution in syringes for continuous ambulatory infusion. Int J Pharm. 1996; 138:125-8. 2148. Khalil F, Dine T, Gressier B et al. Compatibility and stability of vancomycin hydrochloride with PVC infusion material in various conditions using stability-indicating high-performance liquid chromatographic assay. Int J Pharm. 1996; 139:243-7. 2149. Sautou M, F. Maswoswe J, Norman B et al. Compatibility of gentamicin sulfate and its stability under various storage conditions. Int J Pharm. 1997; 154:95-102. 2150. Rabouan-Guerrero M, Guel AF, Courtois PY et al. Stability study of cefepime in different infusion solutions. Int J Pharm. 1997; 154:185-90. 2151. Anon. How I survived a direct injection of potassium chloride. Hosp Pharm. 1997; 32:298-300. 2152. Kramer J. Stability of meropenem in elastomeric portable infusion devices. Eur Hosp Pharm. 1997; 3:168-71. 2153. Uges DRA, Ruige M. Vancomycin adsorption to teflon tubing. Eur Hosp Pharm. 1996; 2:358. 2154. Dauphars M, Vignerot J, Perrin A et al. Stability of cladribine in either polyethylene containers or polyvinyl chloride bags. Europ Hosp Pharm. 1997; 3:154-6. 2155. Girona V, Prat J, Pujol M et al. Stability of vinblastine sulphate in 0.9% sodium chloride in polypropylene syringes. Boll Chim Farm. 1996; 135:413-4. [PubMed 9035553] 2156. Smith BA, Hilmi SC, McDonald C et al. The stability of foscarnet in the presence of potassium. Aust J Hosp Pharm. 1996; 26:560-1. 2157. Jaffe GJ, Green GDJ. Stability of recombinant tissue plasminogen activator. Am J Ophthal. 1989; 108:90-1. [PubMed 2502019] 2158. Ward C, Weck S. Dilution and reconstitution of recombinant tissue plasminogen activator (Activase) in balanced salt solutions. Am J Ophthal. 1990; 109:98-9. [PubMed 2105057] 2159. Grewing R, Mester U, Low M. Clinical experience with tissue plasminogen activator stored at -20°C. Ophthalmic Surg. 1992; 23:780-1. [PubMed 1484673] 2160. Kramer I. Viability of microorganisms in novel antineoplastic and antiviral drug solutions. J Oncol Pharm Pract. 1998; 4:32-7. 2161. Schneider JJ, Wilson KM. A study of the osmolality and pH of subcutaneous drug infusion solutions. Aust J Hosp Pharm. 1997; 27:29-31. 2162. Vermeire A, Remon JP. The solubility of morphine and the stability of concentrated morphine solutions in glass, polypropylene syringes and PVC containers. Int J Pharm. 1997; 146:213-23. 2163. Kearney MCJ, Allwood MC, Martin H et al. The influence of amino acid source on the stability of ascorbic acid in TPN mixtures. Nutrition. 1998; 14:173-8. [PubMed 9530644] 2164. Casasin ED, T. Roca Massa M. Sistema de distribucion de medicamentos utilizados en anestesia mediante jeringas precargadas. Estudio de estabilidad. Farm Hosp. 1996; 20:55-9. 2165. Malcolmson C, Zilka S, Saum J et al. Investigations into the compatibility of teicoplanin with heparin. Eur J Parenter Sci. 1997; 2:51-5. 2166. Walker SE, Walshaw PR. Impenon stability and staining of teeth. Can J Hosp Pharm. 1997; 50:61-7. 2167. Liu L, Ammar DA, Ross LA et al. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. J Pharm Biomed Anal. 2011; 52:1023-4. [PubMed 2051703] 2168. Burnt J. Stability of amiodarone and flucanazole in 5% dextrose injection and normal saline during Y-site administration. Arch Pharm Res. 1997; 20:171-5. [PubMed 18975196] 2169. Truelle-Hugon B, Tourrette G, Couineau B et al. Etude de stabilite du chlorhydrate de morphine Lavoisier dans differents systemes actifs pour perfusion apres reconstitution dans divers solvents. Ann Pharm Fr. 1997; 55:216-23. [PubMed 9406471] 2170. Sitaram BR, Tsui M, Rawicki HB et al. Stability and compatibility of intrathecal admixtures containing baclofen and high concentrations of morphine. Int J Pharm. 1997; 153:13-24. 2171. Trinkle R. Compatibility of hydromorphone and prochlorperazine, and irritation due to subcutaneous prochlorperazine infusion. Ann Pharmacother. 1997; 31:789-90. [PubMed 9184729] 2172. Guchelar HJ, Hartog ME. De stabiliteit van clonazepaminjectie/loestof. Ziekenhuisfarmacie. 1997; 13:21-3. 2173. Leboucher G, Charpiat B. Incompatibilite physico-chimique entre l'omeprazole et la vancomycine. Pharm Hosp Fr. 1997; 121:124. 2174. Taylor A. Review of clarithromycin mixtures. Pharm Pract. (Oct) 1997; 7:473, 474, 476. 2175. Farhang-Asnafi S, Callaert S, Barre J et al. Influence du solvant de dilution sur la stabilite de la nouvelle forme de 5-fluorouracile en perfusion. J Pharm Clin. 1997; 16:45-7. 2176. Oustrie-Mendes AC, Huart B, Le Hoang MD et al. Study protocol: stability of morphine injected without preservative, delivered with a disposable infusion device. J Clin Pharm Ther. 1997; 22:283-90. [PubMed 9548210] 2177. Schoffski P, Freund M, Wunder R et al. Safety and toxicity of subcutaneous morphine in 20% fat emulsion in neonatal patients with pneumonia or fever of unknown origin, randomised study. BMJ. 1998; 317:379-84. [PubMed 9694753] [Free Fulltext PMC] 2178. Heinemann V, Kahny B, Jehn U et al. Serum pharmacology of ampicillin 3 applied in lipid emulsions. Antimicrob Agents Chemother. 1997; 41:728-32. [PubMed 9087478] [Free Fulltext PMC] 2179. Gupta VD, Maswoswe J. Stability of mitomycin aqueous solution when stored in tuberculin syringes. Int J Pharm Compound. 1997; 1:282-3. 2180. Targett PL, Keeffe PA. Compatibility and stability of drug adjuvants and morphine tartrate in 10 mL polypropylene syringes. Aust J Hosp Pharm. 1997; 27:207-12. 2181. Goren PM, Lyman BA. The stability of mesna in beverages and syrup for oral administration. Cancer Chemother Pharmacol. 1991; 28:298-301. [PubMed 1908750] 2182. Xu QA, Trissel LA. Compatibility of paclitaxel in 5% glucose and 0.9% sodium chloride injections with EVA minibags. Aust J Hosp Pharm. 1998; 28:156-9. 2183. Xu QA, Zhang YP, Trissel LA et al. Stability of busulfan injection admixtures in 5% dextrose injection and 0.9% sodium chloride injection. J Oncol Pharm Pract. 1996; 2:101-5. 2184. Sarver JG, Pryka R, Alexander KS et al. Stability of magnesium sulfate in 0.9% sodium chloride and lactated Ringer's solutions. Int J Pharm Compound. 1996; 2:385-8. 2185. Jobet-Hermelin I, Malvais ML, Jacquot C et al. Proposition d'une concentration limite acceptable du plastifiant libre par le poly(chlorure de vinyle) dans les solutions injectables aqueuses. J Pharm Clin. 1996; 15:132-6. 2186. Jacobson PA, West NJ, Spadoni V et al. Sterility of filgrastim (G-CSF) in syringes. Ann Pharmacother. 1996; 30:1238-42. [PubMed 8913403] 2187. Trissel LA, Spadoni VT. Comment: filgrastim stability in syringes. Ann Pharmacother. 1997; 31:500-1. [PubMed 9101020] 2188. Appenheimer MM, Schepart BS, Poleon GP et al. Stability of albumin-free interferon alfa-2b for 42 days. Am J Health-Syst Pharm. 1998; 55:1602-5. [PubMed 9706188] 2189. Trissel LA, Gilbert DL. Concentration dependency of vancomycin hydrochloride compatibility with beta-lactam antibiotics during simulated Y-site administration. Hosp Pharm. 1998; 33:1515-22. 2190. McLaughlin JP, Simpson C. How stable is acyclovir in PVC bags? The stability of reconstituted acyclovir sodium in a 0.9% w/w sodium chloride infusion when stored at room temperature. Pharm Pract. 1995; 5:53-8. 2191. Mehta AC, Kay EA. How stable is alfentanil? Stability of alfentanil hydrochloride in 5% dextrose stored in syringes. Pharm Pract. 1995; 5:303-4. 2192. McLaughlin JP, Simpson C. How stable are Zinacef & Metrexov? The stability of cefuroxime sodium and metronidazole infusion when stored in a refrigerator. Pharm Pract. 1995; 5:100-6. 2193. Bonferoni MC, Mellerio G, Giunchedi P et al. Photostability evaluation of nicardipine HCl solutions. Int J Pharm. 1992; 80:109-17. 2194. Erdman SH, McElwee CL, Kramer JM et al. Central line occlusion with three-in-one nutrition admixtures administered at home. JPN J Parenter Enteral Nutr. 1994; 18:177-81. [PubMed 8201755] 2195. Allwood MC, Martin H. Factors influencing the stability of ranitidine in TPN mixtures. Clin Nutr. 1995; 14:171-6. [PubMed 16843929] 2196. Hoie EB, Narducci WA. Laser particle analysis of calcium phosphate precipitate in neonatal TPN admixtures. J Ped Pharm Pract. 1996; 1:163-7. 2197. Ambados F, Brealey J. Incompatibilities with trace elements during TPN solution admixture. Aust J Hosp Pharm. 1998; 28:112-4. 2198. Xu QA, Trissel LA. Compatibility of paclitaxel injection diluent with two reduced-phthalate administration sets for the Accclaim pump. Int J Pharm Compound. 1998; 2:382-4. 2199. Stewart JT, Warren FW, King DT et al. Stability of ondansetron hydrochloride and 12 medications in plastic syringes. Am J Health-Syst Pharm. 1998; 55:2630-4. [PubMed 9872702] 2200. Donnelly RF, Bushfield TL. Chemical stability of meperidine hydrochloride in polypropylene syringes. Int J Pharm Compound. 1998; 2:463-5. 2201. Jappinen AL, Kokki H, Rasi AS et al. Stability of subcutanil in a syringe pump under simulated epidural infusion. Int J Pharm Compound. 1998; 2:466-8. 2202. Wilson KM, Schneider JJ. Stability of midazolam and fentanyl in infusion solutions. J Pain Symptom Manage. 1998; 16:52-8. [PubMed 9707657] 2203. Gupta VD, Pramur Y. Stability of lorazepam in 5% dextrose injection. Int J Pharm Compound. 1998; 2:322-4. 2204. Heide PE. Precipitation of amphotericin B from i.v. fat emulsion. Am J Health-Syst Pharm. 1997; 54:1449. [PubMed 9194992] 2205. Heide PE, Hehenberger H. Tensiometrische und konduktometrische stabilitauntersuchungen von amphotericin B in fettmulsionen. Osterreichische Krankenhaus Pharmazie. 1996; 10:36-43. 2206. To TP, Garrett MK. Stability of fluocxacillin in a hospital in the home program. Aust J Hosp Pharm. 1998; 28:289-90. 2207. Levanda M. Noticeable difference in admixtures prepared from lorazepam 2 and 4 mg/mL. Am J Health-Syst Pharm. 1998; 55:2305. [PubMed 95583] 2208. Share MJ, Harris RJ, Folsom J et al. Stability of lorazepam 1 and 2 mg/mL in glass bottles and polypropylene syringes. Am J Health-Syst Pharm. 1998; 55:2013-5. [PubMed 9784790] 2209. Inubaki K, Kambara M, Mizuno M et al. Compatibility and stability of ranitidine hydrochloride with six cephalosporins during simulated Y-site administration. Int J Pharm Compound. 1998; 2:318-21. 2210. Ray LR, Chen DA. Stability of somatropin stored in plastic syringes for 28 days. Am J Health-Syst Pharm. 1998; 55:1508-11. [PubMed 9676297] 2211. Patel K, Craig SB, McBride MG et al. Microbial inhibitory properties and stability of topecatan hydrochloride injection. Am J Health-Syst Pharm. 1998; 55:1584-7. [PubMed 9706184] 2212. English BA, Riggs RM, Webster AA et al. Y-site stability of fosphenytoin and sodium phenobarbital. Int J Pharm Compound. 1999; 3:64-6. 2213. Lieu CL, Chin A. Five-day stability of vinorelbine in 5% dextrose injection and in 0.9% sodium chloride injection at room temperature. Int J Pharm Compound. 1999; 3:67-8. 2214. Akkerman SR, Zhang H, Mullins RE et al. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 i.v. solutions. Am J Health-Syst Pharm. 1999; 56:63-8. [PubMed 10048881] 2215. Trissel LA, Gilbert DL, Martinez JF et al. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPN J Parenter Enteral Nutr. 1999; 23:67-74. [PubMed 10081995] 2216. Johnson CE, vanderBussche HL, Chio CC et al. Stability of tacrolimus with morphine sulfate, hydromorphone hydrochloride, and ceftazidime during simulated intravenous coadministration. Am J Health-Syst Pharm. 1999; 56:164-9. [PubMed 10030533] 2217. Stamatakis MK, Leader WG. Stability of high-dose vancomycin and ceftazidime in peritoneal dialysis solutions. Am J Health-Syst Pharm. 1999; 56:246-8. [PubMed 10030511] 2218. Trissel LA, Martinez JF. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc. 1999; 39:411-5. 2219. Zhang Y, Trissel LA. Physical and chemical stability of etoposide phosphate solutions. J Am Pharm Assoc. 1999; 39:146-50. 2220. Stewart JT, Warren FW. Stability of cefepime hydrochloride injection in polypropylene syringes at -20°C, 4°C, and 22-24°C. Am J Health Syst Pharm. 1999; 56:457-9. [PubMed 10096708] 2221. Stewart JT, Maddox FC. Stability of cefepime hydrochloride in polypropylene syringes. Am J Health-Syst Pharm. 1999; 56:1134. [PubMed 1035463] 2222. Burkiewicz JS. Incompatibility of ceftriaxone sodium with lactated Ringer's injection. Am J Health-Syst Pharm. 1999; 56:384. [PubMed 10690221] 2223. Riggs RM, English BA, Webster AA et al. Fosphenytoin Y-site stability studies with lorazepam and midazolam hydrochloride. Int J Pharm Compound. 1999; 3:235-8. 2224. Trissel LA, Gilbert DL. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound. 1999; 3:241-4. 2225. Johnson CE, Truong NM. Stability and compatibility of tacrolimus and fluconazole in 0.9% sodium chloride. J Am Pharm Assoc. 1999; 39:505-8. 2226. Trissel LA, Martinez JF. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc. 1999; 39:514-8. 2227. Xu Q, Zhang Y. Physical and chemical stability of gemcitabine hydrochloride solutions. J Am Pharm Assoc. 1999; 39:509-13. 2228. Walker SE, Gray S. Stability of reconstituted indomethacin sodium trihydrate in original vials and polypropylene syringes. Am J Health-Syst Pharm. 1998; 55:154-8. [PubMed 9465980] 2229. Schlatter J, Saulnier JL. Inline filtration of ranitidine hydrochloride solutions. Am J Health-Syst Pharm. 1998; 55:840. [PubMed 9568242] 2230. Zhaiang Y, Trissel LA. Paclitaxel compatibility with a triple-lumen polyurethane central catheter. Hosp Pharm. 1998; 33:547-51. 2231. Xu QA, Trissel LA. Paclitaxel compatibility with the IV Express filter unit. Int J Pharm Compound. 1998; 2:243-5. 2232. Xu QA, Trissel LA. Paclitaxel compatibility with a TOTM-lactoflored PVC administration set. Hosp Pharm. 1997; 32:1635-8. 2233. Saltsman CL, Tom CM, Mitchell A et al. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm. 1999; 56:1458-9. [PubMed 10428457] 2234. Trissel LA, Gilbert DL. Compatibility screening of gatifloxacin during simulated Y-site administration with other drugs. Hosp Pharm. 1999; 34:1409-16. 2235. Voytilla KL, Rusho WJ. Compatibility of alatrofloxacin mesylate with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm. 2000; 57:1437-9. [PubMed 10938984] 2236. Johnson CE, Truong NM. Stability and compatibility of tacrolimus and fluconazole in 0.9% sodium chloride. J Am Pharm Assoc. 1999; 39:505-8. 2237. Paul M, Vieillard V, Roumi E et al. Long-term stability of bevacizumab repackaged in 1mL polypropylene syringes for intravitreal administration. Ann Pharm Fr. 2012; 70:139-54. [PubMed 22655582] 2238. Balthasar JP. Concentration-dependent incompatibility of vinorelbine tartrate and heparin sodium. Am J Health-Syst Pharm. 1999; 56:1891. [PubMed 10511236] 2239. Wolfe L, Thomas LA, Du C et al. Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide in 0.9% sodium chloride injection. Am J Health-Syst Pharm. 1999; 56:985-9. [PubMed 10365723] 2240. Peek BT, Webster KD. Stability and compatibility of promethazine hydrochloride and dihydrotetragamine mesylate in combination. Am J Health-Syst Pharm. 1999; 56:1835-8. [PubMed 10512333] 2241. Webster AA, English BA, McGuire JM et al. Stability of dobutamine hydrochloride 4 mg/mL in 5% dextrose injection at 5 and 23 °C. Int J Pharmaceut Compound. 1999; 3:412-4. 2242. Thiesen J, Kramer I. Physico-chemical stability of docetaxel premix solution and docetaxel infusion solutions in PVC bags and polyolefine containers. Pharm World Sci. 1999; 21:137-41. [PubMed 10427584] 2243. Kramer I, Thiesen J. Stability of topecatan infusion solutions in polyvinylchloride bags and elastomeric portable infusion devices. J Oncol Pharm Pract. 1999; 5:75-82. 2244. Hecq JD, Ervard JM, Gillet P et al. Etude de stabilite visuelle du chlorhydrate de chlorpromazine, du chlorure de potassium, de la furosemide et de l'heparine sodique en perfusion continue. Pharmazie. 1998; 53:353-6. [PubMed 19160720] 2253. Hor MM, Chan SY, Yow KL et al. Stability of admixtures of pethidine and metoclopramide in aqueous solution, 5% dextrose and 0.9% sodium chloride. J Clin Pharm Ther. 1997; 22:339-45. [PubMed 19160718] 2254. Hor MM, Chan SY, Yow KL et al. Stability of morphine sulphate in saline under simulated patient administration conditions. J Clin Pharm Ther. 1997; 22:405-10. [PubMed 19160726] 2255. Mitterner A, Vincze Z. Stability of cyclophosphamide containing infusions. Pharmazie. 1999; 54:224-5. 2256. Mitterner A, Vincze Z. Stability of vinblastine sulphate containing infusions. Pharmazie. 1999; 54:625-6. 2257. Schrijvers D, Tai-Api N, De Smet MK et al. Determination of compatibility and stability of drugs used in palliative care. J Clin Pharm Ther. 1998; 23:311-4. [PubMed 9867315] 2258. Kopelent-Frank H, Schimper A. HPTLC-based stability assay for the determination of amiodarone in intravenous admixtures. Pharmazie. 1999; 54:625-6. 2259. Inagaki K, Miyamoto Y, Kurata N et al. Stability of ranitidine hydrochloride with cefazolin sodium, cefepazone sodium, cefoxitin sodium, and cephalothrin sodium during simulated Y-site administration. Int J Pharmaceut Compound. 2000; 4:150-3. 2260. Roy JL, Hildgen P. Stability of morphine-ketamine mixtures in 0.9% sodium chloride injection packaged in syringes, plastic bags and medication cassette reservoirs. Int J Pharmaceut Compound. 2000; 4:225-8. 2261. Grant EM, Zhong MK, Ambrose PG et al. Stability of meropenem in a portable infusion device in a cold pouch. Am J Health-Syst Pharm. 2000; 57:992-5. [PubMed 10832500] 2262. Xu QA, Trissel LA. Compatibility and stability of linezolid injection admixed with three cephalosporin antibiotics. J Am Pharm Assoc. 2000; 40:509-14. 2263. Zhang Y, Xu QA, Trissel LA et al. Compatibility and stability of linezolid injection admixed with aztreonam or piperacillin sodium. J Am Pharm Assoc. 2000; 40:520-4. 2264. Trissel LA, Williams KY. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc. 2000; 40:515-9. 2265. Zhang Y, Xu QA, Trissel LA et al. Physical compatibility of calcium acetate and potassium phosphates in parenteral nutrition solutions containing Amminosin II. Int J Pharmaceut Compound. 1999; 3:415-20. 2266. Ambados F, Brealey J. Precipitation of potassium sulphate during TPN solution admixture. J Clin Pharm Ther. 1997; 22:353-6. [PubMed 19160720] 2253. Hor MM, Chan SY, Yow KL et al. Stability of admixtures of pethidine and metoclopramide in aqueous solution, 5% dextrose and 0.9% sodium chloride. J Clin Pharm Ther. 1997; 22:339-45. [PubMed 19160718] 2254. Hor MM, Chan SY, Yow KL et al. Stability of morphine sulphate in saline under simulated patient administration conditions. J Clin Pharm Ther. 1997; 22:405-10. [PubMed 19160726] 2255. Mitterner A, Vincze Z. Stability of cyclophosphamide containing infusions. Pharmazie. 1999; 54:224-5. 2256. Mitterner A, Vincze Z. Stability of vinblastine sulphate containing infusions. Pharmazie. 1999; 54:625-6. 2257. Schrijvers D, Tai-Api N, De Smet MK et al. Determination of compatibility and stability of drugs used in palliative care. J Clin Pharm Ther. 1998; 23:311-4. [PubMed 9867315] 2258. Kopelent-Frank H, Schimper A. HPTLC-based stability assay for the determination of amiodarone in intravenous admixtures. Pharmazie. 1999; 54:625-6. 2259. Inagaki K, Miyamoto Y, Kurata N et al. Stability of ranitidine hydrochloride with cefazolin sodium, cefepazone sodium, cefoxitin sodium, and cephalothrin sodium during simulated Y-site administration. Int J Pharmaceut Compound. 2000; 4:150-3. 2260. Roy JL, Hildgen P. Stability of morphine-ketamine mixtures in

Pharmaceut Compound. 2001; 5:148-50. 2341. Ling J, Gupta VD. Stability of cefepime hydrochloride after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use. Int J Pharmaceut Compound. 2001; 5:151-2. 2342. Sterling J. Intralipids and tubing changes. Hosp Pharm. 2001; 36:258-9. 2343. Yuan P, Grimes GJ, Shankman SE et al. Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide phosphate in 0.9% sodium chloride injection. Am J Health-Syst Pharm. 2001; 58:594-8. [PubMed 11296609] 2344. Baker MT. Yellowing of metabisulfite-containing propofol emulsion. Am J Health-Syst Pharm. 2001; 58:1042. [PubMed 11402481] 2345. Gupta VD, Ling J. Stability of piperacillin sodium after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use. Int J Pharmaceut Compound. 2001; 5:230-1. 2346. Bethune K, Allwood M, Grainger C et al. Use of filters during the preparation and administration of parenteral nutrition: position paper and guidelines prepared by a British Pharmaceutical Nutrition Group Working Party. Nutrition. 2001; 17:403-8. [PubMed 11377134] 2347. Gellis C, Sautou-Miranda V, Arvouet A et al. Stability of methylprednisolone sodium succinate in pediatric parenteral nutrition mixtures. Am J Health-Syst Pharm. 2001; 58:139-42. [PubMed 11449858] 2348. Redhead HM, Jones CB. Pharmaceutical and antimicrobial differences between propofol emulsion products. Am J Health-Syst Pharm. 2000; 57:1174. [PubMed 10911519] 2349. Mirejovsky D, Ghosh M. Pharmaceutical and antimicrobial differences between propofol emulsion products. Am J Health-Syst Pharm. 2000; 57:1174. [PubMed 10911519] 2350. Mirejovsky D, Ghosh M. Pharmaceutical and antimicrobial differences between propofol emulsion products. Am J Health-Syst Pharm. 2000; 57:1174. [PubMed 10911519] 2351. Thomas LA, Johnson-Singh A, Wood GC et al. Physical compatibility of 10% alcohol in 5% dextrose injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm. 2000; 57:2286-7. [PubMed 11146976] 2352. Chalmers JR, Bobek MB, Millette MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm. 2001; 58:504-6. [PubMed 11286148] 2353. Gupta VD, Bailey RE. Stability of alatrofloxacin mesylate in 5% dextrose injection and 0.45% sodium-chloride injection. Int J Pharmaceut Compound. 2000; 4:66-8. 2354. Gupta VD. Stability of levofloxacin sodium injection in polypropylene syringes. Int J Pharmaceut Compound. 2000; 4:482-3. 2355. Garabito MJ, Jimenez L, Bautista FJ et al. Stability of tirofiban hydrochloride in 0.9% sodium chloride injection for 30 days. Am J Health-Syst Pharm. 2001; 58:1850-1. [PubMed 11596703] 2356. Bergquist PA, Manas D, Hunke WA et al. Stability and compatibility of tirofiban hydrochloride during simulated Y-site administration with other drugs. Am J Health-Syst Pharm. 2001; 58:1218-23. [PubMed 11449879] 2357. Seto W, Trope A, Carfarre L et al. Visual compatibility of sodium chloride injection with other injectable medications given to pediatric patients. Am J Health-Syst Pharm. 2001; 58:1422-6. [PubMed 11494788] 2358. Zhang Y, Trissel LA. Stability of piperacillin and ticarcillin in AutoDose infusion system bags. Ann Pharmacother. 2001; 35:1360-3. [PubMed 11724082] 2359. Godwin DA, Kim NH, Zuniga R. Stability of baclofen and clonidine hydrochloride admixture for intrathecal administration. Hosp Pharm. 2001; 36:950-4. 2360. Quay I, Tan E. Compatibility and stability of potassium chloride and magnesium sulfate in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use. Int J Pharmaceut Compound. 2001; 5:232-4. 2361. Vega E, Sola N. Quantitative analysis of metronidazole in intravenous admixture with ciprofloxacin by first derivative spectrophotometry. J Pharm Biomed Anal. 2001; 25:523-30. [PubMed 11377032] 2362. Inagaki K, Miyamoto Y, Kurata N et al. Stability of ranitidine hydrochloride with cefazolin sodium, cefeprozime sodium, cefotaxime sodium and cephalothin sodium during simulated Y-site administration. Int J Pharmaceut Compound. 2000; 4:150-3. 2363. Trissel LA, Xu QA, Zhang Y et al. Stability of ciprofloxacin and vancomycin hydrochloride in AutoDose infusion system bags. Hosp Pharm. 2001; 36:1170-3. 2364. Galanti LM, Hecq JD, Jeuniau P et al. Assessment of the stability of teicoplanin in intravenous infusions. Int J Pharmaceut Compound. 2001; 5:397-400. 2365. Storms ML, Stewart JT, Warren FW. Stability of epinephrine sulfate at ambient temperature and 4 °C in polypropylene syringes. Int J Pharmaceut Compound. 2001; 5:394-6. 2366. Faozi MA, Khalil F, Dine T et al. Stability, compatibility and plasticizer extraction of guinine injection added to infusion solutions and stored in polyvinyl chloride (PVC) containers. J Pharmaceut Compound. 2001; 57:923-30. 2367. della Cuno FSR, Mella M, Magistrali G, et al. Stability and compatibility of methylprednisolone acetate and ropivacaine hydrochloride in polypropylene syringes for epidural administration. Am J Health-Syst Pharm. 2001; 58:1753-6. 2368. Verville KL, Tyler LS, Rusho VJ. Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery. Am J Health-Syst Pharm. 2000; 57:230-7. [PubMed 12004465] 2369. Trissel LA, Zhang Y, Baker MB. Stability of fenoldopam mesylate in two infusion solutions. Am J Health-Syst Pharm. 2002; 59:846-8. [PubMed 12004463] 2370. Xu QA, Trissel LA, Saenz CA, et al. Stability of three cephalosporin antibiotics in AutoDose infusion system bags. J Am Pharm Assoc. 2002; 42:428-31. 2371. Gupta VD. Stability of cefotaxime sodium after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use. Int J Pharmaceut Compound. 2002; 6:234-6. 2372. Walker SE, Dufour A, Iazzetta J. Concentration and solution dependent stability of cloxacillin intravenous solutions. Can J Hosp Pharm. 1998; 51:13-9. 2373. Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharmaceut Compound. 2002; 6:311-4. 2374. Baroletti S, Hartman C, Churchill W. Visual compatibility of abiraterone with selected drugs. Am J Health-Syst Pharm. 2002; 59:466-7. [PubMed 11887414] 2375. Li WY, Koda RT. Stability of irinotecan hydrochloride in aqueous solutions. Am J Health-Syst Pharm. 2002; 59:539-44. [PubMed 11908247] 2376. Trissel LA, Xu QA, P. Ham L. Physical and chemical stability of morphine sulfate 5 mg/mL and 50 mg/mL packaged in plastic syringes. Int J Pharmaceut Compound. 2002; 6:62-5. 2377. Trissel LA, Xu QA, P. Ham L. Physical and chemical stability of hydromorphone hydrochloride 1.5 mg/mL and 80 mg/mL packaged in plastic syringes. Int J Pharmaceut Compound. 2002; 6:74-6. 2378. Trissel LA, Xu QA, P. Ham L. Physical and chemical stability of low and high concentrations of morphine sulfate with bupivacaine hydrochloride packaged in plastic syringes. Int J Pharmaceut Compound. 2002; 6:70-3. 2379. Xu QA, Trissel LA, Saenz CA et al. Stability of gentamicin sulfate and tobramycin sulfate in AutoDose infusion system bags. Int J Pharmaceut Compound. 2002; 6:152-4. 2380. Xu QA, Trissel LA, P. Ham L. Physical and chemical stability of low and high concentrations of morphine sulfate with clonidine hydrochloride packaged in plastic syringes. Int J Pharmaceut Compound. 2002; 6:66-9. 2381. Zellmer MA, Gosselin KG. Physical compatibility of milrinone lactate injection with intravenous drugs commonly used in the pediatric intensive care unit. Am J Health-Syst Pharm. 2002; 59:452-4. [PubMed 11887412] 2382. Elwell RJ, Spencer AP, Barnes JF et al. Stability of furosemide in human albumin solution. Ann Pharmacother. 2002; 36:1223-5. [PubMed 12004465] 2383. Trissel LA, Saenz CA, Ingram DS et al. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharmaceut Compound. 2002; 6:230-3. 2384. Zhang Y, Trissel LA. Stability of ampicillin sodium, nafcillin sodium, and oxacillin sodium in AutoDose infusion system bags. Int J Pharmaceut Compound. 2002; 6:226-9. 2385. Stewart JT, Storms ML, Warren FW. Stability of tubocurarine chloride injection at ambient temperature and 4 °C in polypropylene syringes. Int J Pharmaceut Compound. 2002; 6:308-10. 2386. El Aatmani M, Poujol S, Astre C et al. Stability of dacarbazine in amber glass vials and polyvinyl chloride bags. Am J Health-Syst Pharm. 2002; 59:1351-6. [PubMed 12132562] 2387. Jappinen A, Kokki H, Naaranlahti T. pH stability of injectable fentanyl, bupivacaine, or clonidine solution or a ternary mixture in 0.9% sodium chloride in two types of propylene syringes. Int J Pharmaceut Compound. 2002; 6:68-70. 2388. Wang C, Wang C, Wang C et al. Stability of cefazolin in heparinized and nonheparinized peritoneal dialysis solutions. Am J Health-Syst Pharm. 2002; 59:1537-8. [PubMed 12185829] 2389. Donnelly RF. Chemical stability of furosemide in minibags and polypropylene syringes. Int J Pharmaceut Compound. 2002; 6:468-70. 2390. Schlusser V, Hecq JD, Vanbeckbergen D et al. Effect of freezing, long-term storage, and microwave thawing of the stability of cefepime in 5% dextrose infusion in polyvinyl chloride bags. Int J Pharmaceut Compound. 2002; 6:391-4. 2391. Hartman CA, Baroletti SA, Churchill WW et al. Visual compatibility of argatroban with selected drugs. Am J Health-Syst Pharm. 2002; 59:1784-5. [PubMed 12298120] 2392. Gupta VD. Chemical stability of dexamethasone sodium phosphate after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes. Int J Pharmaceut Compound. 2002; 6:395-7. 2393. Trissel LA, Zhang Y. Stability of methylprednisolone sodium succinate in AutoDose infusion system bags. J Am Pharm Assoc. 2002; 42:868-70. 2394. Certain E, Beteta F, Goudou-Sinha C et al. Stability of i.v. mephenolate mofetil in 5% dextrose injection in polyvinyl chloride infusion bags. Am J Health-Syst Pharm. 2002; 59:2434-9. [PubMed 12503342] 2395. Beijnen JH, van Gijn R. Chemical stability of the cardioprotective agent ICRF-187 in infusion fluids. J Parenter Sci Technol. 1993; 47:166-71. [PubMed 8410562] 2396. Fatou A, Denis P, Conrath G, et al. Campto 20 mg/mL concentrate for infusion, stability during infusion, stability of the diluted parenteral solution prepared ahead of time in glass bottles and PVC bags. 2397. Boinneau V, Nguyen-Huu JI. CPT-11 (RF 64174A) 20 mg/mL solution for injection, study of the stability of infusion solutions reconstituted in glass bottles or PVC infusion bags after 24 hours' storage at room temperature. 2398. Shih LM, Chiu H, Wang C. Stability of 0.9% sodium chloride injection with intravenous administration. 1999; 36:138-9. 2399. Tiefenbacher EM, Haen E, Przybyla B et al. Photodegradation of some quinolones used as antimicrobial therapeutics. J Pharm Sci. 1994; 83:463-7. [PubMed 8046597] 2400. Galls KA, Cullinane AM, Horne MK. Bioactivity of cryopreserved alteplase solutions. Am J Health-Syst Pharm. 1999; 56:2056-7. [PubMed 10541033] 2401. Kajsner GP, Bejnen JH, Butl A et al. A systematic study on the chemical stability of ifosfamide. J Pharmaceut Biomed Anal. 1991; 9:1061-7. 2402. Lau DWC, Walker SE, Fremes SE et al. Adenosine stability in cardioplegic solutions. Can J Hosp Pharm. 1995; 48:167-71. 2403. Muller HJ, Berg J. Stabilitätsstudie zu apomorphine-hydrochlorid im PVC-Infusionsbeutel. Krankenhauspharmazie. 1997; 18:468-73. 2404. Andrisano V, Gotti R, Leoni A et al. Photodegradation studies on atenolol by liquid chromatography. J Pharmaceut Biomed Anal. 1999; 21:851-7. 2405. Blaise N, Vigeron J, Perrin A et al. Stability of refrigerated and frozen solutions of ondansetron hydrochloride. Eur J Hosp Pharm. 1994; 4:12-3. 2406. Lougheed WD, Wouffe-Flanagan H, Clement JR et al. Insulin aggregation in artificial delivery systems. Diabetologia. 1980; 19:1-9. [PubMed 6771181] 2407. Meyer G, Henneman PL. Buffered lidocaine. Ann Emerg Med. 1991; 20:218-9. [PubMed 1996811] 2408. Murakami CS, Odland PB, Ross BK. Buffered local anesthetics and epinephrine degradation. J Dermatol Surg Oncol. 1994; 20:102-5. [PubMed 8151033] 2409. Hinchab KD, Fissella R, Sugaj J. Preparation of pH-adjusted local anesthetics. Ophthalmol Surg. 1995; 26:194-9. 2410. Avelar MA, Walker SE. Stability and compatibility of reconstituted hydromorphone with potassium chloride or heparin. Can J Hosp Pharm. 1996; 49:140-5. 2411. Crowther J, Hrazdil J, Jolly DT et al. Growth of microorganisms in propofol, thiopental, and a 1:1 mixture of propofol and thiopental. Anesth Analg. 1996; 82:475-8. [PubMed 8623946] 2412. El-Yazigi A, Wahab FM, Afrane B. Stability study and content uniformity of prochlorperazine in pharmaceutical preparations by liquid chromatography. J Chromatogr A. 1995; 690:71-6. 2413. Ekmore RL, Contois ME, Kelly K et al. Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Clin Ther. 1996; 18:246-55. [PubMed 8733985] 2414. Luo D, Dong H, Tang XZ et al. Stability of amphotericin B in 50 g/L dextrose injection. Chin Pharm J. 1998; 33:220-2. 2415. Sewell GJ, Allsopp M, Collinson MP et al. Stability studies on admixtures of 5-fluorouracil with carboxipain and 5-fluorouracil with heparin for administration in continuous infusion regimes. J Clin Pharm Ther. 1994; 19:127-33. [PubMed 8071393] 2416. Lugo RA, MacKay M, Rucho WJ. Stability of lorazepam 0.2 mg/L, 0.5 mg/mL, and 1 mg/mL in polypropylene syringes. J Pediatr Pharmacol Ther. 2001; 6:122-9. 2417. Zhao L, Yalkowsky SH. Stabilization of epitifitide by cosolvents. Int J Pharm. 2001; 218:43-56. [PubMed 1137148] 2418. Gupta VD, Ling J. Stability of piperacillin sodium after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use. Int J Pharmaceut Compound. 2001; 5: 230-1. 2419. Thiesen J, Kramer I. Physicochemical stability of irinotecan injection concentrate and diluted infusion solutions in PVC bags. J Oncol Pharm Pract. 2000; 6:115-21. 2420. Beitz C, Einberger C, Wehling M. Stabilität und Kompatibilität von Zytostatika-Zubereitungen mit Infusionslösungsbehältern aus Polyethylen. Krankenhauspharmazie. 1999; 20:211-5. 2421. Nguyen-Huu JI, Bouqueton JI, Bouqueton JI et al. Stability of cefepime in 5% dextrose injection in polypropylene syringes. Int J Pharmaceut Compound. 2002; 6:316-7. 2422. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2423. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2424. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2425. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2426. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2427. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2428. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2429. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2430. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2431. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2432. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2433. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2434. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2435. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2436. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2437. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2438. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2439. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2440. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2441. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2442. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2443. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2444. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2445. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2446. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2447. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2448. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2449. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2450. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2451. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2452. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2453. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2454. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2455. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2456. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2457. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2458. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2459. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2460. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2461. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2462. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2463. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2464. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2465. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2466. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2467. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2468. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2469. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2470. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2471. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2472. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2473. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2474. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2475. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2476. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2477. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2478. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2479. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2480. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2481. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2482. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2483. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2484. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2485. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2486. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2487. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2488. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2489. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2490. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2491. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2492. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2493. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2494. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2495. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2496. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2497. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2498. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2499. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2500. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2501. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2502. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2503. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2504. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2505. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2506. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2507. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2508. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2509. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2510. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2511. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2512. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2513. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2514. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2515. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2516. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2517. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2518. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2519. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2520. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2521. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2522. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2523. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2524. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2525. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2526. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2527. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2528. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2529. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2530. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2531. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2532. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2533. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2534. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2535. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2536. Andrisano V, Hrelia P, Gotti R et al. Photostability and phototoxicity of cefepime in intravenous infusion solutions. J Pharmaceut Compound. 2002; 6:316-7. 2537. Andrisano V

Am J Med (Medical Information Department, Scios Inc., Fremont, CA). Stability and sterility of dolostron mesylate in syringes stored at room temperature. Am J Health-Syst Pharm. 2005; 62:696. 698-9. [PubMed 15851493] 2627. Trissel LA, Zhang Y. Physical and chemical stability of palonosetron hydrochloride with fluorouracil and with gentamicin hydrochloride during simulated Y-site administration. Int J Pharmaceut Compound. 2005; 9:320-2. 2628.

Lee G, Saira K. Stability of morphine sulphate in ANAPA Plus ambulatory infusion device and PEGA infusion sets. Europ J Hosp Pharm Sci. 2006; 12:76-80. 2629. Chin A, Liu S, Ting-Chan J et al. Extended stability of ascorbic acid in 5% dextrose injection and 0.9% sodium chloride injection. Am J Health-Syst Pharm. 2005; 62:1073-4. [PubMed 15901593] 2630. Patel K, Hursting MJ. Compatibility of argatroban with abximab, epifibatide, or tirofiban during simulated Y-site administration. Am J Health-Syst Pharm. 2005; 62:1381-4. [PubMed 15972381] 2631. Wazny L, Walker S, Moist L. Visual compatibility of gentamicin sulfate and 4% sodium citrate solutions. Am J Health-Syst Pharm. 2005; 62:1548. 1550. [PubMed 160630359] 2632. Barcia E, Martin A, Azuara ML et al. Tramadol and hyoscine N-butyl bromide combined in infusion solutions: compatibility and stability. Support Care Cancer. 2007; 15:57-62. [PubMed 16847606] 2633. Laville I, Mercier L, Cachaty E et al. Shelf-lives of morphine and pethidine solutions stored in patient-controlled analgesia devices: physico-chemical and microbiological stability study. Pathol Biol (Paris). 2005; 53:210-6. [PubMed 15850954] 2634. Barcia E, Reyes R, Azuara ML et al. Stability and compatibility of binary mixtures of morphine hydrochloride with hyoscine-n-butyl bromide. Support Care Cancer. 2005; 13:235-45. [PubMed 15789817] 2635. Finb, JM, Capozzi DL, Shavick JM et al. Alltpease for central catheter clearance: 1 mg/mL versus 2 mg/mL. Ann Pharmacother. 2004; 38:351-2. [PubMed 14742778] 2636. Lian MH, Shao MH, Yuan H et al. Study on the stability of levofloxacin lactate for injection. Chin J Antibiotics. 2004; 29:346-8. 2637. de Lemos M. Vinorelbine and venous irritants: optimal parenteral administration. J Oncol Pharm Pract. 2005; 11:79-81. [PubMed 16460608] 2638. DeFillipis MR, Bell MA, Heyob JA et al. In vitro stability of insulin lispro in continuous subcutaneous insulin infusion. Diabetes Tech Ther. 2006; 8:358-68. 2639. Paul M, Razzoou N, Tixier G et al. Stability of prostaglandin e1 (pge1) in aqueous solutions. Europ J Hosp Pharm Sci. 2005; 11:31-6. 2640. Xu QA, Trissel LA. Compatibility of palonosetron with cyclophosphamide and with ifosfamide during simulated Y-site administration. Am J Health-Syst Pharm. 2005; 62:1998-2000. [PubMed 16174835] 2641. Barker B, Feddema S, Rusho WJ et al. Visual compatibility of vasopressin with other injectable drugs. Am J Health-Syst Pharm. 2005; 62:1969. 1975-6. [PubMed 16174827] 2642. Veggeland T. Visual compatibility of clonidine with selected drugs. Am J Health-Syst Pharm. 2005; 62:1968-9. [PubMed 16174826] 2643. Bouguin C, Thelcide C, Crespin-Maillard F et al. Compatibility of ondansetron hydrochloride and methylprednisolone sodium succinate in multilayer polyolefin containers. Am J Health-Syst Pharm. 2005; 62:2001-5. [PubMed 16174836] 2644. Chemical stability of hydrozoline hydrochloride after reconstitution in 0.9% sodium chloride injection or 5% dextrose injection for infusion. Int J Pharmaceut Compound. 2005; 9:399-401. 2645. Heq JD, Boitquin LP, Vanbeckbergen DF et al. Effect of freezing, long-term storage, and microwave thawing on the stability of ketorolac tromethamine. Ann Pharmacother. 2005; 39:1654-8. [PubMed 16159993] 2646. Onat D, Stathopoulos J, Rose A et al. Reliability of nesiritide infusion via non-paired tubing and heparin-coated catheters. Ann Pharmacother. 2005; 39:1671-20. [PubMed 16159995] 2647. Voges M, Divino-Filho JC, Faict D et al. Compatibility of insulin over 24 hours in standard and bicarbonate-based peritoneal dialysis solutions contained in bags made of different materials. Perit Dial Int. 2006; 26:498-502. [PubMed 16881346] 2648. Donnelly RF. Chemical stability of fentanyl in polypropylene syringes and polyvinyl chloride bags. Int J Pharmaceut Compound. 2005; 9:482-3. 2649. Lewis B, Jarvi E, Cady P. Atropine and ephedrine adsorption to syringe plastic. AANA J. 1994; 64:257-60. 2650. Normo AO, Elwel RJ. Stability of vancomycin in icodextrin peritoneal dialysis solution. Ann Pharmacother. 2006; 40:1950-4. [PubMed 17062839] 2651. Velpandian T, Saluja V, Kumar Ravi A et al. Evaluation of the stability of extemporaneously prepared ophthalmic formulation of mitomycin C. J Ocular Pharmacol Ther. 2005; 21:217-22. 2652. Abanny NO, Zaghloul IY, Radwan MA. Compatibility of tramadol hydrochloride injection with selected drugs and solutions. Am J Health-Syst Pharm. 2005; 62:1299-302. [PubMed 15947129] 2653. Lee DKT, Wand DP, Hanson RA et al. Compatibility of fentanyl, ketorolac, ketorolac hydrochloride, and droperidol in 0.9% sodium chloride injection stored in polyvinyl chloride bags. Am J Health-Syst Pharm. 2005; 62:1190-2. [PubMed 15914879] 2654. Rigge DC, Jones MF. Shelf lives of aseptically prepared medicines—stability of hydrocortisone sodium succinate in PVC and non-PVC bags and in polypropylene syringes. J Pharm Biomed Anal. 2005; 39:339-43. 2655. Robinson RF, Morosco RS, Smith CV et al. Stability of cefazolin sodium in four heparinized and non-heparinized dialysate solutions at 38°C. Perit Dial Int. 2006; 26:593-7. [PubMed 16973516] 2656. Johnson CE. Stability of pantoprazole in 0.9% sodium chloride injection in polypropylene syringes. Am J Health-Syst Pharm. 2005; 62:2410-2. [PubMed 16278334] 2657. Swart EL, van Reij EML, Lee WC et al. Visual compatibility of atosiban acetate with four drugs. Am J Health-Syst Pharm. 2005; 62:2459. 2463. [PubMed 16303899] 2658. Thalhammer F, Maier-Saloman A, Jager W. Examination of stability and compatibility of flucloxacillin (Floaxpen) and ceftazidime (Fortum) in two infusion media: relevance for clinical practice. Wien Med Wochenschr. 2005; 155:337-43. [PubMed 16092041] 2659. Han J, Washington C. Partition of antimicrobial additives in the presence of polymers. Int J Pharm. 2005; 288:263-71. [PubMed 15620866] 2660. Trissel LA, Xu QA, Baker M. Drug compatibility with new polyolefin infusion solution containers. Am J Health-Syst Pharm. 2006; 63:2379-82. [PubMed 17106012] 2661. Rodenbach MP, Hecq JD, Vanbeckbergen D et al. Stability of cefuroxime infusion: the brand-name drug versus a generic product. Europ J Hosp Pharm Sci. 2006; 12:32-4. 2662. Cadrobbi J, Heq JD, Lebrun C et al. Long-term stability of voriconazole 4 mg/mL in dextrose 5% polyvinyl chloride bags at 4°C. Europ J Hosp Pharm Sci. 2006; 12:57-9. 2663. Andre P, Cisternino S, Chiadmi F, Jomes MF. Shelf lives of aseptically prepared medicines—stability of piperacillin/tazobactam in PVC and non-PVC bags. J Pharm Biomed Anal. 2005; 39:339-43. [PubMed 16085149] 2668. Weck S, Cheung S, Hiraoka-Sutow M et al. Alteplase as a catheter locking solution: in vitro evaluation of biochemical stability and antimicrobial properties. J Vasc Intervent Radiol. 2005; 16:79-83. 2669. Pourroy B, Botta C, Solas C et al. Twenty-two-hour stability of Taxol in 5% dextrose or 0.9% sodium chloride in Viaflo, Freeflex, Ecoflac, and Macoflex N non-PVC bags. J Clin Pharm Ther. 2005; 30:455-8. [PubMed 16164492] 2670. Ariz Ozdemir F, Anilnamet B, Pekin M. Spectrophotometric investigation of the chemical compatibility of the anticancer drugs irinotecan-HCl and epirubicin-HCl in the same infusion solution. Cancer Chemother Pharmacol. 2005; 56:529-34. [PubMed 15947932] 2671. Trissel LA, Zhang Y, Douglass K et al. Extended stability of oxytocin in common infusion solutions. Int J Pharmaceut Compound. 2006; 10:156-8. 2672. Negro S, Martin A, Azuara ML et al. Stability of tramadol and haloperidol for continuous subcutaneous infusion at home. J Pain Symptom Manage. 2005; 30:192-9. [PubMed 16125035] 2673. Sautou-Miranda V, Brigas F, Vanheerswynghe S et al. Compatibility of pacitaxel in 5% glucose solution with ECOFLAC low-density polyethylene containers—stability under different storage conditions. Int J Pharm. 1999; 178:77-82. [PubMed 10205627] 2674. Trittler R. Stability of intravenous admixtures of doxorubicin and vincristine confirmed by LC-MS. Europ J Hosp Pharm Sci. 2006; 12:10-2. 2675. Chan J, Walker SE, Law S. Stability of dolesetron mesylate in 0.9% sodium chloride and 5% dextrose in water. Can J Hosp Pharm. 2003; 56:87-92. 2676. Zhang Y, Trissel LA. Physical and chemical stability of fentanyl in plastic syringes. Am Pharmacother. 2005; 39:206-8. [PubMed 16227449] 2677. Watson DG, Lin M, Morton A et al. Compatibility and stability of dexamethasone sodium phosphate and ketamine hydrochloride subcutaneous infusions in polypropylene syringes. J Pain Symptom Manage. 2005; 30:80-6. [PubMed 16043011] 2678. Leo G, Saira K, Doyle L et al. Stability of morphine sulphate in P.C.A.s. Europ J Hosp Pharm Sci. 2003; 8:1-9. 2679. Theou N, Havard L, Maestroni ML et al. Leaching of di(2-ethylhexyl)phthalate from polyvinyl chloride medical devices: recommendations for taxanes infusion. Europ J Hosp Pharm Sci. 2005; 11:55-61. 2680. Hartman CA, Faria CE, Mago K. Visual compatibility of bivalirudin with selected drugs. Am J Health-Syst Pharm. 2004; 61:1774. 1776. [PubMed 15462247] 2681. Trissel LA, Zhang Y, Xu QA. Physical and chemical stability of palonosetron hydrochloride with dacarbazine and with methylprednisolone sodium succinate during simulated Y-site administration. Int J Pharmaceut Compound. 2006; 10:234-6. 2682. Rodenbach MP, Heq JD, Vanbeckbergen ED et al. Effect of freezing, long-term storage and microwave thawing on the stability of vancomycin hydrochloride in 5% dextrose infusions. Europ J Hosp Pharm Sci. 2005; 11:111-3. 2683. Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site administration. Int J Pharmaceut Compound. 2006; 10:230-3. 2684. Robinson JL, Tawfik G, Saxinger L et al. Stability of heparin and physical compatibility of heparin/antibiotic solutions in concentrations appropriate for antibiotic lock therapy. J Antimicrob Chemother. 2005; 56:951-3. [PubMed 16155063] 2685. Corvino TP, Nahata MC, Angeles MG et al. Availability, stability, and sterility of pralidoxime for mass casualty use. Ann Emerg Med. 2006; 47:272-7. [PubMed 16492495] 2686. Robinson RF, Morosco R. Stability of ciprofloxacin in four heparinized and nonheparinized dialysate solutions at 38°C. ASHP Midyear Clinical Meeting Poster. Dec 2005; 40:P442E.

2687. Faria CE, Fiumara K, Patel N et al. Visual compatibility of furosemide with phenylephrine and vasopressin. Am J Health-Syst Pharm. 2006; 63:906. 908. [PubMed 16675646] 2688. Boothby LA, Madabushy R, Kumar V et al. Extended stability of oxytocin in Ringer's lactate solution at 4° and 25°C. Hosp Pharm. 2006; 41:437-41. 2689. Zhang Y, Trissel LA. Physical and chemical stability of pemetrexed in infusion solutions. Ann Pharmacother. 2006; 40:1082-5. [PubMed 16720706] 2690. Driscoll DF. Lipid injectable emulsions: pharmacopeial and safety issues. Pharm Res. 2006; 23:1959-69. [PubMed 16951994] 2691. Anacardio R, Bartolini S, Gentile MM et al. HPLC investigated compatibility between artrosilene injectable solution and other pharmaceutical products frequently used for combined therapy into elastomeric Baxter LV5 infusion device. Inter J Immunopath Pharmacol. 2005; 18:791-8. 2692. Gupta VD. Physicochemical compatibility of pemetrexed in polypropylene syringes. J Pharm Biomed Anal. 2006; 40:1289-92. [PubMed 16822897] 2694. Sahraoui L, Chiadmi F, Schlatter J et al. Stability of voriconazole injection in 0.9% sodium chloride and 5% dextrose injection. Am J Health-Syst Pharm. 2006; 63:1423-6. [PubMed 16849707] 2695. Hamada C, Hayashi K, Shou T et al. Pharmacokinetics of calcitriol and maxacalcitol administered into peritoneal dialysate bags in peritoneal dialysis patients. Perit Dial Int. 2005; 25:570-5. [PubMed 16411524] 2696. Carpenter JF, McNulty MA, Duscii LJ et al. Stability of omeprazole sodium and pantoprazole sodium diluted for intravenous infusion. J Pharm Technol. 2006; 22:95-8. 2697. Mendez ASL, Dalomo J, Stejpe M et al. Stability and degradation kinetics of meropenem in powder for injection and reconstituted samples. J Pharm Biomed Anal. 2006; 41:1363-6. [PubMed 16535586] 2698. Kumarelv V, Gandhimani P, Cundill G. Frozen succinylcholine chloride. Anaesthesia. 2006; 61:202. [PubMed 16430592] 2699. Stone J, Fawcett W. A case of frozen succinylcholine chloride encountered during emergency Cesarean delivery. Anesth Analg. 2002; 95:1465. [PubMed 12401654] 2700. Negro S, Reyes R, Azuara ML et al. Morphine, haloperidol and hyoscine N-butyl bromide combined in s.c. infusion solutions: compatibility and stability evaluation in terminal oncology patients. Int J Pharm. 2006; 307:278-84. [PubMed 16297583] 2701. Negro S, Azuara ML, Sanchez Y et al. Physical compatibility and in vivo evaluation of drug mixtures for subcutaneous infusion to cancer patients in palliative care. Support Care Cancer. 2002; 10:65-70. [PubMed 11777190] 2702. Shields D, Montenegro R, Aclan J. The chemical stability of admixtures combining ziconotide and clonidine during simulated intrathecal administration. 7th Congress International Modulation Society Poster. Jun 2005; . 2704. Shields D, Montenegro R, Aclan J. The chemical stability of admixtures combining ziconotide and bupivacaine hydrochloride during simulated intrathecal administration. 7th Congress International Modulation Society Poster. Jun 2005; . 2705. Huang L. Effect of pH and temperature on the stability of 1% tetracaine hydrochloride injection. Yaxoue Tongbao. 1982; 17:208-9. 2706. Kambia NK, Luyck M, Dine T et al. Stability and compatibility of paracetamol injection admixed with ketoprofen. Europ J Hosp Pharm Sci. 2006; 12:81-4. 2707. Heq JD, Boitquin L, Lebrun C et al. Freeze thaw treatment of ketorolac tromethamine in 5% dextrose infusion polyolefin bags: effect of drug concentration and microwave power on the long-term stability at 4°C. Europ J Hosp Pharm Sci. 2006; 12:72-5. 2708. Donyai P, Sewell GJ. Physical and chemical stability of pacitaxel infusions in different container types. J Oncol Pharm Pract. 2006; 12:211-2. [PubMed 17156593] 2709. Fielding H, Kyatereka N, Skellern GG et al. The compatibility and stability of octreotide acetate in the presence of diamorphine hydrochloride in polypropylene syringes. Palliative Med. 2000; 14:205-7. 2710. Vranken JH, van Kan HJ, van der Vegt MH. Stability and compatibility of a meperidine-clonidine mixture in portable pump reservoirs for the management of cancer pain syndromes. J Pain Symptom Manage. 2006; 32:297-9. [PubMed 17000346] 2711. Negro S, Rendon AL, Azuara ML et al. Compatibility and stability of furosemide and dexamethasone combined in infusion solutions. Armznheim-Freiburg. 2006; 56:714-20. 2712. Fernandez-Zaruy N, Martin P, Espuny A et al. Stability of mofloxacin injection in peritoneal dialysis solution bags (Dianeal P1 3.6%) and Dianeal P1 3.6%). J Clin Pharm Ther. 2006; 31:641-3. [PubMed 17176370] 2713. Shields D, Aclan J, Sztakowski A et al. The chemical stability of an admixture containing 25 mcg/mL ziconotide and 20 mg/mL morphine sulfate during simulated intrathecal administration. N Amer Neuromodulation Soc Poster. 2006; . 2714. Ludwig S, Vencel-Joncic M, Gandhi P et al. Simulated Y-site compatibility testing of various diluents and drug products with tigecycline, a first-in-class intravenous glycylcycline. ASHP Summer Meeting Poster. 2006; .P62E.

2715. Carroll JA. Stability of flucloxacillin in elastomeric infusion devices. J Pharm Pract Res. 2005; 35:90-2. 2716. Trusley C, Ben M, Kupiec TC et al. Physical and chemical stability of palonosetron with metoclopramide and promethazine during simulated Y-site administration. Int J Pharmaceut Compound. 2007; 11:82-5. 2717. Chaplain-Pargrade S, Laville I, Paci A et al. Microbiological and physicochemical stability of fentanyl and sufentanil solutions for patient-controlled delivery systems. J Pain Symptom Manage. 2006; 32:90-7. [PubMed 16824989] 2718. Dalle M, Sautou-Miranda V, Balaayssac D et al. Can solutions of docetaxel be concentrated in PVC bags?. J Pharm Clin. 2006; 25:147-52. 2719. Kovalek LJ, Pikalov AA, Ni N et al. Short-term physical compatibility of intramuscular aripiprazole with intramuscular lorazepam. Am J Health-Syst Pharm. 2008; 65:2007-8. [PubMed 18495855] 2720. Trissel LA, Trusley C, Ben M et al. Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during simulated Y-site administration. Am J Health-Syst Pharm. 2006; 63:79-85. [PubMed 16373469] 2722. Pietroski N (Associate Director, Medical Services, Merck & Co., North Wales, PA). Personal communication; 2007 Jun 15. 2723. Pietroski N (Associate Director, Medical Services, Merck & Co., North Wales, PA). Personal communication; 2007 Jun 29. 2724. Heq JD, Evrard JM, Vanbeckbergen DF et al. Effect of freezing, long term storage and microwave thawing on the stability of ceftriaxone sodium in 5% dextrose infusion polyolefin bags at 2-8°C. Europ J Hosp Pharm Sci. 2006; 12:52-6. 2725. Sudekum MJ (Manager, Clinical Pharmacy Services, Botsford Hospital, Farmington Hills, MI). Personal communication; 2007 Jun 6. 2726. Nolin DT, Lambert DA, Owens RC JR. Stability of cefepime and metronidazole prepared for simplified administration as a single product. Diag Microbiol Infect Dis. 2006; 56:179-84. 2727. Serrurier C, Chenot ED, Vigneron J et al. Assessment of injectable drugs' administration in two intensive care units and determination of potential physico-chemical incompatibilities. Europ J Hosp Pharm Sci. 2006; 12:96-9. 2728. Kraft MD, Johnson CE, Chung C et al. Stability of metoprolol tartrate injection 1 mg/mL undiluted and 0.5 mg/mL in 0.9% sodium chloride injection and 5% dextrose injection. Am J Health-Syst Pharm. 2008; 65:636-8. [PubMed 18359971] 2729. Kattige A. Long-term physical and chemical stability of a generic paclitaxel infusion under simulated storage and clinical-use conditions. Europ J Hosp Pharm Sci. 2006; 12:129-34. 2730. Griffiths W, Favet J, Ing H et al. Chemical stability and microbiological potency of intravenous vancomycin hydrochloride in polypropylene syringes for use in the neonatal intensive care unit. Europ J Hosp Pharm Sci. 2006; 12:135-9. 2731. Vannexu V, Prout V, Cheron M et al. A physical and chemical stability study of amphotericin B lipid complexes (Abelcet) after dilution in dextrose 5%. Europ J Hosp Pharm Sci. 2007; 13:10-3. 2733. Rondelot G, Serrurier C, Vigneron J et al. Stability of pemetrexed 25 mg/mL in a glass vial and 5 mg/mL in a PVC container after storage for one month at 2-8°C. Europ J Hosp Pharm Sci. 2007; 13:14-6. 2735. Johnson CE, Cober MP. Stability of vecuronium in sterile water for injection stored in polypropylene syringes for 21 days. Am J Health-Syst Pharm. 2007; 64:2356-8. [PubMed 17989445] 2736. Johnson CE. Stability of a 12.5 mg/mL dolasetron injection in a 12-mL polypropylene syringe. ASHP Midyear Clinical Meeting Poster. Dec 2006. 2737. Kiser TH, Oldland AR, Fish DN. Stability of phenylephrine hydrochloride injection in polypropylene syringes. Am J Health-Syst Pharm. 2007; 64:1092-3. [PubMed 17494910] 2738. Cochran BG, Sowinski KM, Fausel C et al. Physical compatibility and chemical stability of mycophenolate mofetil during simulated Y-site administration with commonly coadministered drugs. Am J Health-Syst Pharm. 2007; 64:1410-4. [PubMed 17592007] 2739. Karstens A, Kramer I. Chemical and physical stability of diluted busulfan infusion solutions. Europ J Hosp Pharm Sci. 2007; 13:40-7. 2740. Karstens A, Kramer I. Viability of micro-organisms in novel anticancer drug solutions. Europ J Hosp Pharm Sci. 2007; 13:27-32. 2741. Ponton JL, Munoz C, Rey M et al. The stability of (lyophilized) gemcitabine in 0.9% sodium chloride injection. Europ J Hosp Pharm. 2002; 1:23-5. 2742. Adnet F, Le Moyec L, Smith CE et al. Stability of succinylcholine solutions stored at room temperature studied by nuclear magnetic resonance spectroscopy. Emerg Med J. 2007; 24:168-9. [PubMed 17351219] [Free Fulltext PMC] 2743. Brammer MK, Chan P, Heatherly K et al. Compatibility of doripenem with other drugs during simulated Y-site administration. Am J Health-Syst Pharm. 2008; 65:1261-5. [PubMed 18574017] 2744. Andre P, Cisternino S, Roy AL et al. Stability of oxaliplatin in infusion bags containing 5% dextrose injection. Am J Health-Syst Pharm. 2007; 64:1950-4. [PubMed 17823107] 2745. Cohen V, Jellinek SP, Teperikidis L et al. Room-temperature storage of medications labeled for refrigeration. Am J Health-Syst Pharm. 2007; 64:1711-5. [PubMed 17687059] 2746. Dice JE. Physical compatibility of alprostadil with commonly used IV solutions and medications in the neonatal intensive care unit. J Pediatr Pharmacol Ther. 2006; 11:233-6. 2747. Negro S, Salama A, Sanchez Y et al. Compatibility and stability of tramadol and dexamethasone in solution and its use in terminally ill patients. J Clin Pharm Ther. 2007; 32:441-5. [PubMed 17875108] 2748. Parti R, Schoppmann A, Lee H et al. Stability of intrathecal and rectal enema plasma/albume free recombinant human factor VIII (ADVATE RAH-PFM). Haemophilia. 2005; 11:492-6. [PubMed 16128893] 2749. Ben M, Trusley C, Kupiec TC et al. Palonosetron hydrochloride compatibility and stability with three β -lactam antibiotics during simulated Y-site administration. Int J Pharmaceut Compound. 2007; 12:20-4. 2750. Giribay JL, Dilliazem-HF. 1 mg/mL prediluted in normal saline and dextrose 5% compounding with the Gri-Fill 3.0 system and stability study up to 90 days in Gri-Bag. November 2007. 2751. Shields D, Montenegro R, Aclan J. Chemical stability of an admixture combining ziconotide and bupivacaine during simulated intrathecal administration. Neuromodulation. 2007; 10:51-5. 2752. Shields D, Montenegro R. Chemical stability of ziconotide-hydrochloride admixtures with and without morphine sulfate during simulated intrathecal administration. Neuromodulation. 2007; 10:56-11. 2753. Shields D, Montenegro R, Aclan J. Chemical stability of admixtures combining ziconotide with baclofen during simulated intrathecal administration. Neuromodulation. 2007; 10:512-17. 2754. Avadel Legacy Pharmaceuticals, LLC. Akovav® (epheдрine sulfate) injection prescribing information. Chesterfield, MO; 2017 Apr.

2755. Dura JV, Hinkle GH. Stability of a mixture of technetium Tc 99m sulfur colloid and lidocaine hydrochloride. Am J Health-Syst Pharm. 2007; 64:2477-9. [PubMed 18029954] 2756. Cober MP, Johnson CE. Stability of 70% alcohol solutions in polypropylene syringes for use in ethanol-lock therapy. Am J Health-Syst Pharm. 2007; 64:2480-2. [PubMed 18029955] 2757. Psathas PA. Stability of doripenem for injection (500 mg) in representative infusion fluids and containers. ASHP Summer Meeting Poster. 2007; 64(Jun):P576. 2758. Chan P, Heatherly K, Kupiec TC et al. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site administration. Int J Pharmaceut Compound. 2008; 12:276-8. 2759. Kaiser JD, Vigneron J, Zenier H et al. Chemical and physical stability of dexamethasone, diluted with Ringer's lactate solution, in polyvinyl and polyethylene syringes. Europ J Hosp Pharm. 2007; 13:55-9. 2760. Kupiec TC, Alounanis V, Ben M et al. Physical and chemical stability of esomeprazole sodium solutions. Ann Pharmacother. 2008; 42:1247-51. [PubMed 18614750] 2761. Walker SE. Stability of docetaxel solution in ethanol in ethanol and storage in vials and after dilution in normal saline and storage in bags. Can J Hosp Pharm. 2007; 60:231-7. 2762. Chan P, Bishop A, Kupiec TC et al. Compatibility of cefotriprole medocarl with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm. 2008; 65:145-51. [PubMed 18693210] 2763. Roy JJ, Boismenu D, Mamer OA et al. Room temperature stability of injectable succinylcholine dichloride. Int J Pharmaceut Compound. 2008; 12:83-5. 2764. Trusley C, Ben M, Kupiec TC et al. Compatibility and stability of palonosetron hydrochloride with four neuromuscular blocking agents during simulated Y-site administration. Int J Pharmaceut Compound. 2008; 12:156-60. 2765. Kupiec TC, Ben M, Trusley C et al. Compatibility and stability of palonosetron hydrochloride with gentamicin, metronidazole, or vancomycin during simulated Y-site administration. Int J Pharmaceut Compound. 2008; 12:170-3. 2766. Condie CK, Tyler LS, Barker B et al. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery. Am J Health-Syst Pharm. 2008; 65:454-7. [PubMed 18281738] 2767. Brousseau P, Nickerson J, Dobson G. Dexamethasone and ondansetron incompatibility in polypropylene syringes. Can J Anesth. 2007; 54:953-4. [PubMed 17975246] 2768. Walker SE, Miliken D, Law S. Stability of bortezomib reconstituted with 0.9% sodium chloride at 4°C and room temperature (23°C). Can J Hosp Pharm. 2008; 61:14-20. 2769. Chandler C, Gryniwicz CM, Pringle T et al. Insulin temperature and stability under simulated transit conditions. Am J Health-Syst Pharm. 2008; 65:953-63. [PubMed 18463345] 2770. Walker SE, Law S. Physical [visual] Y-site compatibility of Voluven with 38 other intravenous medications. CSHP Annual Meeting Poster. Aug 2007. 2771. Kupiec TC, Trusley C, Ben M et al. Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration. Am J Health-Syst Pharm. 2008; 65:1735-9. [PubMed 18769000] 2772. Shields DE, Aclan J, Sztakowski A. Chemical stability of admixtures combining ziconotide with fentanyl or sufentanil during simulated intrathecal administration. Int J Pharmaceut Compound. 2008; 12:463-6. 2773. Ben M, Trusley C, Kupiec TC et al. Physical and chemical stability of palonosetron hydrochloride with glycopyrrate and neostigmine during simulated Y-site administration. Int J Pharmaceut Compound. 2008; 12:368-72. 2774. Goldenberg NA, Jacobson L, Hathaway H et al. Anti-Xa stability of diluted dalteparin for pediatric use. Ann Pharmacother. 2008; 42:511-5. [PubMed 18349310] 2775. Ben M, Kupiec TC, Trusley C et al. Compatibility and stability of palonosetron hydrochloride with lactated Ringer's, hetastarch in lactated electrolyte, and mannitol injections during simulated Y-site administration. Int J Pharmaceut Compound. 2008; 12:460-2. 2776. Tremblay M, Lessard MR, Trepanier CA et al. Stability of norepinephrine infusions prepared in dextrose and normal saline solutions. Can J Anesth. 2008; 55:163-7. [PubMed 18310626] 2777. Kaestner S, Sewell G. A sequential temperature cycling study for the investigation of carbolipin infusion stability to facilitate "dose-banding". J Oncol Pharm Pract. 2007; 13:119-26. [PubMed 17873112] 2778. Newton DW, Driscoll DF. Chemistry and safety of phosphates injections. Am J Health-Syst Pharm. 2008; 65:1767-6. [PubMed 18769005] 2779. Stucki MC, Fleury-Souverain S, Sautter AM et al. Development of ready-to-use ketamine hydrochloride syringes for safe use in post-operative pain. Europ J Hosp Pharm Sci. 2008; 14:14-8. 2780. Shields DE, Aclan J, Sztakowski A. Chemical stability of admixtures containing ziconotide 25 mcg/mL and morphine sulfate 10 mg/mL or 20 mg/mL during simulated intrathecal administration. Int J Pharmaceut Compound. 2008; 12:553-7. 2781. Donnelly RF, Corman C. Physical compatibility and chemical stability of a concentrated solution of atropine sulfate (2 mg/mL) for use as an antidote in nerve agent casualties. Int J Pharmaceut Compound. 2008; 12:550-2. 2782. Junker A, Roy S, Desroches MC et al. Stability of oxaliplatin solution. Ann Pharmacother. 2009; 43:390-1. [PubMed 19133594] 2783. Taiwo T (Medical Communications, Hospira, Inc., Lake Forest, IL). Personal communication; 2009 Feb 23. 2785. Martinez JN, Alminna MA, Sales OD. Estabilidad en suero fisiologico del busulfan intravenoso en polipropileno. J Oncol Pharm Pract. 2007; 13:119-26. [PubMed 17873112] 2786. Trissel LA, Trusley C, Kupiec TC et al. Compatibility and stability of palonosetron hydrochloride and propofol during simulated Y-site administration. Int J Pharmaceut Compound. 2009; 13:78-80. 2789. Valverde Molina E, Gonzalez Munoz V, Gomez-Maldonado J et al. Stability of pantoprazole in parenteral nutrition units. Farm Hosp. 2008; 32:290-2. [PubMed 19150045] 2790. Donnelly RF, Willman E, Adolfo G. Stability of ketamine-propofol mixtures for procedural sedation and analgesia in the emergency department. Can J Hosp Pharm. 2008; 61:426-30. 2791. McCluskey SV, Graner KK, Kemp J et al. Stability of fentanyl 5 mcg/mL diluted with 0.9% sodium chloride injection and stored in polypropylene syringes. Am J Health-Syst Pharm. 2009; 66:860-3. [PubMed 19386950] 2792. Alounanis V, Ben M, Kupiec TC et al. Drug compatibility with a new generation of VISIV polyolefin infusion solution containers. Int J Pharmaceut Compound. 2009; 13:162-5. 2793. Xu M, Warren FW, Bartlett MG. Stability of low-concentration cefazidime in 0.9% sodium chloride injection and balanced salt solutions in plastic syringes under various storage conditions. Int J Pharmaceut Compound. 2009; 13:166-9. 2794. Canann D, Tyler LS, Barker B et al. Visual compatibility of i.v. medications routinely used in bone marrow transplant recipients. Am J Health-Syst Pharm. 2009; 66:727-9. [PubMed 19336832] 2795. Newland AM, Mauro VF, Alexander KS. Physical compatibility of metoprolol tartrate injection with selected cardiovascular agents. Am J Health-Syst Pharm. 2009; 66:986-7. [PubMed 19451606] 2796. Vazquez R, Le Hoang MD, Martin J et al. Simultaneous quantification of water-soluble and fat-soluble vitamins in parenteral nutrition admixtures by HPLC-UV-MS/MS. Eur J Hosp Pharm Sci. 2009; 15:23-5. 2797. Donnelly RF. Physical compatibility and chemical stability of ketamine-morphine mixtures in polypropylene syringes. Can J Hosp Pharm. 2009; 62:28-33. [Free Fulltext PMC] 2798. Walker S, Iazzetta J, Law S. Extended stability of pantoprazole for injection in 0.9% sodium chloride or 5% dextrose at 4°C and 23°C. Can J Hosp Pharm. 2009; 62:135-41. [Free Fulltext PMC] 2799. Ensom MY, Decarie D, Leung K et al. Stability of hydromorphone-ketamine solutions in glass bottles, plastic syringes, and IV bags for pediatric use. Can J Hosp Pharm. 2009; 62:112-8. [Free Fulltext PMC] 2800. Pourroy B, Bausset EM, Boulamery A et al. Incompatibility of impipenem-clastatin and amoxicillin. Am J Health-Syst Pharm. 2009; 66:1253-4. [PubMed 19574595] 2801. Psathas P, Gilmore TP, Schaufelberger DE, et al. Stability of high and low concentrations of doripenem (500 mg) for injection in representative infusion fluids and containers. ASHP Summer Meeting Poster. Jun 2009. 2802. Gole JD, Illias J, Vermeersch H et al. Stability of cefotriprole for injection (500 mg) in representative infusion fluids and containers. ASHP Summer Meeting Poster. Jun 2009. 2803. Newton DW, Driscoll DF. Calcium and phosphate compatibility: revisited again. Am J Health-Syst Pharm. 2008; 65:73-80. [PubMed 1815904] 2804. Erwin AS, Bafaluy IM, Amari JAS. Stability of docetaxel diluted to 0.3 to 0.9 mg/mL with 0.9% sodium chloride injection and stored in polyolefin or glass containers. Am J Health-Syst Pharm. 2009; 66:1565-8. [PubMed 19710441] 2805. Michel M (Medical Information, Eisai, Woodcliff Lake, NJ). Personal communication; 2016 Jan 12. 2806. Donnelly RF. Stability of aseptically prepared tазosin solutions in polyvinyl chloride bags. Can J Hosp Pharm. 2009; 62:226-31. [Free Fulltext PMC] 2807. Galanti L, Lebittasy MP, Heq JD et al. Long-term stability of 5-fluorouracil in 0.9% sodium chloride after freezing, microwave thawing, and refrigeration. Can J Hosp Pharm. 2009; 62:334-8. [Free Fulltext PMC] 2808. Crandon JL, Sutherland C, Nicolau DP. Enhanced room temperature (RT) stability of doripenem (DOR) within two infusion devices. Infectious Disease Society of America Meeting Poster. Oct 2009. 2809. Crandon JL, Sutherland C, Nicolau DP. Stability of doripenem in polyvinyl chloride bags and elastomeric pumps. Am J Health-Syst Pharm. 2010; 67:1539-44. [PubMed 20811032] 2810. Almoazen H, Bhattacharjee H, Samsa AC et al. Stability of mesna in ReadyMix infusion devices. Ann Pharmacother. 2010; 44:224-5. [PubMed 2028956] 2811. Athanopoulos A, Heq JD, Vanbeckbergen D et al. Long-term stability of tramadol chlorhydrate and metoclopramide hydrochloride in dextrose 5% polyolefin bag at 4°C. J Oncol Pharm Pract. 2010; 15:195-200. [PubMed 19759051] 2812. Reviewers' comments (personal observations) on infliximab. 2813. Walker SE, Law S, Garland J et al. Stability of norepinephrine solutions in normal saline and 5% dextrose in water. Can J Hosp Pharm. 2010; 64:113-19. [Free Fulltext PMC] 2814. Moriyma B, Henning SA, Jin H et al. Physical compatibility of magnesium sulfate and sodium bicarbonate in a pharmacy-compounded hemofiltration solution. Am J Health-Syst Pharm. 2010; 67:562-5. [PubMed 20237384] [Free Fulltext PMC] 2815. Pascuet E, Donnelly RF, Garceau D et al. Buffered lidocaine hydrochloride solution with and without epinephrine: stability in polypropylene syringes. Can J Hosp Pharm. 2009; 62:375-80. [Free Fulltext PMC] 2816. He, J. Figueroa DA, Tze-Peng L et al. Stability of polymyxin B sulfate diluted in 0.9% sodium chloride injection and stored at 4 or 25°C. Am J Health-Syst Pharm. ; 67:1191-4. 2817. Wear J, McPherson TB, Kolling WM. Stability of sodium bicarbonate solutions in polyolefin bags. Am J Health-Syst Pharm. 2010; 67:1026-9. [PubMed 20516474] 2818. Khondkar D, Chopra P, McArthur JP et al. Chemical stability of hydromorphone hydrochloride in patient-controlled analgesia injector. Int J Pharmaceut Compound. 2010; 14:160-4. 2819. Walker SE, Iazzetta J, Law S et al. Stability of

Information. Philadelphia, PA; 2018 Apr. 2916.

Information. Inc. Doribax® (doripenem) for injection powder for solution for intravenous use prescribing information. Florham Park, NJ; 2014 Jan. 2917. Ludwig S (Corresponding Author): Personal communication; 2014 May 8. 2918. Wyeth Pharmaceuticals Inc. Zosyn® (piperacillin sodium and tazobactam sodium) for injection single-dose and pharmacy information. Philadelphia, PA; 2014 Feb. 2919. Hospira, Inc. Piperacillin sodium and tazobactam sodium for injection ADD Vantage® vials prescribing information. Lake Forest, IL; 2013 Sep. 2920.

Apotex Corp. Piperacillin sodium and tazobactam sodium for injection pharmacy bulk vials prescribing information. Weston, FL; 2014 Jun. 2921. Mylan Institutional LLC. Piperacillin sodium and tazobactam sodium for injection single dose vials prescribing information. Rockford, IL; 2014 Aug. 2922. (Medical Information, Pfizer): Personal communication; 2014. 2923. Gilead Sciences, Inc. Vistide® (cidofovir) injection prescribing information. Foster City, CA; 2010 Sep. 2925. Heritage Pharmaceuticals Inc. Cidofovir injection prescribing information. Eatontown, NJ; 2013 Oct. 2926. JHP Pharmaceuticals, LLC. Breval® sodium (methohexital sodium) for injection prescribing information. Rochester, MI; 2014 Feb.

2927. The Medicines Company. Orbiact® (oritavancin) for injection prescribing information. Parsippany, NJ; 2014 Aug. 2928.

Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health Syst Pharm. 2010; 67:1640-4. [PubMed 20852166] 2929. Novartis Pharmaceuticals Corporation. Sandimmune® (cyclosporine) capsules, oral solution, and injection prescribing information. East Hanover, NJ; 2015 Mar. 2930. Li M, Forest JM, Coursol C et al. Stability of cyclosporine solutions stored in polypropylene bags and polypropylene syringes. Am J Health Syst Pharm. 2011; 68:1646-50.

[PubMed 21856911] 2931. Li M, Coursol C, Lech C, Lech G. Stability of cyclosporine diluted with 0.9% sodium chloride injection or 5% dextrose injection and stored in ethylene-vinyl acetate containers. Am J Health Syst Pharm. 2013; 70:1970-2. Letter. [PubMed 24173005] 2932. Desai NR, Shah SM, Cohen J et al. Zosyn (piperacillin/tazobactam) reformulation: Expanded compatibility and compatibility with lactated Ringer's solutions and selected aminoglycosides. Ther Clin Risk Manag. 2008; 4:303-14. [PubMed 18728835] 2933. Nichols KR, Demarco MW, Vertin MD et al. Y-site compatibility of vancomycin and piperacillin/tazobactam at commonly utilized pediatric concentrations. Hosp Pharm. 2013; 48:44-7. [PubMed 24421422] 2934. Lam WJ, Bhowmik T, Gross A et al. Using higher doses to compensate for tubing residuals in extended-infusion piperacillin-tazobactam. Ann Pharmacother. 2013; 47:886-91. [PubMed 23715072] 2935. Leung E, Venkatesan N, Ly SC et al. Physical compatibility of vancomycin and piperacillin sodium-tazobactam at concentrations typically used during prolonged infusions. Am J Health Syst Pharm. 2013; 70:1163-6. [PubMed 23784164] 2936. Fresenius Kabi USA, LLC. Bleomycin sulfate for injection prescribing information. Lake Zurich, IL; 2014 Feb. 2937. Hospira, Inc. Bleomycin for injection prescribing information. Lake Forest, IL; 2013 Jan. 2938. Fresenius Kabi USA, LLC. Cladribine injection prescribing information. Lake Zurich, IL; 2013 May. 2939. Teva Pharmaceuticals USA. Carboplatin injection prescribing information. North Wales, PA; 2016 Jan. 2940.

Accord Healthcare, Inc. Carboplatin injection prescribing information. Durham, NC; 2019 Jul. 2941. APP Pharmaceuticals, LLC. Cytarabine injection prescribing information. Schaumburg, IL; 2008 Jan. 2942. Hospira, Inc. Cytarabine injection for intravenous, intrathecal and subcutaneous use only prescribing information. Lake Forest, IL; 2012 Apr. 2943. Hospira, Inc. Cytarabine injection pharmacy bulk package prescribing information. Lake Forest, IL; 2012 Apr. 2944. Hospira, Inc. Cytarabine injection for intravenous or subcutaneous use only prescribing information. Lake Forest, IL; 2012 Apr. 2945. Recordati Rare Diseases Inc. Cosmegen® (daunorubicin) for injection prescribing information. Lebanon, NJ; 2013 Feb. 2946. APP Pharmaceuticals, LLC. Vincristine sulfate injection prescribing information. Schaumburg, IL; 2011 Oct. 2947. Hospira, Inc. Vincristine sulfate injection prescribing information. Lake Forest, IL; 2013 Jul. 2948. Hospira, Inc. Mitoxantrone hydrochloride injection concentrate prescribing information. Lake Forest, IL; 2013 Feb. 2949. Pfizer Labs. Mitoxantrone hydrochloride injection concentrate prescribing information. New York, NY; 2013 May. 2950. Teva Parenteral Medicines, Inc. Daunorubicin hydrochloride injection prescribing information. Whitehouse Station, NJ; 2014 Oct. 2953. Merck & Co., Inc. Intron® A (interferon alfa-2b, recombinant) for injection prescribing information. Whitehouse Station, NJ; 2014 Oct. 2953. Merck & Co., Inc. Intron® A (interferon alfa-2b, recombinant) powder for solution instructions for use. Whitehouse Station, NJ; 2011 Feb.

2954. Fresenius Kabi USA, LLC.

Fluorouracil injection solution pharmacy bulk package prescribing information. Lake Zurich, IL; 2014 Jun. 2955. Fresenius Kabi USA, LLC. Fluorouracil injection solution prescribing information. Lake Zurich; 2014 Jun. 2956. Accord Healthcare, Inc. Fluorouracil injection solution pharmacy bulk package prescribing information. Durham, NC; 2013 Nov. 2957. Accord Healthcare, Inc. Fluorouracil injection solution prescribing information. Durham, NC; 2013 Nov. 2958. Merck & Co., Inc. Zerbaxa® (ceftriaxone and tazobactam) for injection prescribing information. Whitehouse Station, NJ; 2019 Jun. 2959. Johnson PR (Medical Information, Cubist Pharmaceuticals, Lexington, MA): Personal communication; 2014 Dec 23. 2960. BioCryst Pharmaceuticals, Inc. Rapivab® (peramivir) injection prescribing information. Durham, NC; 2014 Dec. 2961.

Lipäinen T, Peltoniemi M, Sarkhel S et al. Formulation and Stability of Cytokine Therapeutics. J Pharm Sci. 2014; :. [PubMed 25492409] 2962. Baxter Healthcare Corporation. Cyclophosphamide powder for injection. Deerfield, IL; 2014 Oct. 2963. Jansen JJ, Oldland AR, Kiser TH. Evaluation of phenylephrine stability in polyvinyl chloride bags. Hosp Pharm. 2014; 49:455-7. [PubMed 24958958] 2964. Pharmacia and Upjohn Company. Idamycin PFS® (darubicin hydrochloride injection) prescribing information. New York, NY; 2014 Dec. 2965.

[PubMed 21856911] 2966. Li M, Coursol C, Lech C, Lech G. Stability of cyclosporine diluted with 0.9% sodium chloride injection or 5% dextrose injection and stored in ethylene-vinyl acetate containers. Am J Health Syst Pharm. 2013; 70:1970-2. Letter. [PubMed 24173005] 2967. Mylan Institutional LLC. Methotrexate sodium injection prescribing information. Rockford, IL; 2013 Dec. 2968.

Fresenius Kabi USA, LLC. Methotrexate sodium for injection prescribing information. Lake Zurich, IL; 2013 Nov. 2969. Antares Pharma, Inc. Otrexup® (methotrexate) injection for subcutaneous use prescribing information. Ewing, NJ; 2014 Nov. 2970. Medac Pharma Inc. Rasuvo® (methotrexate) injection for subcutaneous use prescribing information.

Chicago, IL; 2014 Jul. 2971. Almagambetova E, Hutchinson D, Blais DM et al. Stability of diluted adenosine solutions in polyolefin infusion bags. Hosp Pharm. 2013; 48:484-8. [PubMed 24421510] 2972. Walker SE, Charbonneau LF, Law S. Stability of Bortezomib 2.5 mg/mL in Vials and Syringes Stored at 4°C and Room Temperature (23°C). Can J Hosp Pharm. 2014; 67:102-7. [PubMed 24997191] 2973. Merck & Co., Inc. Intravenous injection prescribing information. Philadelphia, PA; 2014 Feb. 2919. Hospira, Inc. Intravenous injection prescribing information. Lake Forest, IL; 2013 Sep. 2920.

Whitehouse Station, NJ; 2012 Sep. 2974. Jain JC, Subramanian C, Nicolau DP et al. Stability of etanercept 100 mg/mL in polypropylene syringes stored at 25, 4, and -20°C. Am J Health Syst Pharm. 2014; 71:1480-4. [PubMed 25147172] 2975. Dutta S (Medical Information, Merck, North Wales, PA): Personal communication; 2015 Feb 6. 2976. McCuskey SV, Vu N, Rueter J. Stability of nitroglycerin 100 mcg/mL stored in polypropylene syringes. Int J Pharm Compd. 2013 Nov-Dec; 17:515-9. [PubMed 24579303] 2977. Merck & Co., Inc. Cubicin® (daptomycin) for injection prescribing information. Whitehouse Station, NJ; 2017 Mar. 2978. Ortega R, Salmerón-García A, Cabeza J et al. Stability of daptomycin 5 mg/mL and heparin sodium 100 units/mL combined in lactated Ringer's injection and stored in polypropylene syringes at 4 and -20°C. Am J Health Syst Pharm. 2014; 71:956-9. [PubMed 24831000] 2979. Parra MA, Campanero MA, Sádaba B et al. Effect of glucose concentration on the stability of daptomycin in peritoneal solutions. Perit Dial Int. 2013 Jul-Aug; 33:458-61. [PubMed 23843594] 2980. Peyro Saint Paul L, Albessard F, Gaillard C et al. Daptomycin compatibility in peritoneal dialysis solutions. Perit Dial Int. 2011 Jul-Aug; 31:492-5. [PubMed 21799057] 2981. Hossain MA, Fricu M, Aboin S et al. Stability of penicillin G sodium diluted with 0.9% sodium chloride injection or 5% dextrose injection and stored in polyvinyl chloride bag containers and elastomeric pump containers. Am J Health Syst Pharm. 2014; 71:669-73. [PubMed 24680042] 2982. Otsuka America Pharmaceutical, Inc. Busulfex® (busulfan) injection prescribing information. Rockville, MD; 2018 Jan. 2983. Cueto-Sola M, Belda-Furió M, Borrell-García J et al. Incompatibility of undiluted busulfan injection with a needle-free valve. Am J Health Syst Pharm. 2014; 71:1436-7. Letter. [PubMed 25147165] 2984. Patel RP, Li K, Shastri M et al. Stability of ampicillin and amoxicillin in peritoneal dialysis solutions. Am J Health Syst Pharm. 2015; 72:13-4. Letter. [PubMed 25511830] 2985. Woodcock J. Food and Drug Administration.

FDA Letter re: Doctect nos. FDA-2005-P-0003, FDA-2006-P-0019, FDA-2006-P-0331, and FDA-2006-P-0391: Determine that the discontinued formulation Zosyn (piperacillin and tazobactam for injection), was not discontinued for safety and efficacy reasons. Rockville, MD; US Food and Drug Administration. From regulations.gov website (www.regulations.gov/#documentDetail;D=FDA-2012-P-0507-0001). Accessed 2015 Feb 26. 2986. Donnelly RF. Stability of cefazolin sodium in polypropylene syringes and polyvinylchloride minibags. Can J Hosp Pharm. 2011; 64:241-5. [PubMed 22479065] 2987. McCuskey SV, Sztajnkrzycki MD, Jenkins DA et al. Stability of tranexamic acid in 0.9% sodium chloride, stored in type 1 glass vials and ethylene/polypropylene copolymer plastic containers. Int J Pharm Compd. 2014 Sep-Oct; 18:432-7. [PubMed 25577894] 2988. de Guzman R, Polykratis IA, Sundeel JL et al. Stability of tranexamic acid after 12-week storage at temperatures from -20°C to 50°C. Prehospital Emerg Care. 2013 Jul-Sep; 17:394-400. [PubMed 23734991] 2989. Kanchanach M, Hutchingson DJ, Bollinger JE et al. Stability of diluted adenosine solutions in polyvinyl chloride infusion bags. Am J Health Syst Pharm. 2011; 68:1533-6. [PubMed 21817085] 2990. Hutchinson D (Associate Professor, Wegmans School of Pharmacy at St. John's Fisher College, Rochester, NY): Personal communication; 2014 Aug. 2991. Fresenius Kabi USA, LLC. Adenosine injection for intravenous use prescribing information. Northbrook, IL; 2014 Aug. 2993. Fresenius Kabi USA, LLC. Adenosine injection for rapid bolus intravenous use prescribing information. Schaumburg, IL; 2013 Jan. 2994. Teva Pharmaceuticals USA, Inc. Treanda® (bendamustine hydrochlor

1. Hovav M. (clevipidine butyrate) injectable emulsion safety data sheet. Cary, NC; 2016 Jun 17. 3237. Medicis. Calcium Disodium Versenate® (edetate calcium disodium) injection prescribing information. Scottsdale, AZ; 2012 Oct. 3238. Howland MA. Antidotes in depth: edetate calcium disodium (CaNa2EDTA). In: Hoffman RS, Howland MA, Lewin NA, eds. *Handbook of toxicologic emergencies*. 14th ed. New York: McGraw-Hill; 2014. 3239. Medical Information, Sigma Tau Pharmaceuticals). Personal communication; 2016 Oct 6. 3240. Baxalta US Inc. Cuvitru® (immune globulin subcutaneous [human], 20% solution) prescribing information. Westlake Village, CA; 2016 Sep. 3241. Hospira, Inc. Cefepime® (cefepime hydrochloride) injection prescribing information. Lake Forest, IL; 2015 Dec. 3242. Hart M, Acott S. Physical and chemical stability of Taxotere (docetaxel) one-vial (20 mg/mL) infusion solution following refrigerated storage. *Eur J Pharm Biopharm*. 2010; 4:202. [PubMed 22276044] 3243. Lee S (Medical Information, Chiesi, Cary, NC); Personal communication; 2016 Sep 30. 3244. Ghazi I, Hamada Y, Nicolau DP. Physical compatibility of tedizolid phosphate with selected i.v. drugs during simulated Y-site administration. *Am J Health Syst Pharm*. 2016; 73:1769-1776. [PubMed 27769972] 3245. Sullivan T, Forest J, Leclair G. Compatibility of cloxacillin sodium with selected intravenous drugs during simulated Y-site administration. *Hosp Pharm*. 2015; 50:214-20. [PubMed 26405311] 3246. Chan A, Tawfik G, Cheng W. Physical incompatibility between parenteral cloxacillin and vancomycin. *Can J Hosp Pharm*. 2013; 66:310-11. [PubMed 24159234] 3247. Nicolaou DP (Corresponding Author): Personal communication; 2016 Oct 28. 3248. SteriMax Inc. Cloxacillin for injection prescribing information. Oakville, Ontario; 2016 Feb. 3249. Hospira, Inc. Enalaprilat injection prescribing information. Lake Forest, IL; 2015 May. 3250. Baxter Healthcare Corporation. Intralipid® 20% (lipid injectable emulsion) prescribing information. Deerfield, IL; 2015 May. 3252. Baxter Healthcare Corporation. Intralipid® 20% (lipid injectable emulsion) prescribing information. Deerfield, IL; 2015 May. 3253. Baxter Healthcare Corporation. Intralipid® 30% (lipid injectable emulsion) prescribing information. Deerfield, IL; 2015 May. 3254. B. Braun Medical Inc. Nutrilipid® 20% (lipid injectable emulsion) prescribing information. Bethlehem, PA; 2014 Aug. 3255. Fresenius Kabi USA, LLC. Smoflipid® 20% (lipid injectable emulsion) prescribing information. Lake Zurich, IL; 2016 May. 3256. Sturgeon A (Medical Information, Baxter Healthcare Corporation): Personal communication; 2016 Sep 23. 3257. Collins L (Medical Information, B. Braun Medical): Personal communication; 2016 Sep 20. 3258. Patten L (Medical Affairs, Fresenius Kabi USA, LLC, Lake Zurich, IL): Personal communication; 2016 Sep 20. 3259. Ayers P, Adams S, Boullata J et al. A.S.P.E.N. parenteral nutrition safety consensus recommendations. *JPN J Parenter Enteral Nutr*. 2014 Mar-Apr; 38:296-333. [PubMed 24820129] 3260. Institute for Safe Medication Practices. IV fat emulsion needs a filter. *ASHP Adva*. 2014; 14:4-5. 3261. Jan M, Brodski H, Vecka M et al. Comparison of long-term stability of parenteral all-in-one admixtures containing new lipid emulsions prepared under hospital pharmacy conditions. *Medicina (Kaunas)*. 2011; 47:323-33. [PubMed 21968885] 3262. Thabit AK, Hamada Y, Nicolau DP. Physical compatibility of ceftriaxone-azobactam with selected i.v. drugs during simulated Y-site administration. *Am J Health Syst Pharm*. 2017; 74:e47-e54. [PubMed 28007721] 3263. So W, Kim L, Thabit AK et al. Physical compatibility of isavuconazole sodium with select i.v. drugs during simulated Y-site administration. *Am J Health Syst Pharm*. 2017; 74:e55-e63. [PubMed 28007722] 3264. Fresenius Kabi. Kabiven® (amino acids, electrolytes, dextrose and lipid injectable emulsion) for intravenous use prescribing information. Uppsala, Sweden; 2016 Apr. 3265. Fresenius Kabi. PeriKabi® (amino acids, electrolytes, dextrose and lipid injectable emulsion) for intravenous use prescribing information. Uppsala, Sweden; 2016 Apr. 3266. Mauro VF (Corresponding Author): Personal communication; 2017 Apr 5. 3267. Baxter Healthcare Corporation. 20% ProSof® (amino acid injection) pharmacy bulk package prescribing information. Deerfield, IL; 2014 Apr. 3268. B. Braun Medical Inc. TrophAmine® (amino acid injections) prescribing information. Irvine, CA; 2013 Nov. 3269. TrophAmine® (amino acid injections) prescribing information. Irvine, CA; 2013 Nov. 3270. Yousaf F, Zaidi ST, Wanandy T et al. Stability of cefepime in pH-neutral peritoneal dialysis solutions packaged in dual-compartment bags. *Perit Dial Int*. 2016 Jul-Aug; 36:457-9. [PubMed 27385807] 3271. Feutry F, Simon N, Genay S et al. Stability of 10 mg/mL cefuroxime sodium for intracranial injection in commonly used polypropylene syringes and new ready-to-use cyclic olefin copolymer sterile vials using the LC-UV stability-indicating method. *Drug Dev Ind Pharm*. 2016; 42:166-174. [PubMed 26006333] 3272. Heq J, Rolin C, Godet M et al. Long-term stability of esomeprazole in 5% dextrose polyolefin polyolefin bags at 5 degrees C +/- 3 degrees C after microwave freeze-thaw treatment. *Int J Pharm Compd*. 2015 Nov-Dec; 19:521-4. [PubMed 26891566] 3273. Briot T, Vignaud S, Lagarde F. Stability of micafungin sodium solutions at different concentrations in glass bottles and syringes. *Int J Pharm*. 2015; 492:137-40. [PubMed 26187166] 3274. Karlage K, Earhart Z, Green-Boesen K et al. Stability of midazolam hydrochloride injection 1-mg/mL solutions in polyvinyl chloride and polyolefin bags. *Am J Health Syst Pharm*. 2011; 68:1537-40. [PubMed 21817086] 3275. Perks W, Iazzetta J, Chan PC et al. Extended stability of sodium phosphate solutions in polyvinyl chloride bags. *Can J Hosp Pharm*. 2017 Jan-Feb; 70:7-12. [PubMed 28348427] 3276. Walker S (Corresponding Author): Personal communication; 2017 May 3. 3277. Myers AL, Zhang Y, Kawedia JD et al. Stability of tacrolimus injection diluted in 0.9% sodium chloride injection and stored in Excel bags. *Am J Health Syst Pharm*. 2016; 73:2083-2088. [PubMed 27198766] 3278. Janssen Biotech, Inc. ReoPro® (abciximab) prescribing information. Horsham, PA; 2016 Aug. 3279. Mylan Institutional LLC. Amiodarone hydrochloride injection prescribing information. Rockford, IL; 2016 Oct. 3280. Pfizer Inc. Cerebyx® (fosphenytoin sodium) injection prescribing information. New York, NY; 2017 Mar. 3281. West-Ward Pharmaceuticals. Fosphenytoin sodium injection prescribing information. Eatontown, NJ; 2017 Feb. 3282. Valeant Pharmaceuticals North America LLC. Nitropruss (sodium nitroprusside) injection prescribing information. Bridgewater, NJ; 2016 Oct. 3283. Exela Pharma Sciences, LLC. Nipride RTU (sodium amplicillin sodium/sulbactam sodium) prescribing information. New York, NY; 2017 Feb. 3286. Hospira, Inc. Azithromycin for injection prescribing information. Lake Forest, IL; 2017 May. 3287. The Medicines Company. Angiomax® (bivalirudin) for injection prescribing information. Parsippany, NJ; 2016 Mar. 3288. Hospira, Inc. Bumetanide injection prescribing information. Lake Forest, IL; 2017 Apr. 3289. Fresenius Kabi. Calcium gluconate injection prescribing information. Lake Zurich, IL; 2017 Jun. 3291. Sandoz Inc. Ampicillin sodium for injection prescribing information. Princeton, NJ; 2015 Aug. 3292. Sandoz Inc. Ampicillin sodium for injection in ADD-Vantage vials prescribing information. Princeton, NJ; 2011 Jun. 3293. Sandoz Inc. Ampicillin sodium for injection pharmacy bulk package prescribing information. Princeton, NJ; 2015 Aug. 3294. Hospira, Inc. Ampicillin sodium for injection prescribing information. Lake Forest, IL; 2015 Aug. 3295. Hospira, Inc. Maxipime® (cefepime hydrochloride) for injection prescribing information. Lake Forest, IL; 2017 May. 3296. Baxter Healthcare Corporation. Cefepime hydrochloride injection prescribing information. Deerfield, IL; 2016 May. 3297. B. Braun Medical Inc. Cefepime hydrochloride for injection and dextrose injection prescribing information. Bethlehem, PA; 2015 Nov. 3298. Carlier M, Stove V, Verstraete AG et al. Stability of generic brands of meropenem reconstituted in isotonic saline. *Minerva Anestesiologica*. 2015; 81:283-7. [PubMed 25220554] 3299. Novartis Pharmaceuticals Corporation. Methergine® (methylergonovine maleate) tablets and injection prescribing information. East Hanover, NJ; 2012 Jun. 3300. Dewulf J, Galanti L, Godet M et al. Long-term stability of acyclovir in 0.9% NaCl infusion polyolefin bags at 5+3°C after freeze-thaw treatment: a generic product from the brand name. *Ann Pharm*. 2015; 73:108-13. [PubMed 25488516] 3301. Hospira, Inc. Sodium phosphates injection prescribing information. Lake Forest, IL; 2017 Jun. 3302. Fresenius Kabi. Dilaudid® (hydromorphone hydrochloride) injection and Dilaudid-HP® (hydromorphone hydrochloride) injection prescribing information. Lake Zurich, IL; 2017 Feb. 3303. Hospira, Inc. Hydromorphone hydrochloride injection prescribing information. Lake Forest, IL; 2016 Dec. 3304. Akorn, Inc. Hydromorphone hydrochloride injection prescribing information. Lake Forest, IL; 2016 Dec. 3305. Hospira, Inc. Hydromorphone hydrochloride injection prescribing information. Lake Forest, IL; 2017 Mar. 3306. West-Ward Pharmaceuticals. Bumetanide injection prescribing information. Eatontown, NJ; 2014 Oct. 3310. Pipkin JD, Aztreonam, Inc. Connors KA, Amidon GL, Stella VJ, eds. Chemical stability of pharmaceuticals: a handbook for pharmacists. 2nd ed. New York: John Wiley; 1986:250-6. 3311. APP Pharmaceuticals, LLC. Pentam® 30 (pentamidine isethionate for injection) prescribing information. Schaumburg, IL; 2008 Mar. 3312. Sturgeon A (Medical Affairs, Fresenius Kabi): Personal communication; 2017 Mar 23. 3313. Fresenius Kabi. Calcium gluconate injection prescribing information. Lake Zurich, IL; 2015 Aug. 3314. Arnott MA, Hay J, Croft SL. Pentamidine: which salt? *Lancet*. 1988; 1:1057-8. Letter. [PubMed 2896902] 3316. Dorio TP, Kager PA. Pentamidine dosage: a base/salt confusion. *PLoS Negl Trop Dis*. 2008; 2:e225. [PubMed 18509543] 3317. Pharmacia & Upjohn Co. Bacitracin for injection prescribing information. Princeton, NJ; 2013 Oct. 3318. Lundbeck. Carmex® (carbamazepine) injection prescribing information. Deerfield, IL; 2016 Oct. 3319. Hospira, Inc. Amidate® (etomidate) injection prescribing information. Lake Forest, IL; 2017 Apr. 3320. Liebel-Flarsheim Company LLC. Conray 30 (iothalamate meglumine) 30% injection prescribing information. Raleigh, NC; 2017 Mar. 3321. Liebel-Flarsheim Company LLC. Conray 45 (iothalamate meglumine) 45% injection prescribing information. Raleigh, NC; 2017 Mar. 3322. Liebel-Flarsheim Company LLC. Conray (iothalamate meglumine) 60% injection prescribing information. Raleigh, NC; 2017 Mar. 3323. Liebel-Flarsheim Company LLC. Cysto-Conray® II (iothalamate meglumine) 17.2% injection prescribing information. Raleigh, NC; 2016 Sep. 3324. Qilu Pharmaceutical Co., Ltd. Cefepime hydrochloride for injection prescribing information. Jinan, China; 2016 Feb. 3325. Celgene Corporation. Vidaza® (azacitidine) for injection prescribing information. North Wales, PA; 2015 Jul. 3326. Actavis Pharma, Inc. Azacitidine for injection prescribing information. Parsippany, NJ; 2018 Jan. 3327. Celgene Europe Ltd. Vidaza® (azacitidine) for injection. Parsippany, NJ; 2018 Jan. 3328. Food and Drug Administration. Center for Drug Evaluation and Research. Application number: 208216Orig1s000: Medical review(s). From FDA website. 3329

United Kingdom; 2020 Mar. 3561. DeAngelis M, Ferrara A, Gregory K et al. Stability of 2 mg/mL adenosine solution in polyolefin infusion bags. Hosp Pharm. 2018; 53:73-74. [PubMed 29581597] 3562. Zhao F (Corresponding Author): Personal communication; 2020 Apr 30. 3563. Tobudic S, Prager I, Kussmann M et al. Compatibility of aztreonam in four commercial peritoneal dialysis fluids. Sci Rep. 2020; 10:1788. [PubMed 32019947] 3564. Patel RP, Jacob J, Sedeeq M et al. Stability of cefazolin in polyisoprene elastomeric infusion devices. Clin Ther. 2018; 40:664-667. Letter. [PubMed 29496321] 3565. Harmanjeet H, Jani H, Zaidi STR et al. Stability of ceftolozane and tazobactam in different peritoneal dialysis solutions. Perit Dial Int. 2020; :896860820902590. [PubMed 32052692] 3566. Vercheval C, Streel S, Servais AC et al. Stability of 90 mg/mL cefuroxime sodium solution for administration by continuous infusion. J Chemother. 2018 Oct - Dec; 30:371-374. [PubMed 30663549] 3567. Teligent Pharma, Inc. Zinacef® (cefuroxime for injection) prescribing information. Buena, NJ; 2020 Feb. 3568. Cies JJ, Moore WS, Chopra A et al. Stability of furosemide and chlorothiazide stored in syringes. Am J Health Syst Pharm. 2015; 72:2182-8. [PubMed 26637518] 3569. van der Schaar JA], Grouls R, Franssen EJF et al. Stability of furosemide 5 mg/mL in polypropylene syringes. Int J Pharm Compd. 2019 Sep-Oct; 23:414-417. [PubMed 31513540] 3570. Lardinois B, Dimitriou A, Delcave C et al. Long-term physicochemical stability of concentrated solutions of isosorbide dinitrate in polypropylene syringes for administration in the intensive care unit. Int J Pharm Compd. 2020 Jan-Feb; 24:64-68. [PubMed 32023217] 3571. Merus Labs Luxco II S.à R.L. Isoket® (isosorbide dinitrate) 0.5 mg/mL solution for infusion or injection. Luxembourg; 2018 May. 3572. Torbay Pharmaceuticals. Isosorbide dinitrate 0.05% w/v solution for injection or infusion. Devon, United Kingdom; 2019 Feb. 3573. Merus Labs Luxco II S.à R.L. Isoket® (isosorbide dinitrate) 1 mg/mL concentrate for solution for injection or infusion. Luxembourg; 2019 Dec. 3574. Torbay Pharmaceuticals. Isosorbide dinitrate 0.1% w/v concentrate for solution for injection or infusion. Devon, United Kingdom; 2019 Feb. 3575. Allergan USA, Inc. INFeD® (iron dextran) injection prescribing information. Madison, NJ; 2018 Nov. 3576. Koutroubakis IE, Oustamanolakis P, Karakoidas C et al. Safety and efficacy of total-dose infusion of low molecular weight iron dextran for iron deficiency anemia in patients with inflammatory bowel disease. Dig Dis Sci. 2010; 55:2327-31. [PubMed 19834803] 3577. Lew I, Mullarkey T, Adamson RT et al. Integrated care of anemia in chronic kidney disease patients: concepts in intravenous iron management: part one. Hosp Pharm. 2010; 45:225-36. 3578. Reddy CM, Kathula SK, Ali SA et al. Safety and efficacy of total dose infusion of iron dextran in iron deficiency anaemia. Int J Clin Pract. 2008; 62:413-5. [PubMed 18005041] 3579. Auerbach M, Pappadakis JA, Bahrain H et al. Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia. Am J Hematol. 2011; 86:860-2. [PubMed 21922526] 3580. Auerbach M, Macdougall I. The available intravenous iron formulations: History, efficacy, and toxicology. Hemodial Int. 2017; 21 Suppl 1:S83-S92. [PubMed 28371203] 3581. Gilead Sciences, Inc. Veklury® (remdesivir) for injection and injection prescribing information. Foster City, CA; 2020 Oct. 3582. Foy G, Poinsignon V, Mercier L et al. Microbiological and physico-chemical stability of ketamine solution for patient-controlled analgesia systems. J Hosp Clin Pharm. 2015; 1:31-37. [PubMed 32296511] 3583. Gu J, Qin W, Chen F et al. Long-term stability of tramadol and ketamine solutions for patient-controlled analgesia delivery. Med Sci Monit. 2015; 21:2528-34. [PubMed 26306476] 3584. Closset M, Hecq JD, Gonzalez E et al. Does an interaction exist between ketamine hydrochloride and Becton Dickinson syringes?. Eur J Hosp Pharm. 2017; 24:230-234. [PubMed 31156944] 3585. Daouphars M, Hervouët CH, Bohn P et al. Physicochemical stability of oxycodone-ketamine solutions in polypropylene syringe and polyvinyl chloride bag for patient-controlled analgesia use. Eur J Hosp Pharm. 2018; 25:214-217. [PubMed 31157023] 3586. Daouphars M (Corresponding Author): Personal communication; 2020 May 18. 3587. Beiler B, Barraud D, Vigneron J et al. Physicochemical stability of an admixture of lidocaine and ketamine in polypropylene syringe used in opioid-free anaesthesia. Eur J Hosp Pharm. 2020; 27:e79-e83. [PubMed 32296511] 3588. Chen IH, Martin EK, Nicolau DP et al. Assessment of meropenem and vaborbactam room temperature and refrigerated stability in polyvinyl chloride bags and elastomeric devices. Clin Ther. 2020; 42:606-613. [PubMed 32139176] 3589. Gilliot S, Masse M, Feutry F et al. Long-term stability of ready-to-use 1-mg/mL midazolam solution. Am J Health-Syst Pharm. 2020; 77:681-689. [PubMed 32300788] 3590. Hospira, Inc. Midazolam hydrochloride injection prescribing information. Lake Forest, IL; 2018 Aug. 3591. Hospira, Inc. Midazolam hydrochloride (preservative-free) injection prescribing information. Lake Forest, IL; 2018 Aug. 3592. Hospira, Inc. Midazolam hydrochloride (preservative-free) injection prescribing information. Lake Forest, IL; 2019 May. 3593. Meridian Medical Technologies, Inc. Seizalam® (midazolam hydrochloride) injection prescribing information. Columbia, MD; 2018 Oct. 3594. Fresenius Kabi USA, LLC. Potassium phosphates injection prescribing information. Lake Zurich, IL; 2019 Nov. 3595. CMP Pharma Inc. Potassium phosphates injection prescribing information. Farmville, NC; 2019 Oct. 3596. Hospira, Inc. Potassium phosphates injection prescribing information. Lake Forest, IL; 2017 Jun. 3597. Al Madfai F, Zaida ST, Ming LC et al. Stability of milrinone in continuous ambulatory delivery devices. Am J Health-Syst Pharm. 2018; 75:e241-e245. [PubMed 29691268] 3598. GlaxoSmithKline UK. Ventolin® 500 micrograms injection summary of product characteristics (SmPC). Middlesex, United Kingdom; 2019 Oct. 3599. GlaxoSmithKline UK. Ventolin® solution for IV infusion summary of product characteristics (SmPC). Middlesex, United Kingdom; 2019 Oct. 3600. GlaxoSmithKline NZ Limited. New Zealand Data Sheet for Ventolin® injection 500 micrograms/mL and Ventolin® solution for intravenous infusion 5 mg/5 mL. Auckland, New Zealand; 2018 Dec. 3601. Lardinois B, Baltzis A, Delcave C et al. Long-term physicochemical stability of concentrated solutions of salbutamol (albuterol) in polypropylene syringes for use in the intensive care unit and in obstetrics. Int J Pharm Compd. 2019 Sep-Oct; 23:434-437. [PubMed 31513544] 3602. Godet M, Simar J, Closset M et al. Stability of concentrated solution of vancomycin hydrochloride in syringes for intensive care units. Pharm Technol Hosp Pharm. 2018; 3:23-30. 3603. d'Huart E, Vigneron J, Charmillon A et al. Physicochemical stability of vancomycin at high concentrations in polypropylene syringes. Can J Hosp Pharm. 2019 Sep-Oct; 72:360-368. [PubMed 31692543] Package insert / product label Dosage form: injection, solution Drug class: Anticholinergic antiemetics J Code (medical billing code): J1240 (Up to 50 mg injection) Medically reviewed by Drugs.com. Last updated on Nov 21, 2022. Rx only Dimenhydrinate Description Dimenhydrinate, an anti-nauseant/antiemetic, is the 8-chlorotheophylline salt of diphenhydramine. It contains not less than 53% and not more than 55.5% of diphenhydramine, and not less than 44% and not more than 47% of 8-chlorotheophylline, calculated on the dried basis. Chemically, it is 8-chlorotheophylline compound with 2(diphenylmethoxy)-N,N-dimethylethylamine (1:1), and the structural formula is: C17H21NO•C7H7ClN4O2 M.W. 469.96 Dimenhydrinate Injection, USP contains a sterile solution of Dimenhydrinate 50 mg/mL; Propylene Glycol 50%; Benzyl Alcohol 5% as preservative; and Water for Injection q.s. Sodium Hydroxide and/or Hydrochloric Acid may have been used to adjust pH. Dimenhydrinate - Clinical Pharmacology While the precise mode of action of Dimenhydrinate is not known, it has a depressant action on hyperstimulated labyrinthine function. Indications and Usage for Dimenhydrinate Dimenhydrinate Injection, USP is indicated for the prevention and treatment of nausea, vomiting, or vertigo of motion sickness. Contraindications Neonates and patients with a history of hypersensitivity to Dimenhydrinate or its components (diphenhydramine or 8-chlorotheophylline) should not be treated with Dimenhydrinate. Note: This product contains Benzyl Alcohol. Benzyl Alcohol has been associated with a fatal "Gasping Syndrome" in premature infants and infants of low birth weight. Warnings Caution should be used when Dimenhydrinate is given in conjunction with certain antibiotics that may cause ototoxicity, since Dimenhydrinate is capable of masking ototoxic symptoms, and an irreversible state may be reached. This drug may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks, such as driving a vehicle or operating machinery. The concomitant use of alcohol or other central nervous system depressants may have an additive effect. Therefore, patients should be warned accordingly. Dimenhydrinate should be used with caution in patients having conditions which might be aggravated by anticholinergic therapy (i.e., prostatic hypertrophy, stenosing peptic ulcer, pyloroduodenal obstruction, bladder neck obstruction, narrow-angle glaucoma, bronchial asthma, or cardiac arrhythmias). The preparation should not be injected intra-arterially. Pediatric Patients For infants and children especially, antihistamines in overdosage may cause hallucinations, convulsions, or death. As in adults, antihistamines may diminish mental alertness in pediatric patients. In the young child, particularly, they may produce excitation (see CONTRAINDICATIONS). Precautions General Drowsiness may be experienced by some patients, especially with high dosage. This effect frequently is not undesirable in conditions for which the drug is used. Information for Patients Because of the potential for drowsiness, patients taking Dimenhydrinate should be cautioned against operating automobiles or dangerous machinery (see WARNINGS). Carcinogenesis, Mutagenesis, Impairment of Fertility Mutagenicity screening tests performed with Dimenhydrinate, diphenhydramine, and 8-chlorotheophylline produced positive results in the bacterial systems and negative results in the mammalian systems. There are no human data that indicate Dimenhydrinate is a carcinogen or mutagen or that it impairs fertility. Pregnancy Pregnancy Category B. Reproduction studies have been performed in rats at doses up to 20 times the human dose, and in rabbits at doses up to 25 times the human dose (on a mg/kg basis), and have revealed no evidence of impaired fertility or harm to the fetus due to Dimenhydrinate. There are no adequate and well-controlled studies in pregnant women. However, clinical studies in pregnant women have not indicated that Dimenhydrinate increases the risk of abnormalities when administered in any trimester of pregnancy. It would appear that the possibility of fetal harm is remote when the drug is used during pregnancy. Nevertheless, because the studies in humans cannot rule out the possibility of harm, Dimenhydrinate should be used during pregnancy only if clearly needed. Labor and Delivery The safety of Dimenhydrinate given during labor and delivery has not been established. Reports have indicated Dimenhydrinate may have an oxytocic effect. Caution is advised when this effect is unwanted or in situations where it may prove detrimental. Nursing Mothers Small amounts of Dimenhydrinate are excreted in breast milk. Because of the potential for adverse reactions in nursing infants from Dimenhydrinate, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Adverse Reactions The most frequent adverse reaction to Dimenhydrinate is drowsiness. Dizziness may also occur. Symptoms of dry mouth, nose and throat, blurred vision, difficult or painful urination, headache, anorexia, nervousness, restlessness or insomnia (especially in pediatric patients), skin rash, thickening of bronchial secretions, tachycardia, epigastric distress, lassitude, excitation, and nausea have been reported. Overdosage Drowsiness is the usual clinical side effect. Convulsions, coma, and respiratory depression may occur with massive overdosage. No specific antidote is known. If respiratory depression occurs, mechanically assisted respiration should be initiated and oxygen should be administered. Convulsions should be treated with appropriate doses of diazepam. Phenobarbital (5 to 6 mg/kg) may be given to control convulsions in pediatric patients. The oral LD 50 in mice and rats is 203 mg/kg and 1320 mg/kg, respectively. The intraperitoneal LD 50 in mice is 149 mg/kg. Dimenhydrinate Dosage and Administration Dimenhydrinate in the injectable form is indicated when the oral form is impractical. Adults Nausea or vomiting may be expected to be controlled for approximately 4 hours with 50 mg, and prevented by a similar dose every 4 hours. Its administration may be attended by some degree of drowsiness in some patients, and 100 mg every 4 hours may be given in conditions in which drowsiness is not objectionable or is even desirable. For intramuscular administration, each milliliter (50 mg) of solution is injected as needed, but for intravenous administration, each milliliter (50 mg) of solution must be diluted in 10 mL of 0.9% Sodium Chloride Injection, USP and injected over a period of 2 minutes. Pediatric For intramuscular administration, 1.25 mg/kg of body weight or 37.5 mg/m 2 of body surface area is administered four times daily. The maximum dose should not exceed 300 mg daily (see CONTRAINDICATIONS). Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. How is Dimenhydrinate Supplied Dimenhydrinate Injection, USP, 50 mg/mL is available in multiple dose amber vials, as follows: Protect from light. Store at 20° to 25°C (68° to 77°F)[see USP Controlled Room Temperature]. Vial stoppers do not contain natural rubber latex. 45981B Revised: April 2008 PACKAGE LABEL - PRINCIPAL DISPLAY - Dimenhydrinate 1 mL Vial Label NDC 63323-366-01 361601 Dimenhydrinate INJECTION, USP 50 mg/mL For IM Use For IV Use: See package insert. Rx only 1 mL Multiple Dose Vial PACKAGE LABEL - PRINCIPAL DISPLAY - Dimenhydrinate 1 mL Vial Tray Label NDC 63323-366-01 361601 Dimenhydrinate INJECTION, USP 50 mg/mL For IM Use *For IV Use Rx only 1 mL Multiple Dose Vial Dimenhydrinate Dimenhydrinate injection, solution Product Information Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:63323-366 Route of Administration INTRAMUSCULAR, INTRAVENOUS DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength Dimenhydrinate (CHLORTHEOPHYLLINE) Dimenhydrinate 50 mg in 1 mL Inactive Ingredients Ingredient Name Strength BENZYL ALCOHOL 0.05 mL in 1 mL PROPYLENE GLYCOL 0.5 mL in 1 mL SODIUM HYDROXIDE HYDROCHLORIC ACID Packaging # Item Code Package Description 1 NDC:63323-366-01 25 VIAL in 1 TRAY 1 1 mL in 1 VIAL Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA040519 11/29/2004 Labeler - Fresenius Kabi USA, LLC (608775388) Establishment Name Address ID/FEI Operations Fresenius Kabi USA, LLC 840771732 manufacture(63323-366) Fresenius Kabi USA, LLC More about dimenhydrinate Patient resources Professional resources Related treatment guides Insomnia Motion Sickness Nausea/Vomiting Medical Disclaimer